Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Spring 5-15-2015

Ketone Body Metabolism Preserves Hepatic Function during
Adaptation to Birth and in Overnutrition
David Graham Cotter
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Biology Commons

Recommended Citation
Cotter, David Graham, "Ketone Body Metabolism Preserves Hepatic Function during Adaptation to Birth
and in Overnutrition" (2015). Arts & Sciences Electronic Theses and Dissertations. 444.
https://openscholarship.wustl.edu/art_sci_etds/444

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology & Biomedical Sciences
Molecular Cell Biology
Dissertation Examination Committee:
Peter Crawford, Chair
Thomas Baranski
Brian Finck
Shin-ichiro Imai
Joel Schilling
Clay Semenkovich

Ketone Body Metabolism Preserves Hepatic Function during Adaptation to Birth and in Overnutrition
by
David Graham Cotter

A dissertation presented to the
Graduate School of Arts and Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2015
St. Louis, Missouri

© 2015, David Graham Cotter

Table of Contents
1. List of Figures…………………………………………………………………………………………iii
2. List of Tables…………………………………………………………………………………………..vi
3. Acknowledgements……………………………………………………………………………..….....vii
4. Abstract………………………………………………………………………………………………..ix
5. Body of Dissertation
a. Chapter 1: Introduction: Ketone Body Metabolism and Cardiovascular Disease………..……2
b. Chapter 2: Obligate role for ketone body oxidation in neonatal metabolic homeostasis…….30
c. Chapter 3: Successful adaptation to ketosis by mice with tissue-specific deficiency of ketone
body oxidation …………………………………………………………………………….…54
d. Chapter 4: Impact of peripheral ketolytic deficiency on hepatic ketogenesis and
gluconeogenesis during the transition to birth. ………………………………………………81
e. Chapter 5: PPARα-dependent ketogenesis prevents hepatic steatosis in neonatal mice……121
f.

Chapter 6: Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia through
coenzyme A recycling………………………………………………………………………138

g. Chapter 7: 13C-edited proton NMR spectroscopy method for measurement of gluconeogenesis
from pyruvate in the perfused mouse liver………..………………………………………...176
h. Chapter 8: Impaired fasting glucose and hepatic steatosis in ketogenesis insufficient
mice…………………………………………………………………………………………181
i.

Concluding Remarks…………………………………………………………………..……184

6. Literature Cited………………………………………………………………………………………191
7. Curiculum Vitae……………………………………………………………………………………..212

ii

List of Figures
Figure 1.1: Ketone body metabolism pathways…………………………………………...………………24
Figure 1.2: Hepatic integration of ketogenesis……………………………………………………………25
Figure 1.3: Ketogenic flux through CoA transferase.………………………………………………..……26
Figure 1.4: Regulatory mechanisms for HMGCS2 and CoA transferase (SCOT).……………………….27
Figure 1.5: Diverse roles of CoA transferase in mitochondrial function…………………………….……28
Figure 2.1: Ketolysis-deficient Oxct1-/- mice……………………………………………………………...45
Figure 2.2: Metabolic resuscitation of Oxct1-/- mice………………………………………………………46
Figure 2.3: Normal glucose disposal but refractory hyperketonemia in glucose-resuscitated suckling
Oxct1-/- mice……………………………………………………………………………………………….47
Figure 2.4: Increased phosphorlyaion of AMPKα within brain of Oxct1-/- mice…………………………48
Figure 2.5: Enhanced autophagy in brain of Oxct1-/- mice………………………………………………...49
Figure 2.6: Tissue-specific adaptations to ketolytic insufficiency………………………………………...50
Figure S.2.1: Absence of terminal ketone body oxidation in muscle and brain of Oxct1-/mice………………………………………………………………..............................................................52
Figure 3.1: Strategy for the generation of transgenic overexpresser and tissue-specific SCOT-KO
mice………………………………………………………………………………………………………..71
Figure 3.2: Restoration of ketone body oxidative capacity selectively within cardiomyocytes of germline
SCOT-KO mice.…………………………………………………………………………………………...72
Figure 3.3: Absence of CoA transferase protein and enzymatic activity in tissue-specific SCOT-KO
mouse strains…………………………………………………….………………………………………...73
Figure 3.4: Circulating metabolites in neonatal tissue-specific SCOT-KO strains……..………………...74
Figure 3.5: Increased glucose consumption by brains of neonatal SCOT-Neuron-KO mice ………….....75
Figure 3.6: Adult tissue-specific SCOT-KO mice tolerate starvation.………………………….………...76
Figure 3.7: Diminished total body ketone body oxidative capacity impairs adaptation to ketotic nutrient
states.……………………………………………………………………………………….……………...77
Figure 4.1: Absence of extrahepatic ketone body oxidation engages an hepatic gluconeogenic program
in neonatal mice.…………………………………………………………………….…………………...102
Figure 4.2: Alterations of terminal fatty acid oxidation and pyruvate handling in livers of SCOT-KO
mice……………………………………………………………………………………………………...103
Figure 4.3: Mother’s milk-induced impairment of de novo βOHB production in neonatal SCOT-KO
liver ……………………………………………………………………………………………………...104
iii

Figure 4.4: Normal in vitro hepatic ketogenesis of livers from SCOT-KO mice…………...…………...105
Figure 4.5: D-βOHB inhibits neonatal hepatic ketogenesis in vivo……………………………...……...106
Figure 4.6: Oxidized hepatic redox potential in P1 SCOT-KO mice……………………………….…...107
Figure S4.1: PDH-E1α Ser293 phosphorylation in P1 Liver……………………………...……………..108
Figure S4.2: Normal oxidative and ketogenic machinery in livers of P1 SCOT-KO mice………….......109
Figure S4.3: Normal hepatic fractional enrichment of 13C-glutamate from [13C]octanoate in P0
SCOT-KO mice……………………………...…………………………………………………………...110
Figure S4.4: Normal oxidative and ketogenic machinery in livers of milk-fed P0 SCOT-KO mice........111
Figure S4.5: Relative abundances of mRNAs encoding mediators of NAD+ metabolism and signaling
in livers of P0 and P1 mice.……………………………………………………………………………...112
Figure S4.6: CoA transferase protein abundance in neonatal tissues.…………………………………...113
Figure 5.1: PPARα-KO mice exhibit neonatal hypoglycemia…………………………………………...132
Figure 5.2: PPARα promoted gluconeogenesis from glycerol in neonatal mice………………………...133
Figure 5.3: Normal hepatic fatty acid oxidation in PPARα-KO neonates……………..………………...134
Figure 5.4: PPARα-KO neonates exhibit hypoketonemia due to decreased expression of ketogenic
enzymes.………………………………………………………………………………..………………...135
Figure 5.5: Ketogenic suppression is associated with neonatal hepatic steatosis…………...…………...136
Figure 6.1: Ketogenic insufficiency in mice treated with Hmgcs2 ASO………………………………...161
Figure 6.2: Hepatic injury in ketogenesis insufficient HFD-fed mice…………………………………...162
Figure 6.3: Hepatic metabolic reprogramming in ketogenesis insufficient mice…………………...…...163
Figure 6.4: Replenishing CoA precursors restores gluconeogenesis and TCA cycle intermediate
abnormalities in livers of ketogenesis insufficient mice………….……………………………………...164
Figure S6.1: Metabolic parameters of ketogenesis insufficient neonatal mice, specificity of HMGCS2
ASO treatment in adult mice, and quantification of ketogenesis in perfused livers.…………………….165
Figure S6.2: Metabolic parameters of ketogenesis insufficient adult mice fed a standard chow diet…...166
Figure S6.3: Serum metabolites of ASO-treated mice fed a 60% HFD…...………………………….....167
Figure S6.4: Body weight, energy intake, and body composition of ketogenesis insufficient mice fed
either a 60% HFD or a 40% fat diet……………………………………………………………………...168
Figure S6.5: Metabolite concentrations and gene expression in livers of ketogenesis insufficient
mice….………………………………..……………………………………………………………….....169
Figure S6.6: Hepatic injury in ketogenesis insufficient mice fed a 40% HFD…...……………………...170

iv

Figure S6.7: Elevation of short- and medium-chain blood acylcarnitines in ketogenesis insufficient mice
fed a 40% fat diet………………………………………………………………………………………...171
Figure S6.8: Hepatic glucose pools in livers perfused with supplemental CoASH precursors..………...172
Figure 7.1: Fasting alters pyruvate fate in perfused livers……………………………………………….180
Figure 8.1: Fasting-induced hyperglycemia is associated with hepatic steatosis in ketogenesis insufficient
mice………………………………….........………..……………….........………..………………..........182
Figure 8.2: Altered hepatic pyruvate fate in ketogenesis insufficient mice……………….........………..183

v

List of Tables
Table 1.1: Implications of ketone body metabolism………………………………………………………29
Table 2.1: Plasma metabolite concentrations in P0-P1 mice……………………………………………...51
Table S2.1: Oligonucleotide primer sequences used for PCR in this study…………………………....…53
Table 3.1: Genotyping primer sequences………………………………………………………..………...78
Table 3.2: RT-qPCR primer sequences……………………………………………...…………………….79
Table 3.3: Serum AcAc-to-D-βOHB ratios in adult mice…………………………………………….......80
Table S4.1: RT-qPCR Primers……………………………………………...……………………………114
Table S4.2: P0 Hepatic Taurine Concentrations……………………………………………...………….115
Table S4.3: P1 Hepatic Taurine Concentrations……………………………………………...………….116
Table S4.4: P0 Blood Amino Acid Profile………………………………………….…………………...117
Table S4.5: P1 Blood Amino Acid Profile…………………………………….………………………...118
Table S4.6: P1 Blood Acylcarnitine Profile……………………………………………………………...119
Table S4.7: P0 Blood Acylcarnitine Profile…………………………………………….………...……...120
Table 5.1: RT-qPCR Primers……………………………………………………………………..……...137
Table S6.1: Blood acylcarnitine profiles of ASO-treated mice fed a chow diet…………………………173
Table S6.2: Blood acylcarnitine profile of ASO-treated mice fed a 40% fat diet…………………….....174
Table S6.3: RT-qPCR Primers…………………………………………………………………….…......175

vi

Acknowledgements
This work was supported in part by NIH grants HL007873, DK091538, plus grants from the
Diabetic Cardiovascular Disease Center at Washington University, and the March of Dimes.
Many people have contributed to my scientific development. During my undergraduate training, I
was extremely fortunate to find outstanding mentors, including Frank van Breukelen, Peter Starkweather,
Abayomi Animashaun, Matt Lawrenz, Jon Lenz, and Virginia Miller. As a graduate student, past and
present members of the Crawford lab, including Rebecca Schugar, Baris Ercal, Jamison Leid, Ashley
Moll, Annie Wentz, Mary Weber, Charles Shyng, and Debra Whorms, have provided numerous helpful
conversations and technical assistance. In particular, Rebecca Schugar and her fiancé have become
treausured friends. Baris Ercal and Jamison Leid, the ASO squad, have always made work fun. The
studies presented herein have greatly benefitted from helpful discussions with and experimental assistance
from many collaborators, including Dennis Dietzen, Brian Finck, Shin Imai, Trey Coleman and Clay
Semenkovich, Tom Baranski, and D. Andre d’Avignon. No one has spent more time in the trenches with
me than Andre, who has even come into work at 11:30 PM, beer in hand, to help me trouble shoot
intrument problems. Most importantly, this work would not exist without the unwavering support,
guidance, and friendship of my thesis advisor Peter Crawford. Peter, thank you for helping me to obtain
and to maintain “momentum.”
Science offers unique psychological challenges. Without extracurricular outlets, one could easily
unravel. Fortunately, my best friends, James Byers and Anthony Marlon, helped me maintain sanity
through martial arts, hiking, and all around “fun-having.” My mother- and father-in-law have offered
unrivaled love and support. Brian and Valerie, thank you for letting me into your home and into your
lives. Most of all, my beautiful, strong, and loving wife Brianna has made tremendous personal sacrifices
to stand beside me in pursuit of this degree. Bri, I would be lost without you.

vii

Dedication
Quinn, even as I write, your mother and I eagerly await your arrival. All that I have done and will ever do
is for you.

viii

ABSTRACT OF THE DISSERTATION
Ketone Body Metabolism Preserves Hepatic Function during Adaptation to Birth and in Overnutrition
by
David Graham Cotter
Doctor of Philosophy in Biology & Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2015
Professor Peter Crawford, Chair
Mammalian ketone body metabolism partially oxidizes hepatic acyl-chains to ketone body intermediates,
which can serve as alternative fuels in extrahapetic tissues during carbohydrate restricted states. Ketone
body production (ketogenesis) occurs primarily in liver, due to hepatocyte-specific expression of the fate
committing ketogenic enzyme, mitochondrial 3-hydroxymethylglutaryl-CoA synthase (HMGCS2). In
contrast, the fate committing enzyme of ketone body oxidation, mitochondrial Succinyl-CoA:3-oxoacid
CoA Transferase (SCOT), is expressed ubiquitously, except in liver. Here I demonstrate novel roles for
ketone body metabolism during a classically ketogenic period, the transition to birth, and in a classically
‘non-ketogenic’ state, overnutrition, using novel genetic mouse models, high-resolution measures of
dynamic metabolism using
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C-labeled substrates, and systems physiology approaches. I show that

germline SCOT-knockout (KO) mice cannot oxidize ketone bodies in any tissue. These mice developed
lethal hyperketonemia and hypoglycemia within the first 48 hr of life and died in a manner that
phenocopied human sudden infant death syndrome. Nonetheless, my studies of tissue-specific SCOT-KO
mice revealed that ketone body oxidation is dispensable during the transition to birth and during
starvation in the adult when individually eliminated in neurons, cardiomyocytes, or skeletal myocytes,
which comprise the three largest consumers of ketone bodies. Surprisingly, the inability to dispose of
ketone bodies in germline SCOT-KO mice drove derangements of carbohydrate and fatty acid
metabolism, oxidized redox potential, and inhibited ketogenesis in liver. Moreover, I show that adultonset loss of HMGCS2 ablated the liver’s capacity to effectively convert fat into ketone bodies, and thus

ix

induced ketogenesis insufficiency. Ketogenesis insufficient mice exhibited increased hepatic
gluconeogenesis from pyruvate and mild hyperglycemia in the fed state. High-fat diet feeding of
ketogenesis insufficient mice caused extensive hepatocyte injury and inflammation that was associated
with decreased glycemia due to fatty acid-induced sequestration of free coenzyme A that caused
secondary derangements of hepatic tricarboxylic acid (TCA) cycle intermediate concentrations and
impaired gluconeogenesis. Together, my studies have revealed a critical and novel role for ketone body
metabolism in preservation of the dynamic intermediary metabolic network in liver during the adaptation
to birth and in overnutrition.
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Epigraph
"Though it be in deep sadness and pain,
in cold or heat...
gasping after breath... I will go on!
Now! Open the Gate!"
… Along the Road of the Sun L he journeyed—
one league he traveled...,
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
Two leagues he traveled...,
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
[22 lines are missing here.]
Four leagues he traveled...,
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
Five leagues he traveled...,
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
Six leagues he traveled...,
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
Seven leagues he traveled...
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
Eight leagues he traveled and cried out!
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
Nine leagues he traveled... the North Wind.
It licked at his face,
dense was the darkness, light there was none,
neither what lies ahead nor behind does it allow him to see.
Ten leagues he traveled...
… is near,
… four leagues
…Eleven leagues he traveled and came out before the sun(rise).
Twelve leagues he traveled and it grew brilliant.
...it bears lapis lazuli as foliage,
bearing fruit, a delight to look.
From The Epic of Gilgamesh
Translated by Maureen Gallery Kovacs
Electronic Edition by Wolf Carnahan, 1998
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Chapter 1: Introduction
Ketone Body Metabolism and Cardiovascular Disease
The work presented in this chapter has been adapted from:
Cotter, D. G., Schugar, R. C., and Crawford, P. A. (2013). Am J Physiol Heart Circ Physiol 304(8),
H1060-1076
Abstract
Ketone bodies are metabolized through evolutionarily conserved pathways that support bioenergetic
homeostasis, particularly in brain, heart, and skeletal muscle when carbohydrates are in short supply. The
metabolism of ketone bodies interfaces with the tricarboxylic acid cycle, β-oxidation of fatty acids, de
novo lipogenesis, sterol biosynthesis, glucose metabolism, the mitochondrial electron transport chain,
hormonal signaling, intracellular signal transduction pathways, and the microbiome. Here we review the
mechanisms through which ketone bodies are metabolized, and how their signals are transmitted. We
focus on the roles this metabolic pathway may play in cardiovascular disease states, the bioenergetic
benefits of myocardial ketone body oxidation, and prospective interactions among ketone body
metabolism, obesity, metabolic syndrome, and atherosclerosis. Ketone body metabolism is non-invasively
quantifiable in humans and is responsive to nutritional interventions. Therefore, further investigation of
this pathway in disease models and in humans may ultimately yield tailored diagnostic strategies and
therapies for specific pathological states.

I. Introduction
Metabolism of ketone bodies is conserved among Eukarya, Bacteria, and Archaea (1-3). Ketone bodies
are synthesized in liver from acetyl-CoA derived primarily from fatty acid oxidation and are transported
to extrahepatic tissues for terminal oxidation during physiological states characterized by limited
carbohydrate and surplus fatty acid availability [reviewed in (4,5); (Figs. 1.1A-B)]. Ketone body
oxidation becomes a significant contributor to overall energy metabolism within extrahepatic tissues in
numerous physiological states, including the neonatal period, starvation, post-exercise, and adherence to
low carbohydrate diets, when circulating ketone body concentrations increase from ~ 50 µM in the
2

normal fed state to up to 7 mM. Circulating ketone body concentrations rise to ~1 mM after 16-20h of
fasting in healthy adult humans, but can accumulate to as high as 20 mM in pathological states like
diabetic ketoacidosis (2,4,6). Ketone body metabolism is not solely rooted in energy metabolism, as
ketone bodies also serve as lipogenic and sterol biosynthetic substrates in many tissues, including the
developing brain, lactating mammary gland, and liver (7-10) (Fig. 1.1C). Furthermore, hepatic
ketogenesis interfaces with fatty acid β-oxidation, the tricarboxylic acid (TCA) cycle, and
gluconeogenesis (Fig. 1.2). Derangements of ketone body metabolism occur in numerous disease states,
including types 1 and 2 diabetes and heart failure, and ketone body metabolism changes over the course
of normal aging (11-19). In this review we examine (i) the biochemistry of ketone body metabolism and
its regulation (Section II), (ii) the roles of ketone body metabolism in normal and pathological states of
the myocardium (Sections III-IV), (iii) the concept, and prospective cardiovascular disease relevance of
extrahepatic ketone body production, which may channel ketone bodies into lipogenesis (Section 1.V;
Fig. 1.3), and (iv) intersections among ketone body metabolism, cellular signaling pathways, and the gut
microbiota (Sections VI-VII). Analysis of the known and prospective cardiovascular disease targets of
ketone body metabolism is also provided (Section VIII). The effects of ketone body metabolism are
summarized in Table 1.1.

II. Ketone body metabolism
The fundamental biochemical and physiological roles of ketone body metabolism have been extensively
studied and reviewed (4,5,20). In this Section, we provide a brief overview of ketone body metabolism,
and then focus on recent studies revealing novel aspects of the pathway’s regulatory mechanisms.
A. Hepatic ketogenesis. In liver, 3-hydroxymethylglutaryl-CoA synthase 2 (encoded by the nuclear gene
Hmgcs2) catalyzes a fate committing ketogenic reaction: condensation of β-oxidation-derived
acetoacetyl-CoA (AcAc-CoA) and acetyl-CoA to generate HMG-CoA, which is cleaved by HMG-CoA
lyase (HMGCL) to generate acetoacetate (AcAc). AcAc is reduced to D-β-hydroxybutyrate (D-βOHB), in
an NAD+/NADH-coupled near equilibrium reaction catalyzed by phosphatidylcholine-dependent
3

mitochondrial D-βOHB dehydrogenase (BDH1), in which the Keq favors D-βOHB formation (21,22)
(Fig. 1.1A). Because the BDH1 catalyzed reduction/oxidation of AcAc and D-βOHB is common to the
final reaction of ketogenesis and the first reaction of ketone body oxidation (Figs. 1.1A-B) (22,23), BDH1
modulates mitochondrial redox potential in liver and extrahepatic tissues, wherein the AcAc/βOHB ratio
is directly proportional to the mitochondrial NAD+/NADH ratio (24). A cytoplasmic D-βOHBdehydrogenase (BDH2) with only 20% sequence identity to BDH1 has been identified (25). More work is
needed to elucidate the mechanisms by which the BDH enzymes are regulated and function in vivo. AcAc
is also non-enzymatically decarboxylated to acetone. Ketone bodies are released by the liver via solute
carrier 16A (SLC16A) family members 1, 6, and 7 and circulate to extrahepatic tissues where they
primarily undergo terminal oxidation (26,27).
A.1. Ketogenic substrates. Ketogenesis occurs predominantly in liver mitochondria at rates proportional
to β-oxidation when dietary carbohydrates are limiting, and is highly integrated with the TCA cycle and
gluconeogenesis (Fig. 1.2). Biochemical studies by pioneering investigators including Krebs, McGarry,
and Foster demonstrated that hepatic metabolic fluxes of acetyl-CoA govern rates of ketogenesis
[reviewed in (5,20)]. Fatty acid β-oxidation-derived AcAc-CoA and acetyl-CoA are the primary
ketogenic substrates. Glucose metabolism accounts for less than 1% of circulating ketone bodies in states
of low carbohydrate intake because pyruvate enters the hepatic TCA cycle predominantly via
carboxylation to oxaloacetate or malate, rather than decarboxylation (to acetyl-CoA) (28-30). In addition,
amino acid catabolism accounts for a small percentage of circulating ketone bodies, with leucine
catabolism generating up to 4% of circulating ketone bodies in the post-absorptive state (31).
A.2. Regulation of ketogenic mediators. Key regulatory steps in ketogenesis include lipolysis of fatty
acids from triacylglycerols, transport to and across the hepatocyte plasma membrane, transport into
mitochondria via allosterically-regulated carnitine palmitoyltransferase 1 (CPT1), the β-oxidation spiral,
and the hormonal regulators of these processes, predominantly glucagon and insulin. These classical
mechanisms have been reviewed (5,32-34). Hepatic ketogenesis is a spillover pathway for β-oxidationderived acetyl-CoA generated in excess of the liver’s energetic needs (Fig. 1.2). Acetyl-CoA subsumes
4

several roles integral to hepatic intermediary metabolism beyond ATP generation via terminal oxidation.
Acetyl-CoA allosterically activates (i) pyruvate carboxylase, thereby activating a metabolic control
mechanism that augments anaplerotic entry of metabolites into the TCA cycle (35,36) and (ii) pyruvate
dehydrogenase kinase, which phosphorylates and inhibits pyruvate dehydrogenase (37), thereby further
enhancing flow of pyruvate into the TCA cycle via anaplerosis. Furthermore, cytoplasmic acetyl-CoA,
whose pool is augmented by transport mechanisms that convert mitochondrial acetyl-CoA to
transportable metabolites (see Section V.B.), inhibits fatty acid oxidation: acetyl-CoA carboxylase
catalyzes the conversion of acetyl-CoA to malonyl-CoA, the lipogenic substrate and an allosteric inhibitor
of mitochondrial CPT1, decreasing delivery of acyl chains to the mitochondrial matrix for terminal
oxidation [reviewed in (5,38)]. Thus, the mitochondrial acetyl-CoA pool regulates and is regulated by the
spillover pathway of ketogenesis, which orchestrates key aspects of hepatic intermediary metabolism. The
studies described below focus on recently discovered mechanisms of ketogenic regulation.
Following procession through β-oxidation, ketogenic fate is determined by HMGCS2, whose
regulatory mechanisms are schematized in Fig. 1.4A. Because of its ability to support high rates of
hepatic ketogenesis, divergence of this mitochondrial HMGCS ~500 Mya from the gene encoding
cytoplasmic HMGCS1 may have supported the emergence of increasing brain-weight/body-weight ratios
during vertebrate evolution (39-41). The Hmgcs2 gene and encoded protein are regulatory targets during
the transition to extrauterine life, starvation, diabetes, during adherence to low carbohydrate/high fat
(ketogenic) diets, and in aging (2,11,20,42-44). The Hmgcs2 gene is dynamically regulated at the
transcriptional level. Methylation of 5’ regulatory sequences within the Hmgcs2 gene silences its
transcription in fetal liver, and in non-ketogenic adult tissues (45). At birth, hepatic Hmgcs2 becomes
hypomethylated and thereby becomes responsive to circulating hormones (34,46). Insulin suppresses
Hmgcs2 transcription, prospectively via phosphorylation-induced sequestration of FOXA2 from the
nucleus, while glucagon induces it via activation of the cAMP regulatory element binding protein (44-49).
In addition, free fatty acids induce Hmgcs2 in a peroxisome proliferator activated receptor (PPAR)-α
dependent manner (50,51). In fact, Hmgcs2 is induced in vivo in the post-absorptive state and by
5

adherence to ketogenic diet through the activities of the fibroblast growth factor (FGF)-21/PPARα axis
(50,52,53). HMGCS2 may also reciprocally induce Fgf21 gene expression (54). In addition, following
cysteine palmitoylation, HMGCS2 translocates to the nucleus, physically interacts with PPARα, and
potentiates its own gene transcription (55,56). Inhibition of mTORC1 signaling has been identified as a
primary mechanism responsible for de-repression of PPARα-mediated transcriptional changes responsible
for the induction of ketogenesis in the post-absorptive state (11,57). Hepatic Bdh1 also exhibits a
developmental expression pattern, increasing in brain and liver from birth to weaning, and is also induced
by ketogenic diet in an FGF21 dependent-manner (53,58).
In addition to cysteine palmitoylation, HMGCS2 enzymatic activity is responsive to forms of
post-translational modification. Mitochondrial activity of HMGCS2 is inhibited through allosteric
regulation by succinyl-CoA (44,59,60) and through succinylation of lysine residues (44,46,47,61). While
the regulatory mechanisms remain to be determined, desuccinylation is stimulated by glucagon (47), and
recent discoveries that identify sirtuin (silent mating type information regulation 2 homolog) 5 (SIRT5) as
a mitochondrial NAD+ dependent lysine desuccinylase prompt the hypothesis that SIRT5 function
dynamically regulates mitochondrial HMGCS2 activity (62,63). HMGCS2 activity is also induced in the
post-absorptive state by SIRT3, a mitochondrial NAD+ dependent deacetylase (64). Because SIRT3
regulates multiple enzymatic mediators of β-oxidation, sirtuins may be multi-tiered regulators of
ketogenesis. Genetically obese mice were recently shown to exhibit increased hepatic HMGCS2 serine
phosphorylation, a post-translational modification that enhances HMGCS2 activity in vitro and was
correlated with elevated serum D-βOHB levels in vivo (65).
Despite all of the described transcriptional and post-translational mechanisms that regulate
HMGCS2, it is unknown if regulation of Hmgcs2 gene expression correlates with changes in protein
abundance, and if these changes in gene expression directly regulate ketogenesis. Importantly, it remains
undetermined if HMGCS2 post-translational modification itself is a primary determinant of ketogenic
flux. Nonetheless, HMGCS2 activity is required for the normal ketogenic response to states of diminished
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carbohydrate intake, as its absence in humans yields hypoketotic hypoglycemia and fatty liver in states of
diminished carbohydrate intake (66-68).
B. Ketone body utilization. Ketone body catabolism generates acetyl-CoA that can be terminally
oxidized within the TCA cycle or utilized for sterol biosynthesis and de novo lipogenesis (DNL). Ketone
bodies are an alternative and glucose-sparing fuel source, avidly oxidized in heart and muscle. Moreover,
neurons do not effectively generate high-energy phosphates from fatty acids, and consequently oxidize
ketone bodies during starvation and in the neonatal period [presented and reviewed in (2,4,69-71)]. Below
we review the biochemical activities of the enzymes of ketone body utilization, focusing on recent studies
that reveal the precise physiological roles of ketone body utilization in vivo.
B.1. Ketone body oxidation. Ketone bodies are extracted from the circulation by peripheral tissues via
SLC16A1 and -7 (26). Within mitochondria of peripheral organs, BDH1 catalyzes the oxidation of DβOHB to AcAc. AcAc is activated to AcAc-CoA by succinyl-CoA:3-oxoacid-CoA transferase (SCOT,
CoA transferase), the only mammalian CoA transferase, which catalyzes a near equilibrium reaction that
exchanges coenzyme A between succinate and AcAc (Fig. 1.1B). The free energy released by hydrolysis
of AcAc-CoA is greater than that of succinyl-CoA (72,73). Therefore, the equilibrium of this reaction
thermodynamically favors the formation of AcAc, [(74), also see Section V]. Thus, ketone body
oxidative flux occurs by mass action: an abundant supply of AcAc and rapid utilization of acetyl-CoA
through citrate synthase favors AcAc-CoA formation and contribution of ketone bodies to the TCA cycle.
A reversible AcAc-CoA thiolase reaction yields two molecules of acetyl-CoA, which enter the TCA cycle
(Fig. 1.1B) (4,74-76). CoA transferase is necessary, but not sufficient, for ketone body oxidation in mice
and humans [see below and (77-81)].
Ketone body oxidation becomes a primary contributor to bioenergetic homeostasis during ketotic
states, during which ketone bodies are oxidized in proportion to their delivery in heart, brain, and muscle
until saturation of either uptake or oxidation occurs (2,43,71,82-84). Relative to ketogenesis, little is
known about the regulation of mediators of ketone body oxidation. Perhaps paradoxically, expression of
the gene encoding CoA transferase (Oxct1), CoA transferase protein abundance, and CoA transferase
7

enzymatic activity are all diminished in rodent heart and muscle during states of sustained ketosis (51,8589). In pathological contexts such as diabetic ketoacidosis, diminution of CoA transferase abundance and
activity limit ketone body disposal, while insulin deficiency (or severe impairment of its signaling)
stimulates peripheral fatty acid mobilization and unabated hepatic ketogenesis. This mismatch of
ketogenesis and peripheral disposal predisposes to the extreme hyperketonemia that can emerge in
diabetic ketoacidosis.
In ketotic states, expression of Oxct1 may be negatively regulated through mechanisms involving
PPARs that are abrogated by insulin [(51); Fig. 1.4B]. Myocardial Oxct1 expression may also be downregulated under select non-ketotic metabolic states, as transgenic mice overexpressing the non-insulindependent glucose transporter (GLUT1/SLC2A1) in cardiomyocytes exhibit decreased Oxct1 expression
and diminished ketone body oxidation (90). Future experiments are needed to determine whether
regulation of Oxct1 expression occurs through transcriptional or post-transcriptional mechanisms (or
both), which may help support insight into whether these events are adaptive or maladaptive. Posttranslational modification of CoA transferase occurs through non-enzymatic tyrosine nitration, which has
been observed in hearts of endotoxin-treated rats, hearts of streptozotocin-treated rats, and hearts of db/db
mice (86,91,92). Tyrosine nitration correlates with impairments of enzymatic activity (Fig. 1.4B).
Conversely, nitration of CoA transferase on tryptophan residues in aged rat hearts and kidneys appears to
augment enzymatic activity (93,94). Molecular mechanisms of residue-specific nitration or de-nitration
designed to modulate CoA transferase activity may exist and require elucidation, as do additional
prospective post-translational modifications of CoA transferase.
Although touted as energy efficient substrates (95,96), an energetic requirement for ketone body
oxidation at the cellular level has never been demonstrated, even in states of diminished carbohydrate
supply. Nonetheless, human inborn errors of ketone body oxidation do result in clinically significant
disease, as approximately 30 CoA transferase-deficient patients have been identified. These patients
present early in life with severe ketoacidosis that results in lethargy, vomiting, and coma, requiring
aggressive intravenous hydration, bicarbonate, and glucose and insulin therapy (79-81,97-101). Some
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CoA transferase deficient patients also present with hypoglycemia, and CoA transferase deficiency may
contribute to a subset of idiopathic ketotic hypoglycemia cases (79,102-106). If maintained on
carbohydrate-rich diets that are mildly reduced in protein content, CoA transferase-deficient patients seem
to thrive, albeit with persistent hyperketonemia. To mechanistically dissect the homeostatic roles of
ketolysis, germline CoA transferase-knockout (SCOT-KO) mice were developed (78). These mice cannot
oxidize ketone bodies, and invariably die within 48h of extrauterine life due to hyperketonemic
hypoglycemia that is marked by hypolactatemia and an increase in the serum AcAc/D-βOHB ratio. The
mechanisms and consequences of this unusually high ratio remain to be determined. Despite the critical
nature of CoA transferase and ketone body disposal at an organismal level, recently published studies
demonstrated that mice with selective loss of CoA transferase in either cardiomyocytes, neurons, or
skeletal myocytes – the three greatest consumers of ketone bodies (4,107) – survive the neonatal period
and starvation as adults, with only subtle metabolic abnormalities in these two states (108). Future studies
using these and related models will be important to determine the metabolic and bioenergetic adaptations
to CoA transferase deficiency and the inability to derive energy from ketone bodies.
B.2. Non-oxidative metabolism of ketone bodies. Ketone bodies also contribute to lipogenesis and
sterol biosynthesis in developing brain, lactating mammary gland, and liver following enzymatic and
endergonic activation of AcAc to AcAc-CoA by cytoplasmic acetoacetyl-CoA synthetase (AACS) [(7-10)
and Fig. 1.1C]. While AcAc-CoA serves as a direct substrate for cytoplasmic HMGCS1, which catalyzes
the fate-committing step of sterol biosynthesis, channeling of AcAc-CoA into DNL requires a thiolytic
cleavage reaction (i.e., cytoplasmic ketolysis) to yield acetyl-CoA, which becomes the lipogenic substrate
malonyl-CoA upon carboxylation (8,109-112). Recent studies support the physiological importance of
ketone bodies as anabolic substrates. Genetic knockdown of AACS in mouse liver lowered total blood
cholesterol in vivo, and in vitro AACS knockdown impaired differentiation of primary mouse embryonic
neurons, and inhibited adipocyte differentiation of 3T3-L1 cells [(113-115), also see Section V]. While
lipogenic fates of ketone bodies may support essential biological functions, these pathways do not serve
as a primary pathway for disposal of ketone bodies when hepatic ketogenesis is stimulated, because CoA
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transferase deficiency in mice and humans, which abrogates terminal ketone body oxidation, causes
severe hyperketonemia (77-81). Nonetheless, future studies in models of AACS disruption are merited to
firmly establish the physiological roles for non-oxidative fates of ketone bodies.

III. Bioenergetics of Myocardial Ketone Body Oxidation
In the normal adult heart, mitochondrial oxidative phosphorylation provides more than 95% of the ATP
generated for its mechanical, electrical, and homeostatic activities. Fatty acid oxidation provides up to
70% of the ATP produced by the heart, with metabolism of glucose, lactate, amino acids, and ketone
bodies supplying the balance [reviewed in (116)]. Cardiomyocytes demonstrate considerable metabolic
flexibility during dynamic alterations of nutrient state and hemodynamic stress – conferring an important
adaptive property to the myocardium (117-120). Myocardium is the highest ketone body consumer per
unit mass (2,43,76). Cardiomyocytes oxidize ketone bodies in proportion to their delivery, at the expense
of terminal fatty acid oxidation and glucose oxidation (90,117,121-126). Competition between oxidation
of ketone bodies and fatty acids is independent of changes in myocardial malonyl-CoA concentrations
(127).
Ketone body oxidation is more energetically efficient than terminal fatty acid oxidation. While
terminal fatty acid oxidation yields the highest theoretical payoff of ATP per C2 unit of all the myocardial
substrates, the initial ATP investment required to activate long chain fatty acids for oxidation (i.e. to
generate a fatty acyl-CoA thioester) and fatty acid-induced expression of uncoupling proteins may
actually confer greater energetic density to ketone bodies (96). Furthermore, unlike terminal fatty acid
oxidation all of the reducing equivalents generated by ketone body oxidation are delivered via NADH to
complex I within the electron transport chain. Oxidation of βOHB also increases the redox span between
complexes I and III, by keeping mitochondrial ubiquinone oxidized. This may increase the potential
energy harvested from oxidation of ketone bodies (relative to fatty acids), thereby yielding more energy
available for ATP synthesis per molecule of oxygen invested (P/O ratio), improving the energetic
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efficiency of oxidizing ketone bodies over fatty acids (95,96,128). Because unrestrained mitochondrial
fatty acid oxidation may augment the generation of reactive oxygen species (ROS) to levels that exceed
scavenging mechanisms, competitive contribution of ketone bodies to the TCA cycle in cardiomyocytes
may be adaptive under conditions in which the ability to switch between fatty acids and glucose becomes
impaired (95,96,128). Moreover, ketone bodies diminish oxidative stress by scavenging free radicals and
by maintaining ubiquinone in the oxidized state (Fig. 1.5) (96,129,130).
CoA transferase dependent activation of AcAc to AcAc-CoA sequesters free CoA-SH (131,132).
Rodent hearts perfused ex vivo with AcAc alone exhibit depleted free CoA-SH pools and require addition
of either CoA precursors or anaplerotic substrates to maintain anaplerotic and TCA cycle flux, and to
prevent functional decline in cardiac performance (132-134). Although ketone bodies do not serve as the
sole myocardial fuel under any in vivo circumstance, these studies underscore the important role of
cardiac anaplerosis in maintaining myocardial bioenergetic homeostasis and cardiac function, a topic that
was recently reviewed by Des Rosiers and colleagues (135).
Until recently, it was not known how the myocardium adapts to chronic ketosis – an important
question relevant to the role that ketone body metabolism may serve in myopathic hearts. Mouse models
of physiologic ketotic nutritional states (24h of fasting or four weeks of a ketogenic diet) demonstrate that
the myocardium engages a transcriptional program including, as described above, transcriptional
suppression of Oxct1 and diminution of CoA transferase protein (51). Consistent with diminution of CoA
transferase, nuclear magnetic resonance (NMR) profiling demonstrated that maintenance on a ketogenic
diet decreased myocardial
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C-enrichment of glutamate from
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C-labeled ketone bodies that were

delivered in vivo or ex vivo by 25%, indicating diminished terminal oxidation of ketone bodies in the TCA
cycle (51,136). Furthermore, attenuation of ketone body oxidation correlated with failure of ketone bodies
to inhibit contribution of fatty acids to the TCA cycle. Together, these results indicate that ketotic nutrient
environments induce mechanisms that modulate myocardial utilization of ketone bodies. Because
hemodynamic parameters were preserved in hearts of mice fed a ketogenic diet, these results suggest that
modulation of ketone body metabolism may be adaptive in the setting of sustained ketosis.
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IV. Ketone Bodies and Myocardial Disease
Numerous experimental approaches have established that cardiomyopathy is associated with changes in
cardiac substrate and energy metabolism, and that altered energy metabolism can cause cardiomyopathy
[reviewed in (116,135,137-144)]. Both metabolic and bioenergetic lines of evidence indicate that ketone
body metabolism could play a significant role in the myopathic heart. Hepatic ketogenesis is stimulated
and ketone bodies circulate at increased concentrations in the setting of heart failure – in a relationship
directly proportional to filling pressure (13-17). As previously noted, the myocardium oxidizes ketone
bodies at the expense of fatty acid oxidation (117,124,127,145), and thus reductions of myocardial fatty
acid oxidation that occur during the development of advanced cardiomyopathy may not be coupled to
reductions of ketone body oxidation (116,141,144). A study in humans with advanced heart failure
indicated that myocardial extraction of delivered ketone bodies is maintained in the failing heart, but not
skeletal muscle (146). Similarly, the contribution of ketone bodies to cardiac energy metabolism may be
elevated in patients with dilated and hypertrophic cardiomyopathies (147). Therefore, while the data on
ketone body metabolism in heart failure are currently very limited, diminished myocardial ketone body
oxidation could promote pathological outcomes. Of the identified CoA transferase-deficient patients, two
were reported to present with dilated cardiomyopathy (98,148,149). Future studies in humans that
specifically measure CoA transferase function and ketone body oxidation in cardiomyopathic states,
complemented by mechanistic studies using tissue-selective genetic rodent models, will be required to
definitively determine how myocardial ketone body metabolism changes in pathophysiological states, and
the contexts in which myocardial ketone body utilization may be adaptive or maladaptive.
Studies in rodents demonstrate a possible role for ketone body metabolism in myocardial
adaptation to ischemia/reperfusion injury. In two studies using ex vivo perfusion approaches in rat hearts,
maintenance on low carbohydrate diets prior to ischemia/reperfusion protocols gave conflicting results
with regard to infarct size and hemodynamic performance (150,151). Prospective cardioprotective effects
of a low carbohydrate diet may be attributable to an increase in the number of myocardial mitochondria or
transcriptional upregulation of key mediators of oxidative phosphorylation (150,152). Cardioprotective
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effects have been observed using in vivo ischemia/reperfusion approaches in rats subjected to starvationinduced ketosis, initiated through prolonged fasting, and also via intravenous injection of DL-βOHB
immediately prior to ischemic injury, which conferred a significant decrease in both infarct size and
myocardial cell death (153,154). These studies should stimulate further investigation using genetic and
pharmacological approaches to determine the validity and mechanisms of these preliminary studies, and
whether the observations actually relate to myocardial metabolism of ketone bodies.
Relationships among ketone body metabolism, membrane excitability, and arrhythmogenesis
have also been reported. Metabolomic and proteomic analysis of atrial tissue harvested during cardiac
surgeries demonstrated an increase in both myocardial βOHB content and CoA transferase abundance in
patients with atrial fibrillation, compared to control patients (155). Although myocardial ketone body
utilization in the setting of atrial fibrillation has not been investigated, mechanisms that directly link
ketone bodies to membrane excitability and arrhythmogenesis have been preliminarily assessed. βOHB
blocks the transient outward K+ current (Ito) in murine ventricular myocytes, causing action potential
prolongation (156). However, only L-βOHB inhibits the Ito current. L-βOHB is measurable in myocardial
extracts, but does not circulate and likely results from hydrolysis of the β-oxidation intermediate LβOHB-CoA (157-160). Hepatic ketogenesis only produces D-βOHB, which is the only form that is a
BDH substrate, and thus, a substrate for oxidation. SLC16A transporters in rat myocytes demonstrate no
stereoselectivity for βOHB (161). Prospective pathophysiological significance of the L-βOHB
stereoisomer requires investigation.

V. Reversibility of the CoA Transferase Reaction Extends Cardiovascular Disease Targets of
Ketone Body Metabolism
Each enzyme involved in ketone body oxidation catalyzes a reversible reaction. Thus, each tissue that
oxidizes ketone bodies has the enzymatic potential to synthesize them.
A. Pseudoketogenesis. Brunengraber and colleagues quantified exchange between isotopically labeled
fatty acids and unlabeled ketone bodies in rat hearts perfused ex vivo (162). Des Rosiers et al.
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subsequently quantified dilution of labeled ketone bodies in hepatectomized dogs in vivo (163). This
isotopic dilution by extrahepatic tissues was termed pseudoketogenesis, which occurs because CoA
transferase and AcAc-CoA thiolase catalyze reversible reactions. While a physiological role for
pseudoketogenesis has yet to be established, the process leads to overestimation of ketone body turnover
in whole-body tracer dilution studies, because its rate is up to one-third of the rate of ketone body uptake
(162).
B. CoA transferase-dependent ketogenesis in extrahepatic tissues. CoA transferase is expressed in all
mammalian cells that harbor mitochondria, except hepatocytes, but not all cell types oxidize ketone
bodies, suggesting that CoA transferase may mediate non-oxidative metabolic functions in certain tissues
or physiological states (74,107,164,165). Because AcAc exits mitochondria via monocarboxylate
transporters, ketogenic flux through thiolase and CoA transferase may permit carbon efflux from
mitochondria independent of citrate synthase, thus generating a monocarboxylate transport system that
complements both citrate-dependent tricarboxylate transport (Fig. 1.3) and acetylcarnitine transport (166).
Such a role for CoA transferase reflects its dual evolutionary history as an enzyme of ketone body
production and utilization (167,168). Ketogenic flux through mitochondrial thiolase and CoA transferase
may be poised to regulate discrete cellular functions directly relevant to metabolic syndrome, diabetes,
and atherosclerosis, because ketone bodies are substrates for cytoplasmic DNL and sterol biosynthesis
[Fig. 1.3 and (8,109-111)]. A series of studies have implicated ketogenic flux through CoA transferase as
a putative mechanism through which ketone bodies act as insulin secretagogues in pancreatic β cells (169172). The authors of these reports demonstrated that ketone bodies and ketone body precursors potentiate
insulin release, possibly by contributing to formation of cytoplasmic short-chain acyl-CoAs
(169,171,172), and that diminished CoA transferase expression correlated with impaired glucose
stimulated insulin secretion in a rat insulinoma cell line (170). Future experiments will be required to
determine the biological roles of ketogenic flux in cell types not classically associated with lipogenesis,
including β cells of the pancreas and cardiomyocytes.
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An additional non-oxidative role for CoA transferase may emerge in macrophages, which exhibit
robust CoA transferase enzymatic activity, but do not terminally oxidize ketone bodies (173,174). Recent
discoveries have highlighted the importance of macrophage metabolism in cardiovascular disease
[reviewed in (175)]. As macrophage-specific deficiency of the enzyme required for DNL, fatty acid
synthase (FAS), ameliorates diet-induced atherosclerosis in mice (176), it is intriguing to consider that
anabolic procession of metabolites through mitochondrial thiolase and CoA transferase acts upstream of
FAS to contribute to macrophage DNL flux. CoA transferase is also abundantly expressed in adipose
tissue, in which the enzyme that catalyzes the reaction downstream from CoA transferase, AACS (Fig.
1.3), is dynamically regulated by PPARγ, a key mediator of adipogenesis and adipocyte function
(113,177,178). Adipocyte-specific FAS deficiency increases baseline energy expenditure and improves
diet-induced obesity in mice (179). Because ketone bodies have been proposed as quantitatively
significant DNL substrates in multiple cell types (8,180), these recent findings suggest that use of genetic
models is warranted to draw mechanistic and cardiovascular disease-relevant links among CoA
transferase, lipogenesis from ketone bodies, and metabolic and vascular diseases.

VI. Signaling Roles for Ketone Bodies
Because serum ketone body concentrations vary over a large dynamic range, they may act as
physiologically relevant signals for cell-surface and intracellular receptors. In fact, D-βOHB is an
endogenous ligand for a niacin receptor, G protein-coupled receptor 109A (GPR109A), with an EC50 of
770 mM (181). Like niacin, D-βOHB can inhibit adipose tissue lipolysis, which has been proposed to
create a negative feedback loop in which ketosis curtails ketogenesis by limiting delivery of non-esterified
fatty acids to the liver (182,183). GPR109A signaling also promotes reverse cholesterol transport in
macrophages (184). It is unknown if D-βOHB plays a role in this cascade.
βOHB signaling may also influence cardiovascular biology through additional G protein-Coupled
Receptors (GPCRs). A recent study in mice revealed that βOHB decreases sympathetic outflow and
reduces heart rate and total energy expenditure by antagonizing (through an unknown mechanism)
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GPR41, a Gi/o-coupled receptor for short chain fatty acids (SCFAs, e.g., acetate, propionate, and butyrate)
that is abundantly expressed in sympathetic ganglia (185). Thus, evidence implicating ketone bodies as
signaling molecules further supports roles for ketone bodies that transcend energy metabolism, indicating
that additional experimentation is required to elucidate the receptors and mechanisms through which
ketone bodies serve as extracellular signals.
Recently published findings also demonstrated that D-βOHB inhibits Class I histone deacetylases
(HDACs), resulting in increased histone acetylation, and thus, increased expression of genes encoding
mediators of resistance to oxidative stress (186). The molecular effects of D-βOHB were observed at high
IC50 concentrations (2.4 – 5.3 mM, depending on the HDAC isoform), and were recapitulated by caloric
restriction, fasting, or AcAc. To determine if these effects were dependent on D-βOHB metabolism, small
interfering RNAs (siRNAs) against BDH1/2 were transfected into cells, which were then treated with DβOHB. The authors observed that, up to 3 mM D-βOHB, the effects on histone acetylation were
preserved, leading to the conclusion that most of the influence of D-βOHB on HDAC function was
independent of D-βOHB metabolism. However, residual BDH persisted in the siRNA-transfected cells,
and the control experiment confirming diminished D-βOHB oxidation in BDH ‘knockdown’ cells was not
performed. Thus, it remains plausible that oxidation of D-βOHB to AcAc by BDH1 could alter
mitochondrial redox potential, and that CoA transferase-dependent contribution of AcAc to the TCA
cycle for terminal oxidation could alter cellular energy metabolism (see Section II.B.1 and Fig. 1.5), each
of which may contribute to the observed effects on histone acetylation. Nonetheless, these observations
reveal exciting roles for ketone body metabolism in a multitude of disease states, which will benefit from
the development and application of both pharmacological and genetic tools.

VII. Ketone Body Metabolism, the Microbiota, and Cardiovascular Biology and Disease
A therapeutically tractable interface between ketone body metabolism and cardiovascular disease is
offered through the dynamic community of microorganisms living on our cutaneous and mucosal surfaces
– the microbiota. This ecosystem of ~100 trillion cells – 10 times the total number of our own cells –
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comprises a ~1 kg ‘organ’ that harbors a massive aggregate of genomes (the microbiome) encoding
millions of genes – 100 times that of the human genome – that influence the human metabolome and
coordinate immune function [recently reviewed in (187-195)]. The data supporting causal links between
the microbiota and host cardiovascular disease, in both rodent models and humans, are compelling. Gut
microbial ecology undergoes marked transformation in obese and type 2 diabetic humans and rodents,
and the dynamic energy-harvesting capacity of the gut microbial community plays a significant
contributing role to energy homeostasis in the host (196-209). Acting in synergy, the host’s genome and
microbiome coordinate ‘supraorganismal’ metabolic processes, creating a suite of co-metabolites that
influence a panoply of pathophysiological processes including nonalcoholic fatty liver disease (NAFLD),
hypertension, insulin resistance, and atherosclerosis (210-213). Furthermore, the ability of indigenous
microbial communities to coordinate the functions of the host’s immune system is likely a key influence
over the development of cardiovascular disease [reviewed in (189)], including the development of type 1
diabetes (214). Together, comparative genomics, metabolomics, and gnotobiotic studies (Greek roots:
gnosis, knowledge; bios, life; a technology that allows cultivation of experimental animal models in the
presence of defined microbial communities) may usher an era that ultimately allows caregivers to
administer individualized forms of therapy that configure the microbiota using probiotics and prebiotics
to ameliorate cardiovascular disease.
Studies of gnotobiotic animals have revealed intriguing relationships among the microbiota,
ketone bodies, and cardiovascular biology. Normalized to tibial length or body weight, hearts of germ free
mice, which are born and raised in sterile gnotobiotic isolators, are ~15% smaller than those of normallycolonized mice, but myocardial mass increases within two weeks of microbial colonization (126). In vivo
and ex vivo functional parameters of hearts of germ free mice are normal, but myocardial glucose
oxidation rates are higher. A systematic assessment of substrate delivery and metabolism in germ free
mice revealed that while circulating ketone body concentrations were not significantly different under fed
conditions, ketosis was blunted during nutrient deprivation in germ free mice, due to diminished hepatic
ketogenesis (126). While reduced adiposity of germ free mice (205) is a likely contributor to blunted
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ketogenesis during fasting, hepatic ketogenic machinery, including expression of Hmgcs2, was curtailed
in fasting germ free mice. The reduction in cardiac size and alterations of systemic and myocardial
metabolism were abrogated when germ free mice were maintained on a ketogenic diet (126). It is also
intriguing to consider the aforementioned cross-talk between SCFAs and ketone bodies [(185); see
Section VI]. SCFAs are produced through the fermentative actions of glycan-digesting enzymes
uniquely-encoded by the microbiome, contributing to the host’s energy harvest and to signaling through
GPR41 (185,215). Thus, the microbiome may supervise an expansive and integrated network in which
ketone bodies influence cardiac metabolism, size, and physiology. Future studies using geneticallymodified gnotobiotic animals will permit further construction of the relationship between ketone
metabolism and the microbiome in diseases of the heart and vasculature.

VIII. Diagnostic and Therapeutic Targets of Ketone Body Metabolism
The diversity of metabolic and signaling processes in which ketone body metabolism participates
provides a range of diagnostic and therapeutic applications, only a subset of which is under active
investigation.
A. Abnormalities of Ketone Body Oxidation. CoA transferase deficient humans typically present early in
life with severe ketoacidosis that can result in vomiting, coma, and death if intravenous glucose and
insulin therapy is not rapidly instituted (79,97,98). Neonatal mice with complete loss of terminal ketone
body oxidation (SCOT-KO mice) invariably die within the first 48 hr of life in a manner that mimics
human sudden infant death syndrome (SIDS) (78). Furthermore, a recent observational study that
performed metabolic autopsies on 255 SIDS patients found that three exhibited underlying disorders of
ketone body metabolism (216). Therefore, a small subset of cases that ultimately receive a diagnosis of
SIDS may actually be attributable to latent abnormalities of CoA transferase function. However,
statewide neonatal screening protocols in the United States do not currently detect newborns with isolated
disorders of ketone body oxidation, who exhibit hyperketonemia, but generally normal organic acid and
acylcarnitine profiles (99). Improved screening methods, measuring both AcAc and D-βOHB, may detect
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patients with latent deficiency of ketone body oxidation, further reduce SIDS incidence, and predict
metabolic complications which may manifest later in life.
B. Dietary Therapies: Ketogenic Diets, Ketone Esters, and Odd-Chain Fatty Acids. Ketogenic diets are
actively used for weight loss and anticonvulsant therapy, and are intensively studied as potential
adjunctive therapy for brain cancers and neurodegenerative diseases including Parkinson’s and
Alzheimer’s diseases (217-221). Additionally, limited studies raise the possibility that humans with
NAFLD could benefit from low carbohydrate diet therapy (222,223). An experimental ketogenic diet has
been used to mitigate a mitochondrial cardiomyopathy in mice (152). The full scope of cardiovascular
diseases responsive to nutritional and/or pharmacological manipulation of ketone body metabolism, and
the associated metabolic mechanisms remain underexplored.
Ketogenic diets are often unpalatable, which leads to poor patient compliance. Additionally, such
diets raise blood cholesterol and free fatty acids, and increase the risk of nephrolithiasis and cause
constipation (224-226). Therefore, Veech and Clarke developed and tested ingestible ketone ester
compounds, which can rapidly generate ketoses exceeding 5 mM in rats and humans (227-229), while
sparing the adverse consequences of high fat diets. A small preliminary study indicates that oral ketone
esters are safe in humans (227). Rodents fed these compounds acutely decrease food intake. Although
these animals do not exhibit changes in body weight over an extended time period, they do become more
insulin sensitive, possibly due to increased expression of uncoupling proteins in brain and brown adipose
tissue (228,229). Further studies will evaluate the efficacy of these compounds in the mitigation and
prevention of metabolic, myocardial, and neurological diseases in rodent and human subjects.
In the last decade, studies analyzing the beneficial roles of the anaplerotic five-carbon (C5)ketone bodies and their precursor odd-chain fatty acids for the treatment of long chain fatty acid oxidation
(LCFAO) disorders have emerged (230,231). Conventional management of LCFAO disorders consists of
dietary therapy with the medium-chain fatty acid octanoate. Substitution of octanoate for the odd-chain
fatty acid heptanoate (given as the triglyceride triheptanoin) further improves clinical outcomes,
specifically by reducing the incidence of rhabdomyolysis and cardiomyopathy (230,231). While only
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trace levels of C5 ketone bodies are normally found in human body fluids (232,233), ingestion of odd
chain fatty acids promotes hepatic C5-ketogenesis: β-oxidation of odd chain fatty acids yields propionylCoA, an anaplerotic substrate, which, in the liver, can also be packaged into C5 ketone bodies (234).
Oxidation of C5-ketone bodies in peripheral tissues occurs through CoA transferase (235), regenerating
propionyl-CoA. However, as oxidation of heptanoate within myocytes locally generates anaplerotic
propionyl-CoA, direct evidence linking C5-ketone body metabolism to improved clinical outcome in
LCFAO disorders currently remains lacking. Thus, it may be useful to cross experimental models of
tissue-specific CoA transferase deficiency to existing models of LCFAO defects (108,236) to establish
the metabolic roles of C5-ketone body metabolism in myocyte oxidation. Future studies of the role of
these three approaches: low carbohydrate ketogenic diets, ketone ester-containing diets, or anaplerotic
odd-chain fatty acid-containing diets in cardiomyopathy remain to be systematically performed, but are
warranted (135,237).
C. Modifying Ketone Body Enzymatic Pathways: Targeting HMGCS2 and CoA transferase. As both
nutrients and hormonal factors affect ketogenic regulation, it is not surprising that ketone body
metabolism is dynamically regulated in mouse models of diet-induced obesity and in humans with
metabolic syndrome. Hepatic ketogenesis becomes suppressed at later stages of the evolution of
hyperinsulinemic obesity (12,42,238-240). Because transgene mediated Hmgcs2 overexpression within
hepatocytes enhances ketogenesis and simultaneously diminishes circulating free fatty acid concentrations
in vivo (241), regulation of HMGCS2 activity (Section II.A.2) becomes a prospective therapeutic target.
Diversion of hepatic fatty acyl chains into ketone bodies could diminish carbon that would otherwise
require terminal oxidation, storage, or packaging into lipoproteins for secretion, prospectively mitigating
hepatic steatosis and insulin resistance.
Whole-body ketone body turnover is non-invasively quantifiable in humans, as is tissue-level
oxidative flux of ketone bodies via positron emission tomography using 11C-labeled ketone body tracers,
which have been used for studies in brain, but not yet in other organs (242,243). Additionally, ketone
body metabolism and the mitochondrial enzyme CoA transferase are amenable to a number of nutritional,
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and perhaps ultimately, pharmacological therapies. Importantly, as described above, myocardial CoA
transferase activity plays an important role in the regulation of substrate selection, mitochondrial ROS
generation, and cardiac work and bioenergetic efficiency (Fig. 1.5). Therefore, analysis of animal models
with sophisticated genetic manipulations of ketone body metabolism, coupled with pharmacological
targeting strategies may provide rationale for a suite of translational and clinical studies that validate
ketone body metabolism as a myocardial therapeutic target. Additionally, CoA transferase and AACS
activities may ultimately serve as therapeutic targets in contexts in which the ketone body-lipogenic
pathways play significant roles, particularly within adipocytes, hepatocytes, and macrophages.

IX. Conclusions
Ketone body metabolism maintains bioenergetic homeostasis when dietary carbohydrates are limiting.
Defects in either the synthetic or oxidative arms of ketone body metabolism result in disease pathogenesis
in humans, and ketone body oxidation is required for maintenance of glycemia and survival in neonatal
mice. Ketone bodies regulate mitochondrial metabolism, energetics, and ROS production via their
oxidation, and may therefore have significant signaling roles within cardiomyocytes. Ketogenic flux
through CoA transferase channels ketone bodies to lipogenesis, which could regulate signaling processes
in many cell types, including macrophages, adipocytes and pancreatic β cells, which express CoA
transferase abundantly, but may have relatively diminished need to harvest energy from ketone bodies.
Therefore, the metabolism of ketone bodies may influence numerous human disease states relevant to
cardiovascular disease, including obesity, diabetes, atherosclerosis, and heart failure. Because both CoA
transferase and HMGCS2 experience multi-tiered regulation, these enzymes may be tractable to
pharmacological manipulation. Before these ends are achieved, the scope of viable therapeutic targets of
ketone body metabolism must first be developed. Integrative experiments in both animal models and
humans that exploit the convergence of sophisticated genetic approaches, quantitative substrate fatemapping (‘fluxomics’), metabolomic profiling, physiological studies, and quantification of mitochondrial
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function are needed to elucidate the mechanisms through which ketone body metabolism influences
cardiovascular pathophysiological processes.

Figure Legends
Fig. 1.1. Ketone body metabolism pathways. (A) Ketogenesis within hepatic mitochondria is the
primary source of circulating ketone bodies. (B) The primary metabolic fate of ketone bodies is terminal
oxidation within mitochondria of extrahepatic tissues via CoA transferase (SCOT). Substrate competition
with pyruvate-derived and fatty acyl-CoA-derived (the corkscrew arrows represent the activities of the βoxidation spiral) acetyl-CoA are shown.

(C) Cytoplasmic DNL and cholesterol synthesis are non-

oxidative metabolic fates of ketone bodies. For simplicity of panel C, only acetoacetate (AcAc) is
depicted, although β-hydroxybutyrate (βOHB) is also a substrate for lipogenesis after it has been oxidized
to AcAc via mitochondrial βOHB dehydrogenase (BDH1). Additional abbreviations: AACS, acetoacetylCoA synthetase; ACC, acetyl-CoA carboxylase; AcAc-CoA, acetoacetyl-CoA; ATP, adenosine
triphosphate;

CoA-SH,

free

coenzyme

A;

FAS,

fatty

acid

synthase;

HMG-CoA,

3-

hydroxymethylglutaryl-CoA; HMGCL, HMG-CoA lyase; HMGCS1, cytoplasmic HMG-CoA synthase;
HMGCS2, mitochondrial HMG-CoA synthase; HMGCR, HMG-CoA reductase; NAD+(H), nicotinamide
adenine dinucleotide oxidized (reduced); PDH, pyruvate dehydrogenase; SCOT, succinyl-CoA:3oxoacid-CoA transferase; TCA, tricarboxylic acid; mThiolase, mitochondrial thiolase; cThiolase,
cytoplasmic thiolase. Thiolase activity is encoded by at least six genes: ACAA1, ACAA2 (encoding an
enzyme known as T1 or CT), ACAT1 (encoding T2), ACAT2, HADHA, and HADHB.

Fig. 1.2. Hepatic integration of ketogenesis. Integration of hepatic ketogenesis with hepatic TCA cycle,
DNL, and pyruvate cycling/glucose metabolism. FAO, β-oxidation of fatty acids; GDH, glutamate
dehydrogenase; OAA, oxaloacetate; ME, malic enzyme; PEPCK, phosphenolpyruvate carboxykinase;
PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; PK, pyruvate kinase; PEP, phosphenol
pyruvate; CS, citrate synthase; DNL, de novo lipogenesis.
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Fig. 1.3. Ketogenic flux through CoA transferase. Because CoA transferase catalyzes an equilibrium
reaction, select spatiotemporal metabolic conditions may favor channeling of mitochondrial acetyl-CoA
to AcAc, generating a monocarboxylate shuttle that complements the citrate-dependent tricarboxylate
shuttle and permits mitochondrial efflux of β-oxidation-derived acetyl-CoA independent of the TCA
cycle. ACLY, ATP-citrate lyase.

Fig. 1.4. Regulatory mechanisms for HMGCS2 and CoA transferase (SCOT). (A) HMGCS2 and (B)
SCOT both undergo transcriptional (red) and post-translational modes of regulation (blue). Some
regulatory factors exhibit both classes of effects (violet). mTORC1, mammalian target of rapamycin
complex 1; PPARα, peroxisome proliferator activated receptor-α; PTM; post-translational modification;
SIRT3, sirtuin (silent mating type information regulation 2 homolog) 3.

Fig. 1.5. Diverse roles of CoA transferase in mitochondrial function. βOHB and AcAc cross the
plasma membrane via SLC16A family members, and may employ these or other transporters to enter the
mitochondrial matrix. Within the mitochondria, D-βOHB is oxidized to AcAc by the inner-membrane
bound and phosphatidylcholine-dependent BDH1. CoA transferase (SCOT) catalyzes a near equilibrium
reaction through which coenzyme A is exchanged between succinate and AcAc. Oxidation of ketone
bodies occurs by mass action, and may diminish reactive oxygen species (ROS) formation, compared to
oxidation of fatty acids. See text for details. ADP, adenosine diphosphate; ANT, adenine nucleotide
transporter; CPT, carnitine palmitoyltransferase; Cyt C, cytochrome C; e-, electron; H+, hydrogen ion; I,
II, II, IV, complexes I-IV of the electron transport chain; IMM, inner mitochondrial membrane; OMM,
outer mitochondrial membrane; Q, ubiquinone; ψm, electrochemical potential across the inner
mitochondrial membrane; SLC, solute ligand carrier protein; Tr, translocase; UCPs, uncoupling proteins.
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Chapter 2
Obligate role for ketone body oxidation in neonatal metabolic homeostasis
The work presented in this chapter has been adapted from:
Cotter, D. G., d'Avignon, D. A., Wentz, A. E., Weber, M. L., and Crawford, P. A. (2011) J Biol Chem
286(9), 6902-6910
Abstract
To compensate for the energetic deficit elicited by reduced carbohydrate intake, mammals convert energy
stored in ketone bodies to high-energy phosphates. Ketone bodies provide fuel particularly to brain, heart,
and skeletal muscle in states that include starvation, adherence to low carbohydrate diets, and the neonatal
period. Here, we use novel Oxct1-/- mice, which lack the ketolytic enzyme succinyl-CoA:3-oxo-acid CoAtransferase (SCOT), to demonstrate that ketone body oxidation is required for postnatal survival in mice.
Although Oxct1-/- mice exhibit normal prenatal development, all develop ketoacidosis, hypoglycemia, and
reduced plasma lactate concentrations within the first 48 h of birth. In vivo oxidation of

13

C-labeled β-

hydroxybutyrate in neonatal Oxct1-/- mice, measured using NMR, reveals intact oxidation to acetoacetate
but no contribution of ketone bodies to the tricarboxylic acid cycle. Accumulation of acetoacetate yields a
markedly reduced β-hydroxybutyrate:acetoacetate ratio of 1:3, compared with 3:1 in Oxct1+ littermates.
Frequent exogenous glucose administration to actively suckling Oxct1-/- mice delayed, but could not
prevent, lethality. Brains of newborn SCOT-deficient mice demonstrate evidence of adaptive energy
acquisition, with increased phosphorylation of AMP-activated protein kinase α, increased autophagy, and
2.4- fold increased in vivo oxidative metabolism of [13C]glucose. Furthermore, [13C]lactate oxidation is
increased 1.7-fold in skeletal muscle of Oxct1-/- mice but not in brain. These results indicate the critical
metabolic roles of ketone bodies in neonatal metabolism and suggest that distinct tissues exhibit specific
metabolic responses to loss of ketone body oxidation.
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Introduction
Transition from the intrauterine to the extrauterine environment incurs a marked shift in nutrient delivery
and energy metabolism. A continuous pipeline replete with glucose and lactate, but calorically reduced in
lipid, is replaced by a reduced carbohydrate, high fat milk diet that is cyclically interrupted by periods of
nutrient deprivation (20,71,244). High energy-requiring organs like heart and skeletal muscle are poised
to meet the energetic demands of this new nutrient environment because they are endowed with
enzymatic machinery that avidly generates high energy phosphates from oxidative metabolism of fatty
acids and lactate (245). Unlike cardiomyocytes and skeletal myocytes, most neurons oxidize fatty acids
poorly and therefore remain dependent on hepatic gluconeogenesis to support energetic needs
(69,70,246,247). However, because newborn brain comprises 10% of body weight and requires up to 60%
of total body energy expenditure, maintenance of energetic homeostasis in the nervous system requires
allocation of multiple fuels for metabolic homeostasis in the neonatal period. The rate of ketone body
extraction by human neonatal brain is up to 40-fold higher than adult brain. Furthermore, ketones
contribute uniquely to maturation within the nervous system (2,4,9,20,71,76,82,244,248-250).
Most ketogenesis occurs in the liver and is driven primarily by rates of fatty acid oxidation.
Mitochondrial fatty acid oxidation-derived acetoacetyl-CoA (AcAc-CoA) and acetyl-CoA together serve
as the primary ketogenic substrates. Ketogenic reactions are sequentially catalyzed by HMG-CoA
synthase 2 and HMG-CoA lyase, generating acetoacetate (AcAc), which is converted to D-βhydroxybutyrate (βOHB) in an NAD+/NADH-coupled redox reaction catalyzed by βOHB dehydrogenase.
AcAc and βOHB diffuse into the bloodstream and are delivered to ketolytic organs, in which they are
exceptionally energy-efficient substrates (5,39,76,95,96,251,252). Within mitochondria of ketolytic
organs, βOHB is oxidized back to AcAc in a reaction catalyzed by βOHB dehydrogenase. AcAc receives
a CoA moiety from succinyl-CoA, generating AcAc-CoA in a reaction catalyzed by succinyl-CoA:3-oxoacid CoA-transferase (SCOT, EC 2.8.3.5), encoded by nuclear Oxct1. This enzyme is not expressed in
liver (76,164). Mitochondrial AcAc-CoA thiolase catalyzes conversion of AcAc-CoA to acetyl-CoA,
which is terminally oxidized within the tricarboxylic acid cycle.
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Reports of ~20 individuals who harbor homozygous or compoundheterozygous OXCT1 loss-offunction mutations (Online Mendelian Inheritance in Man 245050) indicate that afunctional allele is
required for ketone body oxidation, and as such patients typically present in infancy with spontaneous
ketoacidosis (79-81,98,100,148,149,253). Numerous single-nucleotide polymorphisms have been
identified within the human OXCT1 locus, but functional significance has been ascribed to relatively few
of them.
Adverse consequences of ketoacidosis are well appreciated, and physiological states that increase
ketone body turnover have been extensively analyzed. Nonetheless, experimental models to date have not
definitively revealed whether loss of ketone oxidation can be energetically tolerated, particularly at the
tissue level, and the metabolic adaptations to ketolytic insufficiency are unknown. In this study, we use
novel Oxct1-/- mice to examine the metabolic roles of ketone body oxidation in the neonatal period and the
adaptations to its absence.

Experimental Procedures
Animals— Oxct1-/- C57BL/6 mouse embryonic stem (ES) cells (clone EPD0082-1-CO2) were acquired
through the National Institutes of Health knock-out mouse project (KOMP) consortium. The targeting
sequence inserts two transcriptional terminators (pA) within intron 5 of the Oxct1 locus, which is
upstream from sequence that encodes critical catalytic SCOT residues (Fig. 2.1A) (254,255). Genotyping
was performed using primer sets schematized in Fig. 1A and listed in supplemental Table S2.1. ES cells
were microinjected into embryonic day 3.5 (E3.5) C57BL/6 blastocysts, and four chimeric mice
(determined by tail biopsy PCR) were obtained. Transmission of the targeted allele was achieved by
breeding chimeric males to C57BL/6 wild-type females. Heterozygote (Oxct1+/-) progeny were then
crossed to generate Oxct1-/- mice. All mice were maintained on standard polysaccharide-rich chow diet
(Lab Diet 5053) and autoclaved water ad libitum. Lights were off between 1800 and 0600. All P0 litters
were obtained at 0900, and tissues/blood were harvested mid-morning. All experiments were performed
using protocols approved by the Animal Studies Committee at Washington University.
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Plasma Metabolite and Insulin Measurement— Measurements of plasma glucose, AcAc, βOHB, free
fatty acids, and triglycerides were performed using biochemical assays coupled to colorimetric substrates
(Wako), as described previously (51). Plasma lactate was measured using a colorimetric assay
(BioVision). Blood glucose was measured in duplicate using a glucometer (Aviva). Measurement of
plasma insulin was performed by ELISA (Millipore) as described previously (51).
Gene Expression Analysis— Quantification of gene expression was performed using real-time RTquantitative PCR using the ΔΔCt approach as described, normalizing to Rpl32, using primer sequences
listed within supplemental Table S2.1 (51).
Immunoblotting—

Immunoblots,

using

protein

lysates

from

neonatal

brain,

heart,

and

quadriceps/hamstring muscles to detect Oxct1/SCOT (rabbit anti-SCOT; Proteintech Group) were
performed as described (51). Detection of phospho-AMPKα (p-AMPKα Thr-172) and total AMPKα was
performed as described previously (126). Microtubule-associated protein 1 light chain 3 (LC3) was
detected using rabbit polyclonal anti-LC3 (NB100-2220; Novus Biologicals) and donkey anti-rabbit IgG
conjugated to horseradish peroxidase (NA9340; GE Healthcare). Band intensities were quantified
densitometrically using QuantityOne software (Bio-Rad).
Measurement of in Vivo Substrate Utilization— P0 mice were injected intraperitoneally with 10 µmol of
sodium [2,4- 13C2]βOHB, [1-13C]glucose, or sodium [3-13C]lactate (Cambridge Isotope Laboratories) per
g of body weight. Because P1 Oxct1-/- mice are hypoglycemic and hypolactatemic, 13C-isotope injections
were supplemented in these animals with either 20µmol/g naturally occurring glucose, for [1-13C]glucose
studies, or 10 µmol/g naturally occurring lactate, for [3-13C]lactate studies, to ensure tissue delivery of
total and

13

C-labeled substrate would remain equal among genotypes. After the indicated incubation

durations in minutes, neonatal mice were killed by decapitation, and tissues were rapidly freeze-clamped
in liquid N2. Neutralized perchloric acid extracts were profiled using gradient heteronuclear singlequantum correlation 13Cedited proton NMR measured at 11.75 T. Quantification of integrals of carbon 2
of [13C]taurine (a normalizing metabolite whose tissue concentrations were constant across conditions and
which is not enriched by administration of these substrates) and [13C]glutamate (carbon 4) was performed
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as described previously (51). Signals were collected from extracts dissolved in 300 µl of D2O + 1 mM
trimethylsilyl propionate, loaded into high precision, thin walled 5-mm tubes (Shigemi).
Statistical Analyses—Analyses were performed usingGraphPad software (Prism), using tests described
under “Results.”

Results
Ketolytic Deficiency in Oxct1-/- Mice—To determine the energetic role of ketone bodies in the neonatal
period, Oxct1-/- mice were generated on the C57BL/6 genetic background (Fig. 2.1, A and B).
Genotyping analysis of Oxct+/- X Oxct1+/- live progeny from 12 litters examined on postnatal days 0–1
(P0–P1) indicated that progeny are born in a Mendelian ratio: 19 +/+, 40 +/-, and 25 -/- mice (χ2 = 0.5, p
= 0.78). Body weights among +/+, +/-, and -/- mice did not vary on P0 or P1; gastric milk spots were
observed with equal frequency within each genotype; and no gross anatomic or behavioral abnormalities
were observed in P0–P1 Oxct1-/- mice (Table 1). As expected, Oxct1 mRNA and SCOT protein were
reduced ~50% in P0 Oxct1+/- mice and were absent in Oxct1-/- mice (Fig. 2.1, C and D). Independent
measurements of plasma biochemical metabolites on P0 and P1 revealed marked and progressive
hyperketonemia in Oxct1-/- mice, with total ketone body concentrations increasing to ~16mM in Oxct1-/mice on P1, consistent with accumulation of unmetabolized substrate (Table 2.1). An abnormally
increased ratio of AcAc to βOHB is also consistent with a ketolytic lesion at the reaction catalyzed by
SCOT: ligation of a CoA moiety to AcAc. Measurement of in vivo metabolism of [13C]βOHB in skeletal
muscle of P0 Oxct1-/- mice, using

13

C-edited proton NMR of extracts acquired 30 min after labeled

substrate administration, confirmed the absence of

13

C-enriched glutamate, a quantitative surrogate for

procession of carbon through the tricarboxylic acid cycle, and accumulation of [13C]acetone and
[13C]AcAc, products of [13C]βOHB that remain unmetabolized due to the absence of SCOT (Fig. 2.1E)
(51,136). These findings were corroborated in P1 skeletal muscle and in P0 and P1 brain (supplemental
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Fig. S2.1). Taken together, these results indicate that (i) Oxct1-/- mice are ketolysis-deficient and (ii)
ketone body oxidation in mice does not notably proceed through SCOT-independent pathways.
Ketoacidosis, Hypoglycemia, and Neonatal Lethality of Oxct1-/-Mice— Unlike P0–P1 progeny of Oxct+/X Oxct1+/- pairings, genotyping analysis of live progeny from 14 litters between P2 and P10 yielded 34
+/+, 50 +/-, and zero -/-mice (χ2 = 24.7, p = 0.0001). No lethality phenotype was evident in heterozygotes
(χ2 = 0.92, p = 0.34). In addition to hyperketonemia, hypoglycemia and reduced plasma lactate
concentrations were also observed in P1, but not P0 Oxct1-/- animals. Significant differences in plasma
insulin, free fatty acid, and triglyceride concentrations were not observed (Table 2.1). In particular, the
rise in plasma free fatty acid concentrations that occurs after birth in association with suckling of high fat
milk was preserved in P1 Oxct1-/- mice(256,257).
Although P1 Oxct1-/- mice exhibit marked hyperketonemia, relatively reduced plasma glucose and
plasma lactate concentrations indicate that ketolytic insufficiency also results in diminution of other
circulating metabolic fuels. To determine whether suckling Oxct1-/- mice could be rescued from these
Metabolic abnormalities and prospective energetic deficiency, we performed metabolic resuscitation
experiments using newborn progeny of Oxct+/- X Oxct1+/- mice. Serial subcutaneous injections of 155 mM
NaHCO3 ± 10% glucose were delivered to suckling neonates (50 µl every 3–6 h; seven injections were
administered/24 hr period). Although NaHCO3 partially buffers the acidifying effects of ketone bodies,
glucose provides an additional energetic substrate that stimulates insulin release, thereby inhibiting
ketogenesis and prospectively curtailing ketoacidosis in suckling Oxct1-/- mice (12,258). As expected,
survival analysis revealed that control suckling Oxct1-/- mice injected with 155mM NaHCO3 alone
exhibited similar survival and weight course as uninjected suckling Oxct1-/- animals, indicating that partial
buffering of the acidifying effects of ketone bodies had no impact on survival (Fig. 2.2, n = 20
pups/group). On the other hand, serial administration of NaHCO3 + glucose markedly improved the
survival and weight trajectory of suckling Oxct1-/- mice in the first 48 h of life. However, by P3, Oxct1-/animals maintained on the NaHCO3 + glucose regimen had fallen off a normal growth curve, and all
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gradually died over an additional 2–3 days. No significant effects of the NaHCO3 + glucose, or NaHCO3
alone regimens were observed in Oxct1+/+ or Oxct1+/- animals.
To determine whether the failure-to-thrive phenotype observed within NaHCO3 + glucoseresuscitated Oxct1-/- animals was attributable to an insufficiency of glucose uptake, plasma glucose
concentrations were measured in resuscitated animals 30 and 180 min after NaHCO3 + glucose
administrations in P2 Oxct1+/+, Oxct1+/-, and Oxct1-/- mice. In addition, because SCOT-dependent ketone
body metabolism within pancreatic β cells may influence glucose-stimulated insulin secretion, we also
measured plasma insulin 30 min after NaHCO3 + glucose administration in these mice (169,170). Our
results indicate that postinjection glucose disposal and plasma insulin concentrations were not reduced in
Oxct1-/- mice (Fig. 2.3, A and B). However, despite treatment with the resuscitation regimen, suckling
Oxct1-/- mice still developed marked hyperketonemia (Fig. 2.3C). These results indicate that although
systemic glucose uptake is intact in Oxct1-/- mice, the lethal metabolic consequences of ketolytic
insufficiency in suckling mice are refractory to frequent glucose administration.
Metabolic Adaptations of Oxct1-/- Mice— To determine whether the development of hypoglycemia and
reduced plasma lactate concentrations result from metabolic adaptations to the loss of ketolytic capacity,
we performed a series of experiments in neonatal Oxct1-/- mice and their littermates. First, we measured
the abundance of the phosphorylated (active) form of the energy sensor/effector AMPKα in skeletal
muscle, heart, and brain of untreated P0 Oxct1-/- mice and their P0 Oxct1+/+ littermates. To ensure that
measured responses of Oxct1-/- mice were not downstream consequences of ketoacidosis and
hypoglycemia, P0 mice were harvested within 3 h of birth. Protein lysates from skeletal muscle and heart
of Oxct1-/- mice did not reveal evidence of AMPKα activation, but the phosphorylated form of AMPKα
was augmented 6.9 ± 1.4-fold in brain of Oxct1-/- mice, suggesting tissue-specific adaptation to the
absence of ketolysis (n = 7/group, p = 0.01; Fig. 2.4).
Second, we determined whether autophagy was altered in Oxct1-/- mice. Autophagy is an AMPKactivated self-degradative intracellular process in which organelles are recycled, prospectively in part for
the purpose of energy conservation during periods of nutrient deprivation (259-261). Adaptation to
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extrauterine life requires normal autophagic progression (262). To determine whether ketolytic deficiency
in brain of P0 Oxct1-/- mice is accompanied by induction of autophagy, we measured a key biomarker of
autophagic progression, the differential processing/migration of protein LC3 on SDS-PAGE (263). The
relative abundance of the faster migrating form of LC3 (LC3-II:LC3-I ratio) was increased 2.0 ± 0.2-fold
(n = 7/group, p = 0.001) in brain lysates of Oxct1-/- mice (Fig. 2.5). This result, which was not observed in
skeletal muscle (data not shown), is consistent with a proautophagic response to energy deficiency in
brain of Oxct1-/- mice.
Third, to determine whether ketolytic insufficiency and the associated ultimate development of
reduced plasma glucose and lactate concentrations were linked to increases in glucose and lactate
utilization by tissues that normally oxidize ketones in Oxct1-/- mice, we used NMR to measure in vivo
oxidative metabolism of independently administered [13C]glucose or [13C]lactate in brains and skeletal
muscle of P0 and P1 Oxct1-/- mice and their littermates. Brain extracts obtained from P0 neonates 30 min
after intraperitoneal administration of 10 µmol/g body weight [13C]glucose revealed 2.4 ± 0.2-fold
increased accumulation of 13C-enriched glutamate in brains of Oxct1-/- mice compared with Oxct1+ mice
(from 3.6 ± 0.8% to 8.5 ± 1.7%; n = 7/group, p = 0.002; Fig. 2.6A; no differences were observed
between Oxct1+/+ and Oxct1+/- mice, which are combined and represented as Oxct1+). As expected, at the
time of tissue harvest, tissue

13

C enrichment of glucose (35.3% and 41.3% in Oxct1+and Oxct1-/- mice,

respectively, p = 0.51) and total blood glucose concentrations were also equivalent between groups that
received [13C]glucose, indicating that increased
increased delivery of

13

13

C-enrichment of glutamate could not be explained by

C-substrate. These findings were corroborated in brain extracts of P0 animals

collected 45 min after substrate injection:

13

C-enrichment of glutamate was increased 2.8 ± 0.3-fold in

brains of Oxct1-/- mice (n = 5/group, p = 0.02). Evidence for increased glucose utilization persisted in
brains of Oxct1-/- mice on P1, which exhibited 1.8 ± 0.2-fold greater

13

C-enrichment of glutamate in

Oxct1-/- brains than by brains of Oxct1+ littermates 30 min after substrate administration (n = 7/group, p =
0.02; Fig. 2.6A). Because P1 Oxct1-/- mice are hypoglycemic, this experiment was performed by
administering a mixture of 13C-labeled and naturally occurring glucose (see “Experimental Procedures”),
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which prevented disproportionately high delivery of labeled glucose to brains of Oxct1-/- mice. Taken
together, these results are consistent with a higher rate of glucose oxidation in brains of Oxct1-/- mice on
both P0 and P1, which possibly contributes to the ultimate development of hypoglycemia.
Unlike brain of Oxct1-/- mice, evidence for increased glucose oxidation was not observed in
skeletal muscle, which, after 30 min of [13C]glucose administration, revealed only scant 13C-enrichment of
glutamate in Oxct1+ (1.4 ± 0.2%) or Oxct1-/- mice (1.9 ± 0.3%). After 45 min,

13

C-enrichment of

glutamate increased equally to ~3% in Oxct1+ and Oxct1-/- mice. Similar results were observed in muscle
of P1 mice.
To obtain surrogates of in vivo lactate oxidation in neonatal mice, we measured [13C]glutamate in
brains and skeletal muscles of P0 animals 30 min after administration of 10 µmol/g [13C]lactate. In Oxct1+
and Oxct1-/- mice, 13C labeling of glutamate in brain was greater through [13C]lactate than that delivered
through [13C]glucose. Nonetheless, there was no difference between brains of Oxct1+ and Oxct1-/- mice
(11.1 ± 3.0% and 12.0 ± 3.7%, respectively, n = 5/group, p – 0.84). Conversely,

13

C enrichment of

glutamate from lactate was enhanced in skeletal muscle of P0 Oxct1-/- mice by 1.7 ± 0.2-fold compared
with skeletal muscle of Oxct1-/- mice (7.9 ± 0.8% and 4.5 ± 0.7%, respectively, n = 5/group, p = 0.02; Fig.
2.6B). As expected,

13

C enrichment of substrate was not greater in skeletal muscle of P0 Oxct1-/- mice.

Increased lactate oxidation rates did not persist to P1 in skeletal muscle, which were 5.5 ± 0.4% and 5.0 ±
0.8% in P1 Oxct1+ and Oxct1-/- mice, respectively (n = 5/group, p = 0.6; Fig. 2.6B). Taken together, these
results indicate (i) increased oxidation of lactate in skeletal muscle of P0 but not P1 and Oxct1-/- mice and
(ii) adaptation of both neonatal brain and skeletal muscle to ketolytic insufficiency.

Discussion
Introduction to the extrauterine environment creates new metabolic and energetic demands. Studies of
metabolic flux and ketone turnover have indicated that ketone bodies serve an important role in neonatal
rodents and humans (20,71,244,248,256,257). This is the first study to use a genetic model to demonstrate
that oxidation of ketones is required for postnatal survival in mice. Oxct1-/- mice exhibit no evidence of
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terminal ketone body oxidation and develop ketoacidosis, indicating that the SCOT pathway is required
for ketolysis in mice. Furthermore, plasma glucose and lactate levels become depleted in Oxct1-/- mice
after the first 24 h of extrauterine life. Increased oxidation of glucose and lactate is observed, starting
prior to the depletion of these metabolites in plasma, suggesting that increased consumption, at least in
part, contributes to their depletion.
Although reduced nutrient ingestion could also contribute to ketoacidosis, hypoglycemia, and
hypolactatemia, our results, together with those of prior investigators, strongly suggest that these
abnormalities occur in actively suckling neonatal Oxct1-/- mice. First, because mice and rats (unlike
humans) possess very little white adipose stores at birth, neonatal ketogenesis, robust in Oxct1-/- mice, is
dependent on suckling (256,257,264). Second, plasma free fatty acid concentration, a reporter of milk
intake and a key determinant of ketogenesis, exhibited increases in P1 versus P0 Oxct1-/- mice,
comparable with the increase observed in Oxct1+ littermates. Plasma triglyceride concentrations were also
not reduced in Oxct1-/- mice. Although ingested milk volumes were not formally quantified, Oxct1-/- mice
exhibited gastric milk spots with equal frequency to their littermates on P0 and P1. Thus, these studies
indicate that loss of ketone oxidation in postnatal mice provokes a metabolic state that ultimately proves
lethal, despite access to metabolic fuels through milk.
Reduced plasma glucose and lactate concentrations in P1 Oxct1-/- mice are prospectively
explained by increased oxidation of glucose and lactate, but hypoglycemia and hypolactatemia also may
occur due to insufficient biosynthesis. During the rodent suckling period, biosynthesis of glucose and
lactate are driven by hepatic gluconeogenesis and extrahepatic glycolysis, respectively (20). Altered
mitochondrial redox potential of Oxct1-/- mice could contribute to prospective synthetic deficiencies. In
neonatal Oxct1+ mice, plasma βOHB:AcAc ratio is 3:1, consistent with reported ratios in ketotic states
(2,258). In hyperketonemic Oxct1-/- mice, this ratio is markedly reduced to 1:2 on P0, due to oxidation of
βOHB to, and no further than, AcAc, which significantly alters mitochondrial [NAD+]:[NADH] ratio,
particularly in extrahepatic tissues. Altered mitochondrial redox potential could in turn impair flux
through the malate-aspartate shuttle, whose function is important for glycolysis, the source of lactate. In
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turn, curtailed lactate production deprives the liver of a key gluconeogenic substrate, via the Cori cycle.
Furthermore, in P1 Oxct1-/- mice, plasma concentrations of βOHB and AcAc accumulate to very high
concentrations, while remaining in a ratio of 1:3, which may evoke extrahepatic and hepatic impairments
of the tricarboxylic acid cycle and fatty acid oxidation. Oxidative impairment within liver disrupts
gluconeogenesis (20,265-267). Emergence of attenuated extrahepatic oxidative capacity was evident in
Oxct1-/- mice on P1, when glucose oxidation in brain and lactate oxidation in skeletal muscle were both
reduced in Oxct1-/- mice, relative to P0 Oxct1-/- mice.
An additional abnormality of ketone metabolism may also occur in Oxct1-/- mice. In humans, up
to 37% of AcAc is spontaneously decarboxylated to acetone (268). Therefore, with accumulation of high
concentrations of AcAc, it is likely that acetone also accumulates in normally ketolytic tissues of Oxct1-/mice, a notion supported by our NMR findings. Acetone is disposed through breath and urine, but a
significant proportion of acetone can also be used as a substrate for anabolic and catabolic processes
through SCOT-independent pathways (268). High circulating concentrations of acetone may also cause
central nervous system depression.
It is important to note that the precise roles of neonatal ketone metabolism differ between mice
and humans. Humans are born at a more mature point in development, and as indicated above, at the time
of birth, body fat percentage is higher in humans than in rats and mice (256,264,269-271). In these
neonatal rodents, ketogenesis is driven by suckling, rather than fasting (256,257). Moreover, due to
increased fat/carbohydrate ratio, rodent milk is more ketogenic than most human milk and infant formulas
(9,20). It is likely for these reasons that two features of Oxct1-/- mice are distinct from those of SCOT
deficient humans: (i) autosomal recessive OXCT1 mutations in humans are compatible with life (albeit
with aggressive nutritional support), whereas analysis of ~100 litters of Oxct1+/- X Oxct1+/- pairings has
yet to reveal any male or female Oxct1-/- neonate that spontaneously survives past 48 h of extrauterine life;
and (ii) Oxct1-/- mice develop hypoglycemia, unlike most SCOT-deficient humans. Despite these
differences, deficiencies of ketone metabolism in neonatal mice bear significant relevance to human
infant metabolism. First, physiological ketosis (1-2mM) occurs in the early neonatal period in both
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humans and mice (2,71,244,272,273). Second, human infants are particularly prone to develop
hyperketonemia and thus, increased energetic utilization of ketones, in response to relatively short periods
of nutrient deprivation, due to adipose lipolysis (2,4,20,248,274). Consequences of common viral
illnesses can rapidly trigger ketosis. Third, human milk exhibits significant variations of macronutrient
content distribution, even within the same mother over different collections (275,276). Therefore, it is
plausible that energetic crisis and/or ketoacidosis could emerge in infants with unsuspected ketolytic
insufficiency. Current newborn screening regimens do not detect individuals with isolated ketolytic
disorders, who exhibit ketosis but normal acylcarnitine and organic acid profiles (99). Therefore, a small
subset of cases which ultimately receive a diagnosis of sudden infant death syndrome (SIDS) may
actually be attributable to SCOT deficiency.
Although our studies did not directly measure prospective changes in glycolytic flux or metabolic
shifts within myocardium (the particularly low mass of neonatal mouse heart, ~10 mg, prevented tractable
NMR approaches), these results indicate both toxic effects of and metabolic adaptation to ketolytic
insufficiency in the neonatal period. Future experiments will determine definitively the relative
contributions of ketoacidosis, hypoglycemia, and energy deficiency to lethality of Oxct1-/- mice. Further
measurement of the energetic roles of ketone bodies in mouse models will be best supported through
studies in which (i) a lower fat nonketogenic nutrient formula replaces mother’s milk in the neonatal
period and/or (ii) additional genetic approaches selectively induce a ketolytic defect within individual
tissues. Such studies will ultimately permit determination of energetic and disease-modifying roles of
ketolysis in neonates and adults in conditions that include nutrient deprivation, maintenance on low
carbohydrate diets, and diabetes. Finally, with increasing utilization of low and very low carbohydrate
diets in clinical trials for conditions including adult obesity, pediatric and adult epilepsy, and
malignancies of the central nervous system, it is important to consider the metabolic and clinical
consequences of latent ketolytic defects that are revealed later in life, possibly caused by single nucleotide
polymorphisms within the OXCT1 locus; case reports describe marked variations of tolerance to
ketogenic milieus (277-279). These studies indicate the critical metabolic role that ketone body oxidation
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serves and adaptations to its absence in the reduced carbohydrate nutrient environment of the neonatal
period.

Figure legends
Figure 2.1. Ketolysis-deficient Oxct1-/- mice. A, targeting strategy for the Oxct1 locus in ES cells. WT,
wild-type locus; Null, loss-of-function allele. Arrows indicate locations of genotyping PCR primers. See
supplemental Table S1 for a list of primer sequences. B, PCR genotyping of Oxct1-/- P0 mice. NTC, no
template control. C, expression of Oxct1 mRNA in heart of P0 Oxct1+/+, Oxct1+/-, and Oxct1-/- mice,
determined by RT-quantitative PCR; n = 5/group. D, immunoblot of SCOT and actin using protein
lysates from brain, heart, and quadriceps/hamstrings skeletal muscle of P0 Oxct1+/+, Oxct1+/- , and Oxct1-/mice. E, 13C-edited proton NMR spectrum (2.1–2.5 ppm, relative to chemical shift of trimethylsilyl
propionate internal standard) from quadriceps/hamstrings of P0 Oxct1+/+ and Oxct1-/- mice that had been
injected with [2,4-13C2]βOHB 30 min prior to collection of tissues and generation of extracts.
[13C]Glutamate is a reporter of tricarboxylic acid flux of a 13C-labeled substrate that is selectively absent
in extracts from Oxct1-/- mice. C2 and C4 correspond to carbon position.

Figure 2.2. Metabolic resuscitation of Oxct1-/- mice. A, Kaplan-Meier curves for neonatal mice in the
untreated, treated with 155 mM NaHCO3 alone, or treated with 155 mM NaHCO3 + 10% glucose (glc)
states. Subcutaneous injections were performed every 3–6 h, starting within 3h of birth, with seven
injections over a 24-h period. Oxct1+/+ and Oxct1+/- mice showed no differences and were pooled (noted as
Oxct1+). Within the first 90 h of life, no statistically significant differences were observed among treated
Oxct1+ mice, untreated Oxct1+ mice, and Oxct1-/- mice treated with NaHCO3 + glucose. Likewise, no
statistically significant difference was observed between Oxct1-/- mice treated with NaHCO3 alone and
untreated Oxct1-/- mice. However, addition of glucose to the NaHCO3 regimen significantly improved
survival of Oxct1-/- mice in the first 90 h of life (p < 0.001 by log-rank test, n = 20/group). B, relative
weights of animals within the genotype and treatment groups described in A. ***, p < 0.001 by two-way
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ANOVA with post hoc Bonferroni testing, independently compared with each of the other treatment
groups.

Figure 2.3. Normal glucose disposal but refractory hyperketonemia in glucose-resuscitated suckling
Oxct1-/- mice. A, blood glucose concentrations measured on P2 within neonatal mice treated with the
NaHCO3 + glucose resuscitation regimen every 3–6 h. Measurements were taken independently 30 and
180 min after administration of NaHCO3 + glucose. B, plasma insulin concentrations within resuscitated
mice, 30 min after NaHCO3 + glucose administration. NS, not significant. C, total plasma ketone
concentration ( βOHB + AcAc) within resuscitated mice, 30 min after NaHCO3 + glucose administration.
For all comparisons, Oxct1+/+ and Oxct1-/- mice showed no differences and were pooled (noted as Oxct1+).
n = 7/group; ***, p < 0.001 by Student’s t test.

Figure 2.4. Increased phosphorylation of AMPKα within brain of Oxct1-/- mice. A–C, immunoblots
of lysates from untreated animals: skeletal muscle (A), heart (B), and brain (C) protein lysates from P0
Oxct1+/+ and Oxct1-/- mice for phospho-AMPKα (p-AMPKα), total AMPKα, SCOT, and actin. D,
densitometric quantification of p-AMPKα:AMPKα ratio in brain lysates. **, p < 0.01 by Student’s t test.

Figure 2.5. Enhanced autophagy in brain of Oxct1-/- mice. A, immunoblots of P0 brain protein lysates
for LC3 and actin. B, densitometric quantification of LC3-II:LC3-I ratios in brain lysates. ***, p < 0.001
by Student’s t test.

Figure 2.6. Tissue-specific adaptations to ketolytic insufficiency. A, accumulation of [13C]glutamate
carbon 4 (C4) in brains of P0 (left) and P1 (right) mice injected with [1-13C]glucose, measured by

13

C-

edited proton NMR. n = 7/group. B, accumulation of [13C]glutamate in skeletal muscle of P0 (left) and P1
(right) mice injected with [3-13C]lactate, measured by 13C-edited proton NMR. n = 5/group; **, p < 0.01
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by Student’s t test.

Figure S2.1. Absence of terminal ketone body oxidation in muscle and brain of Oxct1-/- mice. 13Cedited proton NMR spectra (2.1-2.5 ppm, relative to chemical shift of TSP internal standard) from
extracts derived from muscle (A) and brain (B) of P0 (left panels) or P1 (right panels) Oxct1+/+ and Oxct1/-

mice. Animals were injected with 10 µmol/g body weight [2,4-13C2]βOHB 30 min prior to collection of

tissues and generation of extracts. 13C-glutamate (glu; resonances of protons on carbon #4 are shown) is a
reporter of tricarboxylic acid flux of a 13C-labeled substrate that is selectively absent, above naturallyoccurring enrichment (1.1% abundance), in extracts from Oxct1-/- mice.

44

Figure 2.1

45

Figure 2.2

46

Figure 2.3

47

Figure 2.4

48

Figure 2.5

49

Figure 2.6

50

Table 2.1

51

Figure S2.1

52

Table S2.1

53

Chapter 3
Successful adaptation to ketosis by mice with tissue-specific deficiency of ketone body oxidation
The work presented in this chapter has been adapted from:
Cotter, D. G., Schugar, R. C., Wentz, A. E., d'Avignon, D. A., and Crawford, P. A. (2013) Am J Physiol
Endocrinol Metab 304(4), E363-374
Abstract
During states of low carbohydrate intake, mammalian ketone body metabolism transfers energy substrates
originally derived from fatty acyl chains within the liver to extrahepatic organs. We previously
demonstrated that the mitochondrial enzyme CoA transferase (succinyl-CoA:3-oxoacid CoA transferase,
SCOT, encoded by nuclear Oxct1) is required for oxidation of ketone bodies, and that germline SCOTknockout (KO) mice die within 48h of birth due to hyperketonemic hypoglycemia. Here, we use novel
transgenic and tissue-specific SCOT-KO mice to demonstrate that ketone bodies do not serve an obligate
energetic role within highly ketolytic tissues during the ketogenic neonatal period or during starvation in
the adult. While transgene-mediated restoration of myocardial CoA transferase in germline SCOT-KO
mice is insufficient to prevent lethal hyperketonemic hypoglycemia in the neonatal period, mice lacking
CoA transferase selectively within neurons, cardiomyocytes, or skeletal myocytes, are all viable as
neonates. Like germline SCOT-KO neonatal mice, neonatal mice with neuronal CoA transferase
deficiency exhibit increased cerebral glycolysis and glucose oxidation, and while these neonatal mice
exhibit modest hyperketonemia, they do not develop hypoglycemia. As adults, tissue-specific SCOT-KO
mice tolerate starvation, exhibiting only modestly increased hyperketonemia. Finally, metabolic analysis
of adult germline Oxct1+/- mice demonstrates that global diminution of ketone body oxidation yields
hyperketonemia, but hypoglycemia emerges only during a protracted state of low carbohydrate intake.
Together, these data suggest that, at the tissue level, ketone bodies are not a required energy substrate in
the newborn period or during starvation, but rather that integrated ketone body metabolism mediates
adaptation to ketogenic nutrient states.
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Introduction
Adaptation to limited carbohydrate availability and increased fatty acid supply, as encountered during the
initial transition to extrauterine life, starvation, and adherence to low-carbohydrate diets, requires shifts in
metabolic substrate utilization (2,4,5,20). While many organs are poised to meet the bioenergetic
demands imposed by fat-dominated energy economies, neurons do not effectively derive high-energy
phosphates from fatty acids (69,70). Thus, provision of alternate fuel sources may be required to preserve
bioenergetic homeostasis within some tissues when carbohydrates are limiting. Ketone body metabolism
supports this function by oxidizing hepatic fatty acyl-coenzyme A species (acyl-CoAs) to water-soluble
four carbon ketone body intermediates (via ketogenesis) that are shared with extrahepatic tissues for
terminal oxidation. Most ketogenesis occurs within hepatic mitochondria, at rates proportional to βoxidation of fatty acids (5). Sequential ketogenic reactions catalyzed by mitochondrial thiolase,
hydroxymethylglutaryl-CoA synthase (HMGCS2) and hydroxymethylglutaryl-CoA lyase convert acetylCoA to the ketone body acetoacetate (AcAc), which is reduced by mitochondrial D-β-hydroxybutyrate
(βOHB)-dehydrogenase (BDH1) to D-βOHB in an NAD+/NADH-coupled redox reaction (44). D-βOHB
and AcAc are secreted from the liver via monocarboxylate SLC16A transporters, transported into
extrahepatic cells via SLC16A transporters, and oxidized in the mitochondrial matrix (4,26,27).
Mitochondrial BDH1 re-oxidizes D-βOHB to AcAc, and covalent activation of AcAc by CoA is
catalyzed by the mitochondrial matrix enzyme succinyl-CoA:3-oxoacid CoA transferase [SCOT (encoded
by the nuclear gene Oxct1), the only mammalian CoA transferase] to generate AcAc-CoA, which upon
thiolytic cleavage, liberates acetyl-CoA that enters the tricarboxylic acid (TCA) cycle for terminal
oxidation (74). CoA transferase catalyzes a near equilibrium reaction in which CoA is exchanged between
succinate and AcAc (72,280). As such, unlike glucose and fatty acids, ketone bodies do not directly
require commitment of ATP for activation of the substrate prior to oxidation.
Ketone bodies are efficient energetic substrates that are oxidized in proportion to their delivery
(4,20). The neonatal brain extracts ketones at rates up to 40 times those of the adult brain, and ketone
body oxidation can support as much as 25% of the neonate’s basal energy requirements (71,248).
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Neurons oxidize fatty acids poorly, and glucose utilization accounts for only 70% of the postnatal brain’s
energetic needs (69,71). Thus, ketogenesis, which converts up to two-thirds of hepatic β-oxidationderived acetyl-CoA into ketones (281), has been proposed as a facilitator of evolution of the vertebrate
brain and of human brain size (40,41). Nonetheless, an energetic requirement for ketone body oxidation
has never been demonstrated, even though it is thought to become a primary contributor to bioenergetic
homeostasis (2,84). Ketogenesis is also required for normal fitness in humans, as loss-of-function
mutations in the gene encoding the fate-committing hepatic ketogenic enzyme HMGCS2 result in
pediatric hypoketonemic hypoglycemia (66,68), and CoA transferase deficiency in humans manifests as
spontaneous pediatric ketoacidosis (80,81,98), which is associated with hypoglycemia in severe cases,
and may account for a subset of cases of idiopathic ketotic hypoglycemia (79,102). Germline SCOT-KO
mice, which cannot terminally oxidize ketone bodies in any tissue, universally die within 48 hr of birth
due to hyperketonemic hypoglycemia (78). Here we use novel genetic mouse models of gain- and loss-ofCoA transferase function to determine whether ketone body oxidation is required within specific cell
types for metabolic adaptation and survival during the neonatal period and in adult starvation.

Materials and Methods
Animals. Oxct1-/- (germline SCOT-KO) mice were previously generated by using targeted C57BL/6
mouse embryonic stem cells obtained from the NIH-Knockout Mouse Project (clone EPD0082-1-CO2),
which were obtained and injected into C57BL/6 blastocysts in house (78). Transgenic mice that
overexpress CoA transferase in cardiomyocytes (SCOT-Heart-OVEX mice) were generated on the
C57BL/6 background. Murine Oxct1 cDNA was sub-cloned downstream of the α-MHC (myosin heavy
chain, Myh6) promoter (282), and after liberation of vector sequences, the expression cassette (Fig. 3.1A)
was purified and injected into the male pronucleus of fertilized oocytes prior to implantation. One founder
strain expressing the transgene was obtained, and these SCOT-Heart-OVEX mice are viable, fertile, and
indistinguishable from wild-type littermates. SCOT-Heart-OVEX mice were successively crossed to
Oxct1+/- mice to generate α-MHC-Oxct1;Oxct1-/- mice (SCOT-Heart-OVEX; SCOT-KO mice).
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The targeting construct for the gene that encodes CoA transferase, Oxct1, permitted a ‘germline
knockout first’ (283) approach that allows subsequent generation of a conditional ‘floxed’ allele. To
generate tissue-specific SCOT-KO mice, Oxct1+/- mice were first crossed to C57BL/6 mice that
ubiquitously express Flp recombinase (β-actin-Flp, Jackson Laboratory) to generate Oxct1+/flox mice,
through germline recombination. An additional round of breeding yielded Oxct1flox/flox mice (Fig. 3.1B).
Oxct1 exon 6 contains 107 nucleotides, which in the Oxct1flox allele (which encodes functional CoA
transferase) is flanked by loxP recognition sequences for Cre recombinase. Therefore, when excised by
cell type-specific Cre recombinase, the recombination event results in a nonsense coding mutation. See
Table 3.1 for a list of primers used for genotyping.
Cardiomyocyte-, skeletal muscle-, or neuron-specific SCOT-KO mice were generated by
successive rounds of breeding of Oxct1flox/flox mice independently to three strains expressing Cre
recombinase, each on the C57BL/6 background: α-MHC-Cre, HSA-Cre (human skeletal muscle actin
promoter), or Synapsin I-Cre, respectively (284-286). Each of these strains effects cell type-specific
recombination through loxP recognition sites by embryonic day (E)12.5 (284-287). In addition, Synapsin
I-Cre mediates recombination of floxed alleles in the male germline (288). This facilitated generation of
SCOT-Neuron-KO mouse lines with either one (flox/rec) or two (flox/flox) functional Oxct1 alleles in the
germline (Fig. 3.1B). Mice with the germline flox/rec genotype are functionally whole-body
heterozygotes, and germline flox/flox mice are functionally wild-type mice.
Unless otherwise noted, all mice were maintained on standard polysaccharide-rich chow diet (Lab
Diet 5053) and autoclaved water ad libitum. For the ketogenic diet studies, mice were maintained for two
weeks on a low protein, very low carbohydrate, and high fat ketogenic diet (Bio-Serv F3666) in which
94.1% of calories are from fat, 4.6% from protein, and 1.3% from carbohydrates. Lights were off between
1800 and 0600. All postnatal day (P)0 (i.e., the first day of extrauterine life) litters were obtained at 0900
and tissues and blood were harvested mid-morning. Mice were housed in groups of 3-5 for fasting
experiments on sawdust bedding. Fasting and ketogenic diet were initiated in six week-old male mice. All
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experiments were conducted using protocols approved by the Animal Studies Committee at Washington
University.
CoA transferase activity assay. CoA transferase enzymatic activity was measured in neonatal tissue
lysates using an adapted protocol (92). Neonatal tissues were collected and snap frozen in liquid nitrogen
and stored at -80º C until processing. Tissues were homogenized in phosphate-buffered saline (PBS, pH
7.2) with protease inhibitors (complete mini EDTA-free protease inhibitor cocktail, Roche) in a glass
dounce homogenizer on ice. Lysates were centrifuged at 20,000 x g at 4º C for 20 min and supernatants
were used as a source of CoA transferase. Assays contained 100 µg protein (determined by Micro BCA
Protein Assay Kit, Thermo Scientific) in a final volume of 100 µL, consisting of 50 mM Tris-HCl pH 8.5,
10 mM MgCl2, and 4 mM iodoacetamide. Absorbance at 313 nm, at which AcAc-CoA absorbs
maximally, was followed in unstimulated and stimulated (1 mM succinyl-CoA + 10 mM AcAc) replicates
for 2 min and normalized to an AcAc-CoA standard curve to determine rates of AcAc-CoA production.
Base hydrolysis of ethyl-AcAc (Sigma W241512) was performed by addition of 50% NaOH to pH 12 and
incubation at 60º C for 30 min. Base hydrolyzed AcAc was adjusted to pH 8.5, and [AcAc] was
confirmed using standard biochemical assays coupled to colorimetric substrates (Wako), as described
previously (51).
Serum metabolite measurements. Measurements of serum AcAc, D-βOHB, free fatty acids, and glucose
were performed using standard biochemical assays coupled to colorimetric substrates (Wako), as
described previously (51). AcAc concentrations were determined by measuring total ketone body (TKB)
concentrations and subtracting the corresponding measured D-βOHB concentration. Neonatal blood
glucose was measured in duplicate using glucometers (Aviva).
Gene expression analysis. Quantification of gene expression was performed using real-time RTquantitative PCR using the ΔΔCt approach as described, normalizing to Rpl32, using primer sequences
listed within Table 3.2 (51).
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Immunoblotting. Lysates from neonatal brain, heart, and quadriceps/hamstring muscles were generated in
a protein lysis buffer: 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% phosphatase
inhibitor cocktail (Sigma), and protease inhibitor cocktail (complete mini EDTA-free, Roche), pH 7.5.
Immunoblots to detect CoA transferase (rabbit anti-SCOT, Proteintech Group) and actin (rabbit anti-actin,
Sigma) were performed as described (78). Band intensities were quantified densitometrically using
QuantityOne software (Bio-Rad). For hippocampal immunoblots, brains were rapidly isolated and
hippocampal dissections were performed in PBS on ice using a dissecting microscope.
In vivo substrate utilization. Neonatal mice were injected intraperitoneally with 10 µmol [1-13C]glucose
(Cambridge Isotope Laboratories) per g of body weight. After 30 min incubation durations, neonatal mice
were killed by decapitation, and tissues were rapidly freeze-clamped in liquid N2. Neutralized and
lyophilized perchloric acid extracts were profiled using gradient heteronuclear single-quantum correlation
[13C]edited proton nuclear magnetic resonance (NMR) measured at 11.75 T. Signals were collected from
extracts dissolved in 275 µL D2O + 1 mM trimethylsilyl propionate, loaded into high precision, thin
walled 5-mm tubes (Shigemi). Quantification of integrals of carbon 2 of [13C]taurine (a normalizing
metabolite whose tissue concentrations were constant across conditions and which is not enriched by
administration of these substrates), [13C]lactate (carbon 2), and [13C]glutamate (carbon 4) was performed
as described previously (78).
Measurements of body composition. Percent body fat and lean body mass were determined in awake adult
animals using an EchoMRI instrument (Echo Medical Systems, Houston, TX).

Results
Restoration of myocardial ketone body oxidation in germline SCOT-KO mice does not prevent lethal
hyperketonemic hypoglycemia. Tissues that lack CoA transferase protein and activity cannot terminally
oxidize ketone bodies, and germline SCOT-KO mice invariably die within 48 hr of birth due to lethal
hyperketonemic hypoglycemia (78). Myocardium is the highest ketone body consumer per unit mass
(2,43,76). To determine if selective restoration of myocardial CoA transferase activity was sufficient to
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prevent lethal hyperketonemic hypoglycemia in SCOT-KO mice, transgenic mice harboring Oxct1 cDNA
under control of the α-MHC promoter (α-MHC-Oxct1) were successively bred to Oxct1+/- heterozygous
mice to ultimately yield SCOT-Heart-OVEX; SCOT-KO mice (Fig. 3.1). Selective restoration of CoA
transferase expression and activity on the first postnatal day, P0, was confirmed by immunoblot (Fig.
3.2A) and CoA transferase enzyme activity assays (Fig. 3.2B) using neonatal tissue extracts. Despite
restoration of myocardial CoA transferase activity to a magnitude that modestly exceeded wild type
levels, SCOT-Heart-OVEX; SCOT-KO mice still develop hyperketonemic hypoglycemia with
abnormally elevated AcAc/D-βOHB serum ratios (Fig. 3.2C-D). Genotypic analysis of > 25 litters
derived from α-MHC-Oxct1; Oxct1+/- crosses did not yield any SCOT-Heart-OVEX; SCOT-KO mice
after P1 (data not shown), indicating that neonatal lethality ensues despite restoration of myocardial
ketolysis in germline SCOT-KO mice.
Tissue-specific CoA transferase knockout mice are viable. To mechanistically dissect the energetic roles
of ketone body oxidation in individual tissues, we individually eliminated CoA transferase from the three
cell types most adapted to ketone body oxidation (2,76) – cardiomyocytes, skeletal myocytes, and
neurons – to generate SCOT-Heart-KO, SCOT-Muscle-KO, and SCOT-Neuron-KO mice, respectively
(see Fig. 3.1B). Tissue-specific loss of CoA transferase protein was confirmed in each tissue-specific
mouse strain on P0 by immunoblot and CoA transferase activity assay (Fig. 3.3A-C). CoA transferase is
present and active in astrocytes (70,289), and likely explains residual enzymatic activity in brains of
SCOT-Neuron-KO neonates (Fig. 3.3C). Absence of CoA transferase in neurons of SCOT-Neuron-KO
mice was further confirmed by immunoblot of protein lysates derived from adult hippocampi
(hippocampus exhibits an increase in neuronal density relative to other brain regions) (Fig. 3.3D). Each
tissue-specific SCOT-KO mouse strain is viable, exhibits normal body size (see below), and is fertile.
Unlike germline SCOT-KO mice, which develop neonatal hyperketonemic hypoglycemia with
abnormally elevated plasma AcAc/βOHB ratios by the second postnatal day (P1) [Fig. 3.2C and ref (78)],
tissue-specific SCOT-KO neonatal mice do not exhibit hypoglycemia, marked hyperketonemia, or
abnormal ratios of serum AcAc/βOHB (Fig. 3.4A-B). The Synapsin-1-Cre transgene, used to generate
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SCOT-Neuron-KO mice, also mediates recombination of floxed alleles within the male germline,
resulting in a null (rec) allele (Fig. 3.1B), which is transmitted to most progeny (288). This enabled
generation of SCOT-Neuron-KO and control mice with either one (flox/rec) or two (flox/flox) functional
Oxct1 alleles in the germline. Hypoglycemia and hyperketonemia do not develop in neonatal flox/rec
mice (Fig. 3.4), consistent with previous observations of neonatal Oxct1+/- mice (78). Of the three tissuespecific models of CoA transferase deficiency, only SCOT-Neuron-KO mice develop mild
hyperketonemia on P1 (mean serum total ketone body concentrations 0.85 ± 0.05 mM vs. 1.60 ± 0.25
mM, in flox/flox control and SCOT-Neuron-KO mice on the flox/flox germline background, respectively,
n = 5-8 per group, p < 0.001) (Fig. 3.4B). On P1, ketonemia did not differ between SCOT-Neuron-KO
mice on the flox/flox and flox/rec germline backgrounds (Fig. 3.4B). Furthermore, unlike the large
increase in AcAc/βOHB ratios of germline SCOT-KO mice compared to littermate controls (Fig. 3.2C),
these ratios did not significantly differ in any of the tissue-specific models (Fig. 3.4B).
Neuronal CoA transferase deficiency results in increased glucose utilization in the neonatal brain.
Because brains of neonatal germline SCOT-KO mice exhibit increased glucose oxidation (78), we
quantified the fates of [13C]glucose in brains of P2 SCOT-Neuron-KO mice (flox/rec background) and
genotype control mice, and observed increased glycolytic and oxidative metabolism of glucose in brains
SCOT-Neuron-KO mice: [13C]lactate abundance, a reporter of glycolytic metabolism, was 2.31 ± 0.45
fold greater (p < 0.05, n = 4/group Fig. 3.5A), and [13C]glutamate abundance, which quantitatively reports
the rate of entry of [13C]acetyl-CoA into the TCA cycle for terminal oxidation (136), was 2.11 ± 0.29 fold
greater in SCOT-Neuron-KO mice, compared to flox/rec control neonatal mice (p < 0.05, n = 4/group;
Fig. 3.5B). Nevertheless, SCOT-Neuron-KO mice remain euglycemic (Fig. 3.4A) and do not exhibit
molecular signatures of enhanced hepatic gluconeogenesis [expression of the mRNA encoding
phosphoenolpyruvate carboxykinase (Pck1) is normal in livers of SCOT-Neuron-KO mice], or altered
ketogenesis (hepatic Hmgcs2 and Bdh1 expression were also normal, Fig. 3.5C).
Oxidation of ketone bodies within neurons, cardiomyocytes, and skeletal myocytes is dispensable during
moderate starvation in the adult. Ketone body metabolism supports bioenergetic homeostasis when
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carbohydrate supply is limited, such as in starvation, by providing an alternative fuel source to energy
sensitive tissues (2,4). To directly test the hypothesis that individual tissues require ketone bodies for
energy transfer to support survival and glycemia in the post-absorptive state, SCOT-Neuron-KO (on the
flox/flox and flox/rec germline backgrounds), SCOT-Heart-KO, and SCOT-Muscle-KO mice were fasted
for 48h. Surprisingly, none of these tissue-specific SCOT-KO mouse strains exhibited fasting-induced
hypoglycemia, compared to fasted genotype- and age-matched control mice (Fig. 3.6A). While SCOTMuscle-KO and SCOT-Neuron-KO mice exhibit hyperketonemia compared to SCOT-Heart-KO and
flox/flox control mice (Fig. 3.6B), mice from each of these strains exhibited normal serum AcAc/D-βOHB
ratios after a 48h fast (Table 3.3) and normal fasting-induced weight loss (Fig. 3.6C). In addition, adult
SCOT-Neuron-KO mice on the flox/flox and flox/rec backgrounds are metabolically indistinguishable
during moderate starvation: these SCOT-Neuron-KO mouse strains do not differ in serum ketone body
concentrations, blood glucose, body weight, or serum AcAc/D-βOHB ratios during fasting (Fig. 3.6 and
Table 3.3). Conversely, germline flox/rec mice with intact neuronal CoA transferase do develop
hyperketonemia relative to flox/flox control mice at 48h starvation (Fig. 3.6B). Taken together, these
results indicate that ketone body oxidation is not required for energy transfer at the cellular or tissue level
in the post-absorptive state for survival or preservation of glycemia.
Relative deficiency of ketone body oxidation influences the response to a chronic ketogenic nutrient
milieu. While tissue-specific SCOT-KO models have utility in determining the metabolic roles of
ketolysis within individual tissues, naturally-occurring variations in ketone body oxidative capacity in
humans likely affect all ketolytic cell types (79-81,97,101,148,149,290). Germline CoA transferase
heterozygous (Oxct1+/-) mice are metabolically indistinguishable from Oxct1+/+ (wild-type) littermates in
the ketogenic neonatal period, despite ~50% diminution of CoA transferase protein abundance in Oxct1+/mice (78). To determine if metabolic abnormalities emerge in adult mice with ubiquitous, but partial,
reduction of catalytically active CoA transferase, wild type and Oxct1+/- littermate mice were exposed to
ketogenic milieus at six weeks of age. First, to measure the consequences of acute ketosis, male Oxct1+/and wild type littermate control mice were subjected to a 48h period of starvation. Body composition and
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total body weight was not different between genotypes at the onset of fasting: body fat percentage was
16.7 ± 0.2% in wild type mice vs. 16.3 ± 0.3% in Oxct1+/- mice; n = 6/group, and mice from each
genotype exhibited equivalent weight loss during the fast (Fig. 3.7A). As expected, fasting induces
ketosis in both genotypes, but Oxct1+/- mice developed greater ketonemia than control mice after 24 and
48h of fasting, consistent with a global reduction in ketone body oxidative capacity (Fig. 3.7B). Serum
AcAc/D-βOHB ratios were not different between Oxct1+/- and control mice after 48 hr of fasting (Table
3.3). Furthermore, fasting serum glucose and free fatty acid concentrations did not significantly differ
between genotypes (Fig. 3.7C-D). Next, to determine if reduced ketone body oxidative capacity impairs
adaptation to a chronic ketogenic nutrient milieu, we placed Oxct1+/- and littermate control mice on a low
protein, very low carbohydrate, and high fat ketogenic diet that has been extensively used by our lab and
others to study ketotic states in mice (51,53,126,291-295). Adherence to this diet for 2 weeks induces
ketosis in both genotypes, but ketonemia was nearly three-fold greater in Oxct1+/- mice (Fig. 3.7E).
Furthermore, compared to wild type controls, ketogenic diet-fed Oxct1+/- mice exhibited relative
hypoglycemia (Fig. 3.7F). Taken together, these results indicate that partial ketolytic defects become
metabolically evident after brief periods of nutrient deprivation and upon adherence to low carbohydrate
diet regimens.

Discussion
We have used novel mouse models of CoA transferase deficiency to demonstrate that the inability to
oxidize ketone bodies individually within neurons, cardiomyocytes, or skeletal myocytes does not impair
the ability of mice to survive the ketogenic neonatal period, or moderate-length durations of starvation in
the adult. However, transgene-mediated restoration of myocardial ketone body oxidation in an animal
lacking the ability to oxidize ketone bodies elsewhere does not prevent lethal hyperketonemic
hypoglycemia in the neonatal period. Taken together, these results support the notion that organism-wide
CoA transferase activity provides a ketolytic reservoir that is required to maintain bioenergetic
homeostasis in states of diminished carbohydrate intake, and that no single organ or cell type exhibits an
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obligate energetic requirement for ketone body oxidation to support survival or preserve glycemia under
the conditions tested. The inability of SCOT-Heart-OVEX; SCOT-KO mice to survive the ketogenic
neonatal period, and the mild hyperketonemic hypoglycemia exhibited by adult Oxct1+/- mice maintained
on a ketogenic diet indicate that incremental defects of the global ketolytic reservoir has significant
impact on metabolic homeostasis in ketogenic milieus.
Of the tissue-specific SCOT-KO mouse strains examined in the neonatal period, only SCOTNeuron-KO mice develop mild hyperketonemia, which supports previous observations indicating that
neurons are a significant consumer of ketone bodies in the neonatal period (71,105). Moreover, loss of
ketone body oxidation within neurons increases glycolysis and oxidative metabolism of glucose,
stronglysuggesting that ketolytic impairment in neurons requires additional glucose to meet the energetic
demands of the neonatal brain. Given the relative inability of neurons to oxidize fatty acids for energy
(69,70), increased cerebral consumption of glucose in SCOT-Neuron-KO neonates is not unexpected. The
liver is the most important source of glucose for the neonatal brain, which normally accounts for 60-70%
of total energy expenditure in this period, even though the neonatal brain only comprises 10% of total
body weight (2,71). Loss of terminal ketone body oxidation in neurons may therefore increase the liver’s
glucogenic burden. Increased hepatic glucose production may initially be met through increased
glycogenolysis, although hepatic glycogen stores are normally depleted rapidly after birth (20).
Furthermore, gluconeogenic gene expression markers were not increased in livers of SCOT-Neuron-KO
mice, suggesting that counterregulatory programs are not engaged in these mice. Thus, an alternative
explanation for preservation of euglycemia in newborn SCOT-Neuron-KO mice is that ketone body
oxidation within tissues that remain competent to terminally oxidize ketone bodies spares glucose for the
neonatal brain.
As in the neonatal period, ketone body oxidation subsumes an important role in energy transfer in
the post-absorptive state (2,4). Interestingly, in mice subjected to 48h starvation, survival is maintained
and glycemia is preserved when ketone body oxidation is individually eliminated from neurons,
cardiomyocytes, or skeletal myocytes. However, in this state, SCOT-Muscle-KO and SCOT-Neuron-KO
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mice exhibit hyperketonemia compared to fasted SCOT-Heart-KO and control strains. Hyperketonemia in
these two models suggests that skeletal muscle and neurons each provide a major component of the
ketolytic reservoir in the adult, consistent with previous observations indicating that ketone body
oxidation can account for as much as two-thirds of cerebral metabolism during starvation (2,296). Due to
bioethical considerations, these studies were not designed to determine if tissue-specific energetic
requirements for ketone body oxidation emerge in extremes of starvation. Nevertheless, it is striking that
animals challenged to a ketotic 48h fast, during which ~25% of total body weight is lost, do not require
ketone body oxidation in neurons, cardiomyocytes, or skeletal myocytes for survival or maintenance of
glycemia. In particular, SCOT-Neuron-KO mice on the flox/rec germline background have lost a
substantial proportion of total ketone body oxidative capacity. Nonetheless, these mice do not exhibit
greater starvation-induced ketonemia than SCOT-Neuron-KO mice on the flox/flox germline background,
despite the fact that germline flox/rec (functionally whole-body heterozygote) mice, which have preserved
neuronal ketolytic capacity, manifest greater starvation-induced ketonemia than flox/flox (functionally
wild-type) mice with normal neuronal ketolytic capacity (Figs. 3.6B, 3.7B). Therefore, as dynamic
variation of glucose metabolism occurs in these models, as described above, dynamic variations of both
ketogenic and ketolytic capacity are likely to occur in mice on these genetic backgrounds to meet the
collective energetic demands of all tissues.
In contrast to genetic animal models of tissue-specific ketolytic deficiency, sporadic CoA
transferase deficiency in humans likely affects all cells that oxidize ketones. Studies of CoA transferase
deficient infants and their parents reveal that heterozygous carriers for loss-of-function OXCT1 mutations
exhibit reduced CoA transferase enzymatic activity (290). Thus, we subjected germline adult Oxct1+/mice to a series of ketogenic provocations. Compared to wild type littermate controls, Oxct1+/- mice
developed hyperketonemia upon fasting, but glycemia was preserved. Prospectively, hypoglycemia may
ensue in Oxct1+/- mice at the extremes of starvation, when readily-available gluconeogenic substrate pools
are depleted to meet the increased gluconeogenic demand imposed by ketolytic insufficiency. This notion
is supported by the hyperketonemic hypoglycemic response of Oxct1+/- mice maintained on a low protein,
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very low carbohydrate, and high fat ketogenic diet for 2 weeks. These findings suggest that latent
ketolytic defects may emerge in humans upon introduction to ketogenic nutrient milieus. Indeed, case
reports indicate sporadic but rapid development of severe hyperketonemia with modest durations of
nutrient deprivation or upon adherence to Atkins-style ketogenic diets for weight loss (278,279). Because
ketogenic diets are increasingly employed for treatment of obesity, nonalcoholic fatty liver disease, and
neurological diseases including epilepsy, attentiveness to latent ketolytic insufficiency, and the possibility
of functional consequences of single nucleotide polymorphisms in loci that encode and regulate the
enzymatic mediators of ketone body oxidation, is warranted.
While these studies indicate that cell-type specific preservation of ketone body oxidation is not
required for survival of the murine neonatal period or a moderate degree of starvation in the adult mouse,
these tissue-specific models will also permit highly-penetrating analyses of the diverse bioenergetic roles
that ketone body oxidation plays through physiological and pathophysiological states relevant to each
tissue. For example, within the heart, cardiomyocytes oxidize ketone bodies in proportion to their
delivery, at the expense of fatty acid oxidation and glucose oxidation (90,117,121-127). Compared to
fatty acids, oxidation of ketone bodies is more energetically efficient. Unlike fatty acid oxidation, all of
the reducing equivalents generated by ketone body oxidation are delivered through NADH to complex I
within the electron transport chain (ETC). In addition, oxidation of ketone bodies increases the redox span
between complexes I and III by keeping mitochondrial ubiquinone oxidized. This increases the potential
energy of the mitochondrial proton gradient, thereby yielding more energy available for ATP synthesis
per molecule of oxygen invested, improving the energetic efficiency of ketone bodies, and attenuating
production of reactive oxygen species by the ETC (95,96,128,297). Furthermore, numerous studies
indicate prospective therapeutic applications of harnessing the benefits of ketone body metabolism in
neurons and astrocytes within the central nervous system (9,221,289,298). Therefore, these new models
provide opportunities for metabolic and bioenergetic dissection of both ketone body metabolism and CoA
transferase function in disease pathogenesis relevant to each organ.
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The ability to derive conclusions from tissue-specific loss-of-function models is a function of the
spatiotemporal fidelity of the gene inactivation system employed. The Cre-expressing strains used in this
study effect robust and cell-type-specific recombination during mouse embryogenesis (284-287,299).
HSA-Cre expresses Cre recombinase in a pan-fiber type distribution of skeletal myocytes; α-MHC-Cre
drives the expression of the recombinase abundantly and specifically within cardiac myocytes, and the
Synapsin1-Cre model was selected because it specifically expresses Cre recombinase in a pan-neuronal
manner. Nevertheless, the complexity of the central and peripheral nervous systems is reflected by the
>40 Cre-expressing mouse strains that are employed to target select neuronal and glial populations (300).
Thus, it is likely that novel phenotypes will emerge from study of CoA transferase deficiency through use
of other strains expressing Cre recombinase in other experimental settings. Finally, loss of CoA
transferase during embryogenesis may promote adaptation to the absence of terminal ketone body
oxidation, prospectively limiting the emergence of robust phenotypes in adult tissue-specific SCOT-KO
mice. Use of conditionally-induced Cre expressing strains will support further insight into the metabolic
consequences of ketolytic insufficiency in the adult animal.
In conclusion, we demonstrate that, to sustain survival and glycemia during moderate-duration
starvation, ketone body oxidation is not required for energy transfer in the three cell types that exhibit the
greatest capacity to oxidize ketone bodies: neurons, skeletal myocytes, and cardiomyocytes. However,
diminished ketone body oxidative capacity predisposes to metabolic abnormalities, including the
development of hyperketonemia during fasting, and hyperketonemic hypoglycemia upon adherence to a
low carbohydrate, high fat diet. A minimum threshold of organism-wide ketone body oxidation must be
maintained to preserve bioenergetic homeostasis and support compatibility with life.
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Figure Legends
Fig. 3.1. Strategy for the generation of transgenic overexpresser and tissue-specific SCOT-KO mice.
(A) SCOT-Heart-OVEX mice. Mouse Oxct1 cDNA was sub-cloned downstream of the α-MHC promoter
to generate mice overexpressing CoA transferase specifically within cardiomyocytes. ATG, initiator
methionine codon; TGA, stop codon; kb, kilobase; UTR, untranslated region. (B) Schematics depict the
endogenous Oxct1 mouse gene (Wild-type); targeted Null allele (the germline knockout allele); Flox
allele, which encodes normal CoA transferase protein; and the recombined Rec (also a null) allele.
Polyadenylation (pA) signals in the Null locus terminate transcription after exon 5, and a splice acceptor
(SA)/internal ribosomal entry sequence (IRES) results in a truncated and catalytically inactive product
from residual message. Flp recombinase recognition target (FRT) sites flank the β-gal and neomycin
resistance cassettes and the pA signals. Thus, Flp recombinase mediates removal of the pA transcriptional
stop signals and lacZ/neomycin cassette, restoring an active Oxct1 Flox allele in the germline. Exon 6 is
flanked by loxP recognition sequences in the Flox allele for cell type-specific Cre recombinase-mediated
recombination and inactivation. Genotyping primers for each allele are indicated as horizontal arrows (see
Table 3.1 for sequences). βgal, β-galactosidase-encoding lacZ gene; β-act:neo, neomycin resistance gene
driven by the β-actin promoter.
Fig. 3.2. Restoration of ketone body oxidative capacity selectively within cardiomyocytes of
germline SCOT-KO mice. (A) Immunoblot for CoA transferase (SCOT) and actin in myocardial protein
lysates derived from P0 hearts of wild type mice, SCOT-KO mice with transgene mediated restoration of
cardiomyocyte CoA transferase (SCOT-Heart-OVEX; SCOT-KO mice), and SCOT-KO mice. (B) CoA
transferase activity was measured spectrophotometrically in tissue lysates derived from hearts of P0 wildtype and SCOT-KO mice, and hearts and brains of P0 SCOT-Heart-OVEX; SCOT-KO mice. n = 3/group.
***, p < 0.001 by linear regression t test vs. SCOT-Heart-OVEX; SCOT-KO heart.
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†††

, p < 0.001 by

linear regression t test vs. wild type heart. (C) Serum ketone bodies (mM) in P1 wild type, SCOT-KO,
SCOT-Heart-OVEX, and SCOT-Heart-OVEX; SCOT-KO mice. n = 5-6/ group; ***, p < 0.001; *, p <
0.05 for βOHB;

†††

, p < 0.001 for AcAc;

‡‡‡

, p < 0.001 for AcAc/D-βOHB ratio by 2-way ANOVA,

compared to genotype control on the Oxct1+/+ (wild-type) background. (D) Blood glucose (mg/dL) in P1
mice. n = 4-6/group, ***, p < 0.001; *, p < 0.05 by 2-way ANOVA.
Fig. 3.3. Absence of CoA transferase protein and enzymatic activity in tissue-specific SCOT-KO
mouse strains. CoA transferase activity was measured spectrophotometricaly (left) in tissue lysates
derived from (A) heart, (B) skeletal muscle (quadriceps/hamstrings), and (C) brains of P0 mice. n = 36/group. ***, p < 0.001 by linear regression t test. Brains of SCOT-Neuron-KO mice on both flox/flox and
flox/rec genetic backgrounds were analyzed (depicted as flox/x). Immunoblots for CoA transferase
(SCOT) and actin (right). (D) Immunoblot (left) and densitometric quantification (right) of CoA
transferase protein abundance, normalized to actin in isolated hippocampi from adult SCOT-Neuron-KO
mice. Brains of SCOT-Neuron-KO mice on both flox/flox and flox/rec genetic backgrounds were analyzed
and did not reveal significant differences in CoA transferase protein abundances. ***, p < 0.001, **, p <
0.01, *, p < 0.05 by 1-way ANOVA. ns, not significant.
Fig. 3.4. Circulating metabolites in neonatal tissue-specific SCOT-KO strains. (A) Blood glucose
(mg/dL) in P1 mice. (B) Serum AcAc and D-βOHB in P1 mice. n = 5-8/group. ***, p < 0.001; **, p <
0.01 for serum [ketone] vs. flox/flox by 1-way ANOVA. ††, p < 0.01 for serum [ketone] vs. flox/rec by 1way ANOVA.
Fig. 3.5. Increased glucose consumption by brains of neonatal SCOT-Neuron-KO mice. (A) [113

C]glucose labeling of lactate, a surrogate for glycolysis in brains of SCOT-Neuron-KO (on the flox/rec

germline background) and control mice, 30 min after intraperitoneal injection of [1-13C]glucose into P2
animals. (B) 13C labeling of glutamate (surrogate for terminal oxidation in the TCA cycle) in these same
cerebral extracts. n = 4/group. *, p < 0.05 by Student’s t test. (C) Relative mRNA abundance of
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gluconeogenic (Pck1) and ketogenic (Hmgcs2, Bdh1) genes in livers of P2 SCOT-Neuron-KO and control
mice. n = 5/group.
Fig. 3.6. Adult tissue-specific SCOT-KO mice tolerate starvation. (A) Serum glucose, (B) serum total
ketone bodies (TKB), and (C) body weight were measured in fasting SCOT-Heart-KO, Muscle-KO,
Neuron-KO, and control adult mice after the indicated durations of nutrient withdrawal. ***, p < 0.001;
**, p < 0.01; and *, p < 0.05, by 2-way ANOVA, compared to same genotype at 4 hr. †††, p < 0.001; ††, p
< 0.01 by 2-way ANOVA, compared to flox/flox at same time point.

‡‡‡

, p < 0.001 by 2-way ANOVA,

compared to flox/rec control; n ≥ 6/group for each measurement at all time points and for each genotype.

Fig. 3.7. Diminished total body ketone body oxidative capacity impairs adaptation to ketotic
nutrient states. Metabolic parameters were measured in six week-old Oxct1+/- and Oxct1+/+ (wild-type
littermate control) male mice subjected to ketotic nutrient states. (A) Total body weight, (B) total serum
ketone bodies (TKB), (C) serum glucose, and (D) serum free fatty acids (FFA) were measured in fasting
mice. (E) Total serum ketone bodies and (F) serum glucose were also measured in eight week-old male
Oxct1+/- and littermate Oxct1+/+ (wild-type) mice maintained either on a standard polysaccharide rich
(Chow) diet or low protein, low carbohydrate, high fat ketogenic diet (KD) for two weeks. n = 7/group;
***, p < 0.001; **, p < 0.01; *, p < 0.05, by 2-way ANOVA.
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Chapter 4
Impact of peripheral ketolytic deficiency on hepatic ketogenesis and gluconeogenesis during the
transition to birth
The work presented in this chapter has been adapted from:
Cotter, D. G., Ercal, B., d'Avignon, D. A., Dietzen, D. J., and Crawford, P. A. (2013) J Biol Chem
288(27), 19739-19749
Summary
Preservation of bioenergetic homeostasis during the transition from the carbohydrate-laden fetal diet to
the high fat, low carbohydrate neonatal diet requires inductions of hepatic fatty acid oxidation,
gluconeogenesis, and ketogenesis. Mice with loss-of-function mutation in the extrahepatic mitochondrial
enzyme CoA transferase (succinyl-CoA:3-oxoacid CoA transferase, SCOT, encoded by nuclear Oxct1)
cannot terminally oxidize ketone bodies and develop lethal hyperketonemic hypoglycemia within 48 hr of
birth. Here we use this model to demonstrate that loss of ketone body oxidation, an exclusively
extrahepatic process, disrupts hepatic intermediary metabolic homeostasis after high fat mother’s milk is
ingested. Livers of SCOT-knockout (SCOT-KO) neonates induce the expression of the genes encoding
PGC-1α, PEPCK, pyruvate carboxylase, and glucose-6-phosphatase, and the neonate’s pools of
gluconeogenic alanine and lactate are each diminished by 50%. NMR-based quantitative fate mapping of
13

C-labeled substrates revealed that livers of SCOT-KO newborn mice synthesize glucose from

exogenously administered pyruvate. However, the contribution of exogenous pyruvate to the TCA cycle
as acetyl-CoA is increased in SCOT-KO livers, and is associated with diminished terminal oxidation of
fatty acids. After mother’s milk provokes hyperketonemia, livers of SCOT-KO mice diminish de novo
hepatic β-hydroxybutyrate synthesis by 90%. Disruption of β-hydroxybutyrate production increases
hepatic NAD+/NADH ratios three-fold, oxidizing redox potential in liver but not skeletal muscle.
Together, these results indicate that peripheral ketone body oxidation prevents hypoglycemia and
supports hepatic metabolic homeostasis, which is critical for the maintenance of glycemia during the
adaptation to birth.
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Introduction
At birth, a transplacental nutrient stream replete with carbohydrates is terminated and replaced with a high
fat, low carbohydrate milk diet that is cyclically interrupted by periods of nutrient deprivation. Hepatic
glucose production plays a critical role in providing fuel, particularly to the developing brain (20).
Nonetheless, glucose utilization is thought to support only ~70% of the neonatal brain’s energetic needs,
and additional substrates, including ketone bodies, are required to supply the balance (71). To meet this
demand, a coordinated hepatic metabolic program integrates β-oxidation and terminal oxidation of fatty
acids, gluconeogenesis, and ketogenesis (20). Ketone body metabolism mediates energy transfer by
partially oxidizing hepatic fatty acids to water-soluble four-carbon ketone body intermediates that are
transported to extrahepatic organs for terminal oxidation during physiological states characterized by
limited carbohydrate supply (4,5,301). As such, contributions of ketone body metabolism to neonatal
bioenergetic homeostasis are two-fold: (i) because the neonatal diet has high lipid content, ketogenesis
provides a spill-over pathway for excess fatty acid oxidation-derived acetyl-CoA that would otherwise
require terminal oxidation, storage, or secretion (5,42,302), and (ii) extrahepatic ketone body oxidation
diminishes hepatic gluconeogenic demand because ketone body oxidation spares glucose utilization in
peripheral tissues (4).
Most ketogenesis occurs within hepatic mitochondria, at rates proportional to β-oxidation of fatty
acids (5). Sequential ketogenic reactions catalyzed by mitochondrial thiolase, mitochondrial
hydroxymethylglutaryl-CoA synthase (HMGCS2), and hydroxymethylglutaryl-CoA lyase (HMGCL)
convert β-oxidation-derived acetyl-CoA to the ketone body acetoacetate (AcAc), which is reduced by
mitochondrial D-β-hydroxybutyrate (D-βOHB)-dehydrogenase (BDH1) to D-βOHB in an NAD+/NADHcoupled redox reaction (21,22,44). Within extrahepatic organs, mitochondrial BDH1 re-oxidizes D-βOHB
to AcAc. Covalent activation of AcAc by CoA is catalyzed by the mitochondrial matrix enzyme succinylCoA:3-oxoacid CoA transferase [SCOT (encoded by the nuclear gene Oxct1), the only mammalian CoA
transferase] to generate AcAc-CoA, which upon thiolytic cleavage, liberates acetyl-CoA that enters the
tricarboxylic acid (TCA) cycle for terminal oxidation (74). CoA transferase catalyzes a near equilibrium
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reaction in which coenzyme A is exchanged between succinate and AcAc (72). Ketone bodies are
efficient energetic substrates that are oxidized in proportion to their delivery (4,5,20). The neonatal brain
extracts ketones at rates up to 40-fold greater than the adult brain and ketone body oxidation can support
as much as 25% of the neonate’s total basal energy requirements (71,248). Because neurons oxidize fatty
acids poorly (69,71), ketogenesis has been proposed as a key determinant in vertebrate evolution and the
evolution of human brain size (41).
Prior analysis of germline CoA transferase knockout (SCOT-KO) mice revealed that CoA
transferase is required for terminal ketone body oxidation. SCOT-KO mice are born normal, but exhibit
increased cerebral glucose oxidation. These mice ultimately develop hyperketonemic hypoglycemia and
die within 48h of birth unless their lifespan is prolonged by frequent glucose administration (78). Unlike
mice with a global CoA transferase defect, recent studies using cell type-specific SCOT-KO mice reveal
that the selective absence of ketone body oxidation individually within neurons, cardiomyocytes, or
skeletal myocytes – the three greatest consumers of ketone bodies (4,107) – does not cause
hyperketonemia or hypoglycemia, and does not impair survival during the neonatal period or starvation in
adulthood. As observed in brains of germline SCOT-KO neonates, selective absence of neuronal CoA
transferase activity was associated with increased glycolysis and glucose oxidation in the neonatal brain
(108). Taken together, the phenotypes of germline and tissue-specific SCOT-KO mice reveal that
ketolytic cells do not require the energy stored in ketone bodies, but ketone body oxidation is necessary
for maintenance of glycemia, and therefore survival in the neonatal period.
During states in which dietary carbohydrates are in short supply, the balance of hepatic glucose
output with extrahepatic glucose consumption coordinates glucose homeostasis. Increased extrahepatic
glucose consumption in neonatal germline SCOT-KO mice may therefore contribute to the development
of hypoglycemia. To determine whether the absence of extrahepatic ketone body oxidation influences
hepatic glucose production and intermediary metabolic homeostasis, we used biochemical approaches to
quantify dynamic metabolism in livers of germline neonatal SCOT-KO mice.
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Methods
Animals. Oxct1-/- (germline SCOT-KO) mice were generated on the C57BL/6 genetic background (78).
To obtain unfed neonatal mice, pups were collected within one hour of birth. Pups without gastric milk
spots were confirmed by open examination of the stomach and intestine at the time of sacrifice. Fed
postnatal day zero (P0, the first day of postnatal life) mice were collected within 4 hr of birth. All P1 mice
were maintained with the dam through the first 30h after birth, and were milk fed. All mice were
maintained at 22oC on standard polysaccharide-rich chow diet (Lab Diet 5053) and autoclaved water ad
libitum. Lights were off between 1800 and 0600. All experiments consisted of mouse pups that were
harvested from at least three litters from three different breeder pairings. All experiments were conducted
using protocols approved by the Animal Studies Committee at Washington University.
Plasma metabolite measurements. Measurements of plasma AcAc and D-βOHB were performed using
standard biochemical assays coupled to colorimetric substrates (Wako), as described previously (51).
AcAc concentrations were determined by measuring total ketone body (TKB) concentrations and
subtracting the corresponding measured D-βOHB concentration. Plasma lactate and pyruvate were
measured using colorimetric and fluorescent biochemical assays, respectively (Biovision). Blood glucose
was measured in duplicate using glucometers (Aviva).
Gene expression analysis. Quantification of gene expression was performed using real-time RTquantitative PCR using the ΔΔCt approach as described, normalizing to Rpl32, using primer sequences
listed within supplemental Table S4.1 (51).
Immunoblotting. Immunoblots, using protein lysates from neonatal brain, heart, liver, and
quadriceps/hamstring muscles to detect SCOT (rabbit anti-SCOT; Proteintech Group), actin (rabbit antiactin; Sigma), HMGCS2 (rabbit anti-mHMGCS; Santa Cruz Biotechnology), PDH-E1α (rabbit antiPyruvate Dehydrogenase E1-alpha subunit antibody; abcam ab155096), phospho-serine 293 PDH-E1α
[PhosphoDetect™ Anti-PDH-E1α (pSer293) Rabbit Antibody; Millipore AP1062], and BDH1 (rabbit
anti-BDH1; Proteintech Group) were performed as previously described (34). Band intensities were
quantified densitometrically using QuantityOne software (Bio-Rad).
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In vitro ketogenesis of hepatic explants. Neonatal mice were sacrificed by decapitation. Livers were
collected, weighed, and each liver was placed in a single well of a 6-well tissue culture plate containing 2
mL of phosphate-buffered saline (PBS) on ice. Livers were minced and transferred to a 2 mL eppendorf
tube. Tissues were allowed to settle on ice and were centrifuged at 500 x g for 1 min. Minced-liver pellets
were resuspended in 1 mL of assay media [Dulbecco’s Modified Eagle’s Medium supplemented with
2.78 mM glucose (which reflects glycemia in neonatal mice), 0.63 mM sodium pyruvate, and 150 µM
oleic acid (conjugated to bovine serum albumin in a 2:1 molar ratio)]. Each liver preparation was plated in
a single well of a 12-well plate containing 1 mL of media, and incubated at 37ºC. At time points indicated
in the figure legends, 50 µL of media was removed to quantify ketone body concentrations.
Tissue triglyceride, glycogen, and nicotinamide metabolite quantifications. Hepatic triacyglycerol (TAG)
concentrations were determined using a Folch extract of liver and biochemical quantification using a
biochemical assay (Wako), as previously described (126). Hepatic glycogen and NAD+(H) concentrations
were measured in liver lysates using fluorescent biochemical assays (Biovision).
In vivo substrate utilization. P0 or P1 mice were injected intraperitoneally with 10 µmol of sodium
[1,2,3,4-13C4]octanoate, 10 µmol sodium [3-13C]pyruvate, or co-injected with 10 µmol of sodium [1,2,3,413

C4]octanoate, plus 20 µmol naturally-occurring sodium pyruvate, sodium D-βOHB, sodium L-βOHB, or

AcAc per g of body weight (vendor for stable isotopes: Cambridge Isotope Laboratories). Base hydrolysis
of ethyl-AcAc (Sigma W241512) was performed by addition of 50% NaOH to pH 12 and incubation at
60º C for 30 min. The pH of base hydrolyzed AcAc was adjusted to pH 8.5, and [AcAc] was confirmed
using standard biochemical assays coupled to colorimetric substrates (Wako), as described previously
(51). After intraperitoneal injections, neonatal mice were maintained on a heating pad for the indicated
durations (see text and figure legends), killed by decapitation, and tissues were rapidly freeze-clamped in
liquid N2. Neutralized perchloric acid tissue extracts were profiled using

13

C-edited proton nuclear

magnetic resonance (NMR) measured at 11.75 T (Varian/Agilent Direct Drive-1) via first increment
gradient heteronuclear single-quantum correlation (gHSQC). The majority of studies were carried out
using a traditional probe, but extracts generated from mice injected with sodium [3-13C]pyruvate were
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analyzed using a high-sensitivity cold probe at 11.75 T (Varian/Agilent Direct Drive-1). Signals were
collected from extracts dissolved in 275 µL of D2O + 1 mM trimethylsilyl propionate (TSP), loaded into
high precision, thin walled 5-mm tubes (Shigemi). Quantification of signals by integration from the
1

H{13C} and

13

C-edited (gHSQC) collections of carbon 2 for taurine, carbon 4 for βOHB, carbon 1 for

glucose, carbon 4 for glutamate, and 1H{13C} of carbons 3 for lactate and alanine were all performed as
described previously (78). Tissue concentrations (pool size) of glucose, taurine, glutamate, and βOHB
were calculated by normalizing the integrals for each metabolite obtained from the 1H{13C} collections to
TSP and tissue weight. Because tissue taurine concentrations were constant across conditions (Tables
S4.2-S4.3) and taurine is not enriched by administration of these experimental substrates (51,136), taurine
was used as a normalizing metabolite between the 1H{13C} and gHSQC collections to calculate the moles
of

13

C-labeled metabolites present in each sample. The moles of

13

C-labeled metabolites produced from

the labeled substrate in each sample were calculated by subtracting the moles of 13C-labeled metabolites
attributable to the metabolite pool size (i.e., in the absence of any enrichment from exogenous 13C-labeled
substrates, 1.1% of the metabolites within the entire pool are expected to be 13C-labeled, based upon the
natural abundance of

13

C) from the total amount of

13

C-labeled metabolites detected in the gHSQC

collections. Fractional enrichments of 13C-labeled glutamate and βOHB were then calculated as described
(51), by dividing taurine-normalized integral values for each queried metabolite derived from the gHSQC
collections by the corresponding integral value obtained from the 1H{13C} collections.
Tandem mass spectrometry (MS/MS) analysis of blood amino acids and acylcarnitines. Neonatal blood
was spotted onto 1.3 cm spots on Whatman 903 filter paper. Amino acids were quantified as butyl ester
derivatives using multiple precursor/product combinations in a reversed-phase liquid chromatography
protocol coupled to MS/MS (303). Carnitine esters were measured by scanning for the precursors of the
common m/z 85 carnitine fragment. Quantification was achieved in all cases using stable isotope (2H)
labeled internal standards using an electrospray ionization source coupled to an API 3200-Qtrap tandem
mass spectrometer (Applied Biosystems, Foster City CA, USA).
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Results
Neonatal SCOT-KO mice engage an hepatic gluconeogenic gene program. The liver is the most
important source of glucose for the neonatal brain (2,71), which increases its reliance on this vital fuel
when CoA transferase inactivation prevents ketone body oxidation in the entire brain (78) or selectively
within neurons (108). Therefore, we hypothesized that neonatal germline SCOT-KO mice, which cannot
terminally oxidize ketone bodies, engage compensatory mechanisms in the liver to meet increased
peripheral glucose demand. Increased abundances of the mRNAs encoding peroxisome proliferator
activated receptor gamma-1a (PGC-1α, encoded by Ppargc1a), pyruvate carboxylase (PC, encoded by
Pcx), phosphoenolpyruvate carboxykinase (PEPCK, encoded by Pck1), and glucose-6-phosphatase
(encoded by G6pc) were observed in livers of postnatal day 1 (P1, the day immediately following
delivery) SCOT-KO mice (Fig. 4.1A), and as expected, hepatic glycogen content was depleted in livers of
P1 SCOT-KO mice (Fig. 4.1B). Consistent with increased gluconeogenic demand, tandem mass
spectrometry (MS/MS) analysis of circulating amino acids demonstrated that alanine, which becomes the
gluconeogenic substrate pyruvate following transamination (36), was diminished 51% in blood of P1
SCOT-KO mice (Fig. 4.1C). Serine, which is deaminated to pyruvate by serine dehydratase, also trended
lower in these mice. In addition, blood concentrations of the anaplerotic amino acid glutamate, which can
replenish TCA cycle intermediates following conversion to a-ketoglutarate, were diminished 40% in
SCOT-KO neonates. This contrasted with many glucogenic/ketogenic, glucogenic, ketogenic, and urea
cycle amino acids, whose circulating concentrations were increased in P1 SCOT-KO mice (Fig. 4.1D; see
Tables S4.4-S4.5 for complete P0 and P1 blood amino acid profiles, respectively, of wild type and
SCOT-KO mice), suggesting enhanced skeletal muscle proteolysis in P1 SCOT-KO mice. In addition, the
total circulating pyruvate pool (the sum of pyruvate plus lactate, which form a redox couple with
NAD+/NADH), a critical source of gluconeogenic precursors via the Cori cycle, was diminished 53% in
P1 SCOT-KO mice (Fig. 4.1E). In SCOT-KO neonates, increased extrahepatic glucose and lactate
consumption (78,108) are likely contributors to hypoglycemia. Unlike wild-type littermates, endogenous
hepatic content of free glucose was below the limit of detection by proton NMR in P1 SCOT-KO mice
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(Fig. 4.1F, left), suggesting that hepatic glucose generated from residual endogenous substrates is rapidly
cleared to meet increased peripheral demands, and that this production is insufficient to support the
glycemic requirements for survival in these mice. However, intraperitoneal supplementation of P1 SCOTKO mice with exogenous [13C]pyruvate 30 min prior to harvest of the liver demonstrated robust
generation of

13

C-glucose (Fig. 4.1F, right). Taken together, these data suggest that neonatal hepatic

glucose production is increased to meet enhanced peripheral requirements, but is limited in these mice by
precursor availability and not intrinsic synthetic capacity.
Reprogrammed intermediary metabolism in livers of neonatal SCOT-KO mice. Given marked
hypoglycemia, hyperketonemia, alterations of gluconeogenic precursor pools, and increased
concentrations of circulating amino acids, we hypothesized that livers of P1 SCOT-KO mice would
exhibit alterations of terminal fatty acid oxidation and pyruvate metabolism. Therefore, to determine if
livers of P1 germline SCOT-KO mice exhibit diminished terminal oxidation of acyl-CoA-derived acetylCoA, we quantified the contribution of the fatty acid [1,2,3,4-13C4]octanoate (10 µmol/g body weight, via
the intraperitoneal route) to the acetyl-CoA entering the TCA cycle, by using

13

C-glutamate fractional

enrichment as a quantitative surrogate, because glutamate is in equilibrium with the TCA cycle
intermediate α-ketoglutarate (51,78,108,136,304,305). Hepatic enrichment of 13C-glutamate did not differ
between P1 wild type and SCOT-KO mice that received [13C]octanoate alone (Fig. 4.2A, left), indicating
equal contributions of labeled octanoate to the acetyl-CoA entering the TCA cycle. However, SCOT-KO
mice exhibited a significantly decreased glutamate pool size (Fig. 4.2A, right; 1.03±0.17 nmol
glutamate/mg liver in P0 wild type mice, versus 0.56±0.09 nmol glutamate/mg liver in P1 SCOT-KO
mice, p = 0.046, n = 6-8/group). Therefore, to determine if hepatic terminal fatty acid oxidation remains
equal when glutamate pool sizes in livers of P1 wild-type and SCOT-KO mice are equal, we coadministered [13C]octanoate with unlabeled pyruvate, which augments TCA cycle intermediates by
stimulating anaplerosis. Co-administration of unlabeled pyruvate with [13C]octanoate increased hepatic
glutamate pool sizes in livers of both wild type and SCOT-KO neonatal mice, and abrogated the
diminution of this pool size in livers of SCOT-KO mice (Fig. 4.2B, right). However, compared to livers
88

of wild-type P1 mice, hepatic glutamate enrichment from [13C]octanoate was diminished nearly 50% in
livers of P1 SCOT-KO mice delivered this combination of substrates (22.9±3.05% in wild type mice
versus 11.8±3.0% in SCOT-KO mice, p = 0.026, n = 6-7/group; Fig. 4.2B, left), indicating diminished
contribution of labeled octanoate to the acetyl-CoA entering the TCA cycle in livers of P1 SCOT-KO
mice. The only competing sources of acetyl-CoA in the livers of neonatal mice in this experimental
context are (i) endogenous fatty acids or (ii) pyruvate that is decarboxylated via the pyruvate
dehydrogenase (PDH) complex. Thus, we directly quantified the contribution of pyruvate to the acetylCoA entering the TCA cycle by administering [3-13C]pyruvate (10 µmol/g body weight), which labels >
95% of the circulating pyruvate pool in both wild type and SCOT-KO mice, and measured hepatic
glutamate enrichment. Hepatic 13C-enrichment of glutamate was 2.7-fold greater in SCOT-KO neonates
administered [13C]pyruvate (5.95±1.92% versus 16.32±2.87% in livers of wild-type and SCOT-KO P1
mice, respectively, p=0.04, n=4/group; Fig. 4.2C). As observed in mice receiving unlabeled pyruvate
(Fig. 4.2B), hepatic glutamate pools were not different between wild type and SCOT-KO neonates
injected with [13C]pyruvate (data not shown). Increased

13

C-glutamate enrichment from [13C]pyruvate

occurred in SCOT-KO neonates in the absence of altered phosphorylation of PDH on the E1 a subunit, a
post-translational modification that increases the Km of PDH (138,306,307) (Fig. S4.1).
Because the contribution of labeled fatty acids to the acetyl-CoA entering the TCA cycle was
diminished in livers of P1 SCOT-KO mice when glutamate pools were rendered equal by administration
of unlabeled pyruvate, we hypothesized that signatures of diminished fatty acid oxidation would be
evident in livers of these mice. To determine if there was a defect in the β-oxidation spiral, we quantified
blood acylcarnitines of untreated P1 germline SCOT-KO mice by MS/MS. While medium and long chain
acylcarnitine species were normal (Table S4.6), short chain acylcarnitine concentrations were elevated in
P1 SCOT-KO mice (Fig. 4.2D). This result is consistent with an intact β-spiral, but diminished entry of
its products into the TCA cycle. Abundances of transcripts encoding key mediators of fatty acid transport
and oxidation, including Fabp1, Fgf21, Cpt1a, and Acadm mRNAs, were all normal in SCOT-KO mice
(Fig. S4.2A). However, hepatic triacylglycerol content trended higher in P1 SCOT-KO mice (Fig. 4.2E;
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12.7±5.0 µg/mg liver versus 3.5±1.7, respectively, p = 0.09, n=5-6/group), also suggesting impaired
terminal fatty acid oxidation in livers of SCOT-KO mice.
To determine whether signatures of diminished terminal fatty acid oxidation in livers of SCOTKO neonatal mice are innate, or the result of a perturbed metabolic environment, we delivered
[13C]octanoate to newborn P0 SCOT-KO mice that had been collected prior to their first milk feed, and
observed that hepatic 13C-glutamate fractional enrichment and glutamate pool size were both normal, as
they were in livers of fed P0 SCOT-KO mice (Fig. S4.3). Moreover, unlike the observation of increased
short chain acylcarnitines in the circulation of P1 SCOT-KO mice, blood acylcarnitine species did not
differ between fed, but untreated P0 wild-type and SCOT-KO mice (Table S4.7). Taken together, these
findings indicate that the observed abnormalities of fatty acid and pyruvate metabolism are likely
secondary to increased gluconeogenic demand and the hyperketonemic state that develops in P1 SCOTKO mice.
Accumulated D-βOHB suppresses normal ketogenesis in neonatal liver. Due to (i) the alterations of
hepatic fatty acid oxidation and pyruvate metabolism in SCOT-KO mice, and (ii) our previous
observation that the AcAc/βOHB ratio was significantly elevated in the circulation of markedly
hyperketonemic P1 SCOT-KO mice (78), we hypothesized that regulation of hepatic ketogenesis would
also be altered in these mice. To determine the effects of peripheral ketolytic deficiency on hepatic
ketogenesis, we measured the hepatic 13C fractional enrichment and pool sizes of βOHB in neonatal mice
injected with [13C]octanoate. 13C-βOHB enrichment from [13C]octanoate was decreased 15-fold in livers
of P1 SCOT-KO mice (15.26±1.34% versus 1.21±0.08%, p < 0.0001, n = 6-8/group Fig. 4.3A, left).
Commensurate with the marked increase in the concentration of circulating ketone bodies in P1 SCOTKO mice, the total hepatic βOHB pool size was expanded in P1 SCOT-KO mice (0.51±0.07 nmol
βOHB/mg liver and 3.27±0.73 nmol βOHB/mg liver in wild-type and SCOT-KO mice, respectively, p =
0.0009, n = 6-8/group; Fig. 4.3A, middle). Therefore, to confirm that the decreased 13C-βOHB fractional
enrichment from [13C]octanoate in livers of SCOT-KO mice reflects diminished de novo production of
βOHB (rather than merely an increase in the total pool), we quantified the 13C-βOHB abundance in livers
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of these mice, and observed a 90% decrease in livers of P1 SCOT-KO mice (72.4±12.5 pmol
βOHB/mg liver and 6.3±2.1 pmol

13

13

C-

C-βOHB produced/mg liver in wild-type and SCOT-KO mice,

respectively, p = 0.0007, n=6-8/group; Fig. 4.3A, right). Messenger mRNAs encoding the ketogenic
mediators FGF21 and HMGCS2 were both normal, while Bdh1 mRNA abundance was decreased 50% in
livers of P1 SCOT-KO mice (Fig. S4.2A). At the protein level, SCOT-KO livers exhibited ~ 25%
increased HMGCS2, and normal BDH1 protein abundance (Fig. S4.2B-C).
To determine if the marked impairment of βOHB production in livers of P1 SCOT-KO mice was
innate or acquired, we quantified 13C-βOHB production from [13C]octanoate in livers of unfed P0 SCOTKO mice. Hepatic 13C-βOHB enrichment, βOHB pool size, and 13C-βOHB production were all normal in
unfed P0 SCOT-KO mice (Fig. 4.3B). Prior to milk feeding, endogenous plasma ketones were nearly
undetectable and did not differ between wild type and SCOT-KO mice (Fig. 4.3C). However, after only a
single feed, plasma ketone bodies exceeded 3 mM in SCOT-KO mice (versus ~ 0.3 mM in wild-type
littermate controls), with both D-βOHB and AcAc exhibiting significant increases in SCOT-KO neonates
(Fig. 4.3D). In contrast to the robust

13

C-labeling of hepatic βOHB in unfed SCOT-KO neonates

administered [13C]octanoate, suckling-induced hyperketonemia correlated with the emergence of a 90%
decrease in 13C-βOHB enrichment in milk-fed P0 SCOT-KO mice, compared to littermate controls (Fig.
4.3E, left). Similar to the observations in the pools of βOHB in P1 SCOT-KO mice, suckling in P0 mice
correlated with a marked expansion of the hepatic βOHB pool in SCOT-KO neonates, and was associated
with an 80% decrease in the abundance of

13

C-βOHB (Fig. 4.3E, middle and right). Diminished

13

C-

βOHB enrichment from [13C]octanoate occurred in livers of fed P0 SCOT-KO mice despite normal
abundances of Fabp1, Cpt1a, Acadm, Hmgcs2, and Bdh1 mRNAs, and a 38% increase in HMGCS2
protein (Fig. S4.4). Together, these results indicate that suckling-induced hyperketonemia in SCOT-KO
neonates diminishes the generation of

13

C-βOHB from [13C]octanoate, without impairment of the

upstream β-spiral or diminution of expression of the enzymatic mediators of fatty acid oxidation and
ketogenesis.
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To determine whether the acquired deficiency of de novo hepatic βOHB production in livers of
SCOT-KO mice was mediated by hyperketonemia, we measured ketogenesis in livers explanted into
culture from unfed and fed P0 SCOT-KO and littermate control mice, in order to isolate them from a
hyperketonemic milieu. As expected, explants from unfed wild type and SCOT-KO neonatal mice did not
differ in ketogenic rate (Fig. 4.4A). However, in contrast to the defect in de novo synthesis of βOHB
exhibited by fed P0 SCOT-KO mice in vivo, livers explanted from fed SCOT-KO mice exhibited normal
ketogenic rates, despite the increased baseline ketone body abundance in these explants (Fig. 4.4B).
Therefore, to test the hypothesis that the acquired ketogenic impairment in livers of SCOT-KO mice
requires an environment in which ketone bodies accumulate, we determined the effects of
hyperketonemia on hepatic βOHB production in vivo by performing intraperitoneal co-injections in fed
wild-type P0 mice. Unlabeled AcAc, D-βOHB, or L-βOHB [L-βOHB is a by-product of fatty acid
oxidation that is neither produced during hepatic ketogenesis, nor is a substrate for BDH1 (158,160)]
were co-injected intraperitoneally with [13C]octanoate into milk-fed P0 wild-type neonatal mice, and the
hepatic βOHB pool sizes, fractional enrichments of hepatic

13

C-βOHB, and molar contents of

13

C-

βOHB/mg tissue were quantified. Co-administered AcAc, L-βOHB and D-βOHB each expanded the total
βOHB pool significantly, although hepatic βOHB concentrations were greater in neonates co-injected
with L- or D-βOHB compared to neonates co-injected with AcAc (Fig. 4.5A). While fractional

13

C-

enrichments of βOHB from [13C]octanoate were decreased in livers of mice co-injected with each of the
three unlabeled ketone bodies, neonatal mice co-injected with L- or D-βOHB exhibited greater
suppression of

13

C-βOHB enrichment than neonates co-injected with AcAc (Fig. 4.5B). However, only

co-administered D-βOHB decreased the molar content/mg tissue of 13C-βOHB in livers of wild-type mice
(by 75%), while neither AcAc nor L-βOHB produced this effect (Fig. 4.5C). Because oxidation of DβOHB to AcAc by BDH1 concomitantly reduces NAD+ to NADH (22,24,308), these results suggest that
the exogenously delivered D-βOHB diminished de novo βOHB production by shifting the equilibrium of
the BDH1-catalyzed reaction towards AcAc formation.
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Diminished βOHB production by livers of neonatal SCOT-KO mice results in oxidation of hepatic
redox potential. Despite the impairment of de novo synthesis of βOHB, livers of SCOT-KO neonates
continue to channel fatty acid oxidation-derived acetyl-CoA to AcAc, which exhibits a four-fold increase
in plasma concentration between P0 and P1 in SCOT-KO mice (78). Because AcAc and D-βOHB exist in
an NAD+ and NADH-coupled equilibrium, we hypothesized that preservation of AcAc formation, but
impairment of its reduction to D-βOHB would oxidize hepatic redox potential. While plasma
AcAc/βOHB molar ratios were elevated 3.5-fold (p = 0.03, n=8-9/group) in fed P0 SCOT-KO mice over
wild-type littermate controls, these ratios spanned a large dynamic range among SCOT-KO animals (Fig.
4.6A), and abundances of total NAD+ and NADH were normal in both livers and skeletal muscle of fed
P0 SCOT-KO mice (Fig. 4.6B-C). Plasma AcAc/βOHB ratios were increased 10-fold (p = 1.98X10-8,
n=11-14/group) in P1 SCOT-KO mice compared to littermate controls, but in contrast to fed P0 SCOTKO mice, they exhibited less variability (Fig. 4.6D). Correspondingly, livers of P1 SCOT-KO mice
exhibited a three-fold increased ratio of NAD+/NADH concentrations (Fig. 4.6E). This effect was neither
attributable to, nor contributed to altered hepatic abundances of mRNAs encoding NAMPT, CD38,
SIRT1, or Rictor (Fig. S4.5). Redox potential was unaltered in skeletal muscles of P1 SCOT-KO mice
(Fig. 4.6F), consistent with the notion that persistent AcAc production by the liver is the primary driver
of the redox abnormality of P1 SCOT-KO mice. Because SCOT is normally considered absent in
hepatocytes (74,107,164), and only a scant amount of SCOT was detected in neonatal hepatic lysates
(Fig. S4.6), these results indicate that peripheral disposal of ketone bodies is required to prevent oxidation
of hepatic redox potential.

Discussion
Ketone bodies provide an alternative fuel in states of diminished carbohydrate supply (4,5,20). Ketone
body oxidation is required for adaptation to birth in mice, and for adaptation to low carbohydrate states in
humans (78,97). Here we show that extrahepatic ketone body oxidation is essential for preservation of
hepatic metabolic homeostasis during the ketogenic neonatal period because the absence of ketone body
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oxidation causes impaired hepatic terminal fatty acid oxidation, altered pyruvate metabolism, and
diminished de novo βOHB production, which results in oxidation of hepatic redox potential.
Germline SCOT-KO neonates succumb to neonatal hypoglycemia. Increased peripheral oxidation
of lactate and glucose contribute to hypolactatemia and hypoglycemia (78), and increase the
gluconeogenic burden of SCOT-KO livers. These mice also develop increased blood amino acid
concentrations, indicating that hypoglycemia and the inability to derive high-energy phosphates from
ketone bodies likely stimulate skeletal muscle proteolysis. While increased blood amino acid
concentrations indicate that amino acid supply exceeds hepatic utilization, a subset of these amino acids
yields gluconeogenic carbon backbones within liver and replenishes TCA cycle intermediates via
anaplerosis (36). Notably, blood alanine concentrations are decreased in SCOT-KO neonates, although
absolute plasma pyruvate concentrations are preserved, suggesting that pyruvate generation via both the
glucose-alanine and Cori cycles increase to support increased gluconeogenic demand. Because livers of
SCOT-KO neonates successfully produce glucose from exogenously delivered pyruvate, impairments of
the hepatic gluconeogenic machinery do not account for hypoglycemia. In fact, gluconeogenic enzymes,
which normally exhibit significant postnatal inductions (20), are further induced in livers of SCOT-KO
neonates. Together, these data suggest that the availability of gluconeogenic substrates (i.e., alanine and
the lactate + pyruvate pool), and not expression of enzymatic mediators of gluconeogenesis, exacerbates
the mismatch between neonatal hepatic glucose production and extrahepatic glucose requirements in mice
that lack CoA transferase activity. In states of limited dietary carbohydrate supply, >60% of hepatic
gluconeogenesis is derived from pyruvate (267). Upon carboxylation by PC, pyruvate supplies the TCA
cycle with the intermediate oxaloacetate, which can either remain in the cycle to facilitate terminal
oxidation of acetyl-CoA, or efflux into the gluconeogenic pathway through PEPCK-dependent conversion
to phosphoenolpyruvate (36,309). Such ‘pyruvate cycling’ governs rates of anaplerosis and TCA cycle
intermediate efflux (309), which normally exceed the rate of TCA cycle flux in the liver (30) . Although
limited pyruvate pool availability precludes preservation of euglycemia, transcriptional induction of these
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enzymatic mediators of pyruvate cycling may initially help support gluconeogenesis in livers of SCOTKO mice.
Hyperketonemic states, both physiological and pathophysiological, are almost always
characterized by plasma AcAc/βOHB molar ratios that are < 1. SCOT-KO mice present a unique
hyperketonemic state in which the AcAc/βOHB molar ratio is > 1. Following their first high fat, low
carbohydrate milk meal, SCOT-KO mice develop hyperketonemia, which becomes associated with
diminished de novo production of D-βOHB. NMR studies in wild type mice co-injected with the fatty
acid [13C]octanoate and unlabeled ketone bodies indicate that increased circulating D-βOHB in germline
SCOT-KO mice diminishes hepatic production of βOHB. In the final ketogenic reaction, AcAc is reduced
to D-βOHB in an NAD+/NADH coupled equilibrium reaction catalyzed by BDH1 that normally favors
βOHB production (21,22,44). However, the equilibrium of the BDH1 reaction is sensitive to
concentrations of both AcAc and D-βOHB, such that increases in the molar concentrations of one partner
of the couple diminish the reduction/oxidation of the other (308). Because livers of SCOT-KO mice
initially produce D-βOHB in a normal fashion (Figs. 4.3B and 4.4), a model emerges in which loss of
peripheral ketone body oxidation results in pooling of D-βOHB, which causes the equilibrium of BDH1
to shift towards AcAc, such that AcAc becomes the primary ketone body synthesized by de novo hepatic
ketogenesis. Rising AcAc concentrations initially counteract the propensity of D-βOHB to reduce hepatic
redox potential, explaining why hepatic NAD+/NADH ratios are normal in fed P0 SCOT-KO mice.
Continued channeling of β-oxidation-derived acetyl-CoA to AcAc ultimately results in the high plasma
AcAc/βOHB ratios, and thus elevated hepatic NAD+/NADH ratios observed in P1 germline SCOT-KO
mice.
The development of oxidized hepatic redox potential may partially explain the alteration of
pyruvate and fatty acid handling in livers of P1 SCOT-KO mice. In states of high fat/low carbohydrate
nutrient supply, the vast majority of pyruvate delivered to the liver enters the TCA cycle via
carboxylation, rather than decarboxylation to acetyl-CoA via the PDH complex (29). While the pyruvate
carboxylation pathway is active, and possibly augmented in livers of P1 SCOT-KO mice, the
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fractional enrichments of glutamate observed in both (i) the [13C]octanoate + unlabeled pyruvate and (ii)
the [13C]pyruvate experiments both suggest that flux of pyruvate through PDH is relatively increased in
livers of SCOT-KO mice. Phosphorylation of the E1 a subunit of PDH was not diminished in livers of P1
SCOT-KO mice, which suggests equal PDH activity. However, pyruvate concentrations in these
experiments were high enough that PDH flux could be governed by the concentrations of its cofactor,
NAD+, and one of its allosteric inhibitors, NADH, whose concentrations are increased and decreased,
respectively, in livers of P1 SCOT-KO neonates (138,307,310). These findings are consistent with the
notion that increased gluconeogenic demand, and an oxidized hepatic redox potential together support a
state of increased pyruvate consumption that culminates in the diminished pyruvate pools that lead to
hypoglycemia in SCOT-KO mice. An additional consequence of augmented contribution of pyruvate to
the TCA cycle through acetyl-CoA is diminished contribution of fatty acid oxidation-derived acetyl-CoA.
While the NMR studies of P1 SCOT-KO mice injected with [13C]octanoate alone indicated equal
fractional enrichment of 13C-glutamate, this observation was obtained in the context of a diminished total
glutamate pool, raising the possibility that absolute flux of fatty acids through terminal oxidation is
reduced in livers of P1 SCOT-KO neonates. Increased circulating concentrations of short-chain
acylcarnitines in P1 SCOT-KO mice support this hypothesis. These integrated mechanisms merit further
evaluation in the pathogenesis of human neonatal hypoglycemia, a high-morbidity condition with an
incidence of 10% (311).
At birth, mammals experience a shift towards a lipid-dominated energy economy, inducing
hepatic fatty acid oxidation, ketogenesis, and gluconeogenesis (20). Although rodents are born at an
earlier developmental stage and exhibit lower neonatal body fat percentages, they suckle milk with higher
fat contents than humans, and physiological ketosis develops rapidly after birth in both (2,20,71). Case
reports indicate that HMGCS2- and SCOT-deficient humans adapt poorly to nutrient states that are
marked by diminished carbohydrate intake. Human HMGCS2 deficiency results in pediatric
hypoketonemic hypoglycemia (68), and human CoA transferase deficiency manifests as spontaneous
pediatric ketoacidosis (81,98), which in severe cases is associated with hypoglycemia, and may account
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for a subset of idiopathic ketotic hyopoglycemia cases (79,102). SCOT-KO mice die in a manner that
mimics human sudden infant death syndrome (SIDS)/sudden unexpected death in infancy (SUDI), the
leading cause of death of U.S. infants after the age of one month (312). Inborn errors of ketone body
oxidation are not currently assessed on any statewide screening protocols in the U.S. (99). Therefore,
these metabolic abnormalities merit further evaluation, as supported by a recent observational study in
which metabolic autopsies performed on 255 SIDS patients detected three individuals with underlying
disorders of ketone body metabolism (216). Thus, a small subset of sudden infant death cases could be
attributable to undetected defects in ketone body oxidation.
Due to their small size and delicate nature, steady state analyses of metabolic flux in neonatal
mice are not currently possible. Therefore, we performed NMR substrate fate mapping after bolus
injections of octanoate to quantify hepatic fatty acid fate in neonatal mice. This medium chain fatty acid
avidly enters the mitochondrial matrix independently of allosterically regulated mitochondrial carnitine
palmitoyltransferase 1a (5), and thus reports the activities of β-oxidation, fractional contribution to the
TCA cycle, and ketogenesis.
We have demonstrated that global disruption of ketone body oxidation reprograms hepatic
intermediary metabolism, initiating a cascade that alters ketogenesis and oxidizes hepatic redox potential,
and ultimately consumes pyruvate at the expense of terminal hepatic fatty acid oxidation, resulting in
accumulation of circulating short chain acylcarnitines and hepatic triacylglycerols. Thus, extrahepatic
ketone body oxidation helps integrate hepatic ketogenesis, redox potential, fatty acid oxidation, and
glucose production in the neonatal period. Future studies will be needed to determine whether these
relationships extend to other physiological and pathophysiological states characterized by excess fatty
acid availability and limited carbohydrate supply (or inefficient carbohydrate utilization), including
starvation, adherence to low carbohydrate diets, and Types 1 and 2 diabetes.
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Figure legends
Figure 4.1. Absence of extrahepatic ketone body oxidation engages an hepatic gluconeogenic
program in neonatal mice. (A) Relative mRNA abundance of encoded mediators of pyruvate
metabolism and gluconeogenesis in livers of P1 mice. n = 5/group. (B) Liver glycogen content (µg
glycogen/mg tissue) in P1 neonates. n = 8/group. p = 0.06 by Student’s t test. (C) Blood alanine, serine,
and glutamate concentrations (µM) in P1 mice. n = 5-7/group. (D) Circulating amino acid concentrations
(µM) in blood of P1 mice. n = 5-10/group. (E) Plasma pyruvate pool (pyruvate + lactate) in P1 mice. n =
8-11/group. (F) Endogenous hepatic glucose concentration (left) and accumulated [13C]glucose in livers
(right) of P1 mice that had been injected with [3-13C]pyruvate (10 µmol per g body weight) 30 min prior
to collection of tissues and generation of extracts for NMR. n = 4/group. *, p < 0.05; **, p < 0.01; ***, p
< 0.001 by Student’s t test. Ppargc1a, PPARg coactivator 1α; Pcx, pyruvate carboxylase; Pck1;
phosphoenolpyruvate carboxykinase; G6pc, cytoplasmic glucose-6-phosphatase.

Figure 4.2. Alterations of terminal fatty acid oxidation and pyruvate handling in livers of SCOTKO mice. (A) Hepatic fractional

13

C-enrichments of glutamate (left) and total hepatic glutamate pools

(right) 20 min after ip injection of sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in P1
mice. n=6-8/group. (B) Fractional

13

C-enrichments of glutamate (left) and total hepatic glutamate pools
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(right) 20 min after ip injection of sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) +
unlabeled pyruvate (20 µmol/g) in livers P1 mice. n=6-7/group. (C) Fractional

13

C-enrichments of

glutamate 30 min after ip injection of sodium [3-13C]pyruvate (10 µmol per g body weight) in livers P1
mice. n=4/group. (D) Short-chain acylcarnitine concentrations in blood of untreated P1 mice. n = 5-10/
group. (E) Hepatic triacylglycerol (TAG) content in livers of untreated P1 mice. n = 5-6/group. *, p <
0.05; **, p < 0.01; ***, p < 0.001 by Student’s t test.

Figure 4.3. Mother’s milk-induced impairment of de novo βOHB production in neonatal SCOT-KO
liver. (A) Hepatic fractional

13

C-enrichments of β-hydroxybutyrate (βOHB) (left), total βOHB pools

(middle), and 13C-βOHB concentration (right) 20 min after ip injection of sodium [1,2,3,4-13C4]octanoate
(10 µmol per g body weight) in P1 mice. n=6-8/group. (B) Fractional
total βOHB pools (middle), and

13

13

C-enrichments of βOHB (left),

C-βOHB concentration (right) 20 min after ip injection of sodium

[1,2,3,4-13C4]octanoate (10 µmol per g body weight) in livers of unfed P0 mice. n=6/group. (C) Plasma
total ketone body (TKB) concentration, mM, measured in P0 wild type and SCOT-KO mice prior to the
onset of suckling. n = 4/group. (D) Plasma TKB, mM, measured in P0 wild type and SCOT-KO mice
within 2 hours after the onset of suckling. The distributions of D-βOHB and AcAc are shown. n = 8-10/
group. †, p < 0.05 for AcAc; *, p < 0.05 for βOHB. n = 6-7/group. (E) Fractional

13

C-enrichments of

βOHB (left), total βOHB pools (middle), and 13C-βOHB concentration (right) 20 min after ip injection of
sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in milk-fed P0 mice. n = 6-7/group. ***, p
<0.001 by Student’s t test. AcAc, acetoacetate.

Figure 4.4. Normal in vitro hepatic ketogenesis of livers from SCOT-KO mice. Determination of
ketone body production (pmol ketone/mg liver), 0.25, 1, and 8 hr after stimulation with BSA-conjugated
oleic acid (150 µM), was used to derive ketogenic rate (pmol/mg/liver/hr) in liver explants derived from
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(A) unfed and (B) fed P0 mice. n = 4/group for unfed pups and n = 8-10/group for fed pups. **, p < 0.01;
***, p <0.001 by 1-way ANOVA.

Figure 4.5. D-βOHB inhibits neonatal hepatic ketogenesis in vivo. (A) Total βOHB pools, (B)
fractional

13

C-enrichments of βOHB, and (C)

13

C-βOHB concentrations, 20 min after ip injection of

sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) alone, or co-injected with [13C]octanoate
plus 20 µmol per g body weight unlabeled AcAc, L-βOHB, or D-βOHB, in livers of milk-fed P0 mice.
The [13C]octanoate alone datasets (the white bars in these panels) are reproduced from Fig. 3E for
comparison. n = 5-7/group for each panel. *, p < 0.05; **, p < 0.01; ***, p <0.001 vs. wild type neonates
injected with [13C]octanoate alone, or as indicated by 1-way ANOVA. ††, p < 0.01, †††, p < 0.001 vs. AcAc
co-injected neonates.

Figure 4.6. Oxidized hepatic redox potential in P1 SCOT-KO mice. (A) Plasma AcAc/D-βOHB molar
ratios in milk-fed P0 mice. n = 8-9/group. (B) NAD+/NADH ratios, NAD+, NADH, and total NAD
[NAD+ + NADH; NADt (nmol/g tissue)] in livers (n = 5/group) and (C) skeletal muscles of fed P0
neonates (n = 6/group). (D) Plasma AcAc/D-βOHB molar ratios in P1 mice. n = 11-14/group. (E)
NAD+/NADH ratios, [NAD+], [NADH], and [NADt] (nmol/g tissue) in livers and (F) skeletal muscles of
P1 wild type and SCOT-KO mice. n = 13-14/group. **, p < 0.01; ***, p <0.001 by Student’s t test.

Figure S4.1. PDH-E1α Ser293 phosphorylation in P1 Liver. (A) Immunoblot for phosphorylated
Ser293 of Pyruvate Dehydrogenase (PDH) E1α subunit (PDH-p293) and total PDH-E1α (PDHt) in
protein lysates derived from livers of P0 mice. (B) Densitometric quantification of phosphorylated Ser293
of PDH-E1α (pSer293-PDHE1α) normalized to total PDHE1α. n = 7/group.
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Figure S4.2. Normal oxidative and ketogenic machinery in livers of P1 SCOT-KO mice. (A) Relative
mRNA abundances of Fabp1, Fgf21, Cpt1a, Acadm, Hmgcs2, and Bdh1 in livers of P1 mice. n = 5/group.
(B) Immunoblots for HMGCS2 and actin in protein lysates derived from livers of P1 mice. Densitometric
quantification normalized to actin below. n = 4/group. (C) Immunoblots for BDH1 and actin in protein
lysates derived from livers of P1 mice. Densitometric quantification normalized to actin below. n
=7/group. *, p < 0.05 by Student’s t test.

Figure S4.3. Normal hepatic fractional enrichment of
SCOT-KO mice. (A) Fractional

13

13

C-glutamate from [13C]octanoate in P0

C-enrichments of glutamate (left) and total hepatic glutamate pools

(right) 20 min after intraperitoneal injection of sodium [1,2,3,4-13C4]Octanoate (10 µmol per g body
weight) in livers of unfed (n=6-7/group) and (B) milk-fed P0 mice (n = 6/group).

Figure S4.4. Normal oxidative and ketogenic machinery in livers of milk-fed P0 SCOT-KO mice.
(A) Relative mRNA abundance of Fabp1, Cpt1a, Acadm, Hmgcs2, and Bdh1 in livers of fed P0 mice. n =
5/group. (B) Immunoblots for HMGCS2 and actin in protein lysates derived from livers of P0 mice.
Densitometric quantification normalized to actin on right. n = 4/group. *, p < 0.05 by Student’s t test.

Figure S4.5. Relative abundances of mRNAs encoding mediators of NAD+ metabolism and
signaling in livers of P0 and P1 mice. n = 5/group. Nampt, nicotinamide adenine dinucleotide
phosphoribosyl transferase. Sirt1, silent mating type information regulation 2 homolog 1.

Figure S4.6. CoA transferase protein abundance in neonatal tissues. CoA transferase (SCOT) and
actin immunoblots of protein lysates derived from brain, heart, skeletal muscle, and liver collected from
P0 wild type and SCOT-KO mice.
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Table S4.1

RTqPCR
Primers
Acadm
Bdh1
Cpt1a
Fabp1
Fgf21
G6pc
Hmgcs2
Rpl32
Pck1
Pcx
Ppargc1a

Sequence (5'-3')
Forward

Reverse

GCTGGAGACATTGCCAATCA
TGCAACAGTGAAGAGGTGGAGAAG
CATGTCAAGCCAGACGAAGA
AAAGTGGTCCGCAATGAGTTCACC
CCAGATGTGGGCTCCTCTGAC
AAAGTCAACCGCCATGCAAAGGAC
TGGTTCAAGACAGGGACACAGAAC
CCTCTGGTGAAGCCCAAGATC
GGAAGGACAAAGATGGCAAGTTC
ACAGCACACACACTACCTGCAATG
CGGAAATCATATCCAACCAG

TCTTGGCGTCCCTCATCAG
CAAACGTTGAGATGCCTGCGTTGT
TGGTAGGAGAGCAGCACCTT
TTGTCACCTTCCAGCTTGACGACT
AGAAACAGCCCTAGATTCAGGAAGAGT
TAGCAAAGAAAGACAGGGCTACCAG
AGAGGAATACCAGGGCCCAACAAT
TCTGGGTTTCCGCCAGTTT
AGGCGTTTTCCTTAGGGATGTAG
GCAGGCCCTTATTTGGCAAGAGAT
TGAGGACCGCTAGCAAGTTTG
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Chapter 5
PPARα-dependent ketogenesis prevents hepatic steatosis in neonatal mice
The work presented in this chapter has been adapted from:
Cotter, D. G., Ercal, B., d'Avignon, D. A., and Crawford, P. A. Submitted.
Abstract
Peroxisome Proliferator Activated Receptor alpha (PPARα) is a master transcriptional regulator of
hepatic intermediary metabolism. PPARα mediates the adaptive response to fasting. Like fasting, nutrient
supply is abruptly altered at birth when a transplacental supply of carbohydrates is replaced by a high-fat,
low-carbohydrate milk diet. Here we use

13

C-labeled substrates to quantify dynamic metabolism and

complimentary systems physiology approaches in neonatal mice to demonstrate a critical role for PPARα
in hepatic metabolic adaptation to birth. PPARα-Knockout (KO) neonates exhibit hypoglycemia due to
impaired conversion of glycerol to glucose. Quantitative substrate fate mapping of the medium-chain fatty
acid [13C]Octanoate in neonatal liver revealed normal contribution of this fatty acid to the hepatic TCA
cycle in PPARα-KO neonates. Moreover, livers of PPARα-KO neonates showed evidence of direct
contribution of octanoate-derived

13

C-labeled carbons to glucose. These mice also exhibited

hypoketonemia, which could be mechanistically linked to a 50% decrease in hepatic ketogenesis from
[13C]Octanoate. Decreased ketogenesis was associated with diminished mRNA and protein abundance of
the fate-committing ketogenic enzyme mitochondrial 3-hydroxymethylglutarly-CoA synthase and
decreased protein abundance of the ketogenic enzyme Beta-hydroxybutyrate dehydrogenase 1. Finally,
hepatic triglyceride and free fatty acid concentrations were increased 6.9- and a 2.7-fold, respectively, in
PPARα-KO neonates. Together, these findings indicate an important role for PPARα-dependent
ketogenesis in disposal of excess hepatic fatty acids during the neonatal period.
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Introduction
Nutrient supply and organismal bioenergetics shift dramatically at birth. At birth, a continuous
transplacental nutrient stream replete with carbohydrates ceases and is replaced by a high-fat, lowcarbohydrate milk diet (20,71). Thus, the neonatal liver must coordinate inductions of hepatic fatty acid
oxidation, ketogenesis, and gluconeogenesis to meet the metabolic demands required for adaptation to
extrauterine life (20,71). Fatty acid oxidation yields high-energy phosphates and reducing equivalents
used to fuel the endergonic reactions of hepatic gluconeogenesis, and acetyl-CoA, which can be converted
to ketone bodies through ketogenesis. While glucose produced in the liver is the primary fuel source for
the neonatal brain, ketone bodies serve as an important glucose-sparing fuel source (2,4,71,301). Mice
that cannot oxidize ketone bodies exhibit lethal neonatal hypoglycemia, indicating that ketone body
metabolism is required for adaptation to birth (78).
Ketone body metabolism is a high capacity energy conduit between the liver and extrahepatic
tissues that can dispose of up to two-thirds of the fat entering the liver (281). In liver mitochondria, a
series

of

ketogenic

reactions

catalyzed

by

mitochondrial

thiolase,

mitochondrial

3-

hydroxymethylglutarly-CoA synthase (HMGCS2; fate-committing), and HMG-CoA lyase condense
acetyl-CoA derived from beta-oxidation of fatty acids into the ketone body, acetoacetate (AcAc), which is
reduced to beta-hydroxybutyrate (βOHB) by beta-hydroxybutyrate dehydrogenase 1 [(BDH1); reviewed
in (2,4,5,301)]. Within mitochondria of extrahepatic tissues, BDH1 oxidizes βOHB to AcAc. Terminal
oxidation of ketone bodies requires covalent activation of AcAc by coenzyme A (CoA), which is
catalyzed by mitochondrial succinyl-CoA-3:oxoacid CoA transferase (SCOT), the fate committing
enzyme of ketone body oxidation. SCOT is uniquely required for ketone body oxidation, and thus,
oxidation of ketones does not occur in its absence (301).
Our past studies of germline SCOT-Knockout (KO) mice indicate that ketone body oxidation is
required for life. All germline SCOT-KO mice die within the first 48 hr of life with hyperketonemia and
hypoglycemia, and in a manner that phenocopies human sudden infant death syndrome (78,313).
Surprisingly, ketone body oxidation is dispensable for survival of the neonatal period and starvation in
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adults when individually eliminated from cardiomyocytes, skeletal myocytes, and neurons, which
comprise the three greatest consumers of ketone bodies (108). Paradoxically, ketone body oxidation, an
exclusively extrahepatic process (74,164), contributes to hepatic metabolic homeostasis by preventing
toxic accumulation of ketone bodies, which alters pyruvate metabolism, fatty acid oxidation, inhibits
ketogenesis, and oxidizes redox potential in liver (313). Thus, inter-organ coordination of ketogenesis and
ketone body oxidation is critical for preservation of hepatic intermediary metabolism, which is vital
during the transition to extrauterine life.
The nuclear receptor Peroxisome Proliferator Activated Receptor alpha (PPARα) acts as a master
transcriptional regulator of hepatic intermediary metabolism (314,315). Fasted PPARα-KO mice exhibit
hypoglycemia, hypoketonemia, and hepatic steatosis (316,317). In response to fatty acids, PPARα
promotes ketogenesis by inducing enzymatic mediators of fatty acid oxidation, Fibroblast growth factor
21 (Fgf21), and by directly stimulating Hmgcs2 transcription (50,52,53,318,319). Significant overlap
exists between the bioenergetic challenges faced during fasting and during the transition to birth.
Therefore, we applied high-resolution measures of dynamic metabolism using 13C-labeled substrates and
systems physiology approaches to neonatal mice to determine the mechanisms by which PPARα supports
adaptation to birth.

Methods
Animals. Fed postnatal day zero (P0, the first day of postnatal life) mice were collected within 4 hr of
birth. All P1 mice were maintained with the dam through the first 30h after birth, and were milk fed. The
presence of gastric milk spots was checked in all mice, both by visual inspection of the abdomen prior to
experimentation and by gross examination of the gastric contents after sacrifice. Breeder pairs were
maintained at 22oC on standard polysaccharide-rich chow diet (Lab Diet 5053) and autoclaved water ad
libitum. Lights were off between 1800 and 0600. All experiments consisted of mouse pups that were
harvested from at least two litters from two different breeder pairings. All experiments were conducted
using protocols approved by the Animal Studies Committee at Washington University.
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Plasma Metabolite Quantification. Serum total ketone bodies (TKB) were determined using standard
biochemical assays coupled to colorimetric substrates as described previously (51). Blood glucose was
measured in duplicate using handheld glucometers (Aviva).
Tissue Metabolite Quantification. Hepatic triacylglyceride (TAG) and free fatty acid (FFA)
concentrations were quantified biochemically using a Folch extract of liver, as described previously
(126).
Gene expression analysis. Quantification of gene expression was performed using real-time RTquantitative PCR using the ΔΔCt approach as described (51), normalizing to Rpl32, using primer
sequences listed within Table 5.1.
Immunoblotting. Lysates from liver were generated in a protein lysis buffer: 20 mM Tris-HCl, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1% phosphatase inhibitor cocktail (Sigma), and protease inhibitor
cocktail (complete mini EDTA-free, Roche), pH 7.5. Immunoblots to detect HMGCS2 (rabbit antimHMGCS; Santa Cruz Biotechnology), BDH1 (rabbit anti-BDH1; Proteintech Group), and actin (rabbit
anti-actin, Sigma) were performed as described (78). Band intensities were quantified densitometrically
using Quantity One software (Bio-Rad).
Glycerol and glucose tolerance tests. Glucose and glycerol tolerance were measured in fed P0 mice that
had been removed from the dam and maintained on a heating pad for the duration of the experiment. For
glucose tolerance tests, neonates were injected intraperitoneally (ip) with 4% glucose dissolved in milliQ
H2O (2g/kg body weight). Blood glucose was measured at 15 min and at 60 min after glucose
administration via tail snip and decapitation, respectively. For glycerol tolerance tests, neonates were
injected with 4% glycerol in phosphate buffered saline (2g/kg body weight). Blood glucose was measured
prior to glycerol administration via tail snip and 45 min after glycerol administration via decapitation.
In vivo substrate utilization. P0 or P1 mice were injected ip with 10 µmol of sodium [1,2,3,413

C4]octanoate per g of body weight (vendor for stable isotopes: Cambridge Isotope Laboratories). After

intraperitoneal injections, neonatal mice were maintained on a heating pad for 20 min, killed by
decapitation, and tissues were rapidly freeze-clamped in liquid N2. Neutralized perchloric acid tissue
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extracts were profiled using
(Varian/Agilent

Direct

13

C-edited proton nuclear magnetic resonance (NMR) measured at 11.75 T

Drive-1)

via first

increment

gradient

heteronuclear

single-quantum

correlation (gHSQC). Signals were collected from extracts dissolved in 275 µL of D2O + 1 mM
trimethylsilyl propionate (TSP), loaded into high precision, thin walled 5-mm tubes (Shigemi).
Quantification of signals by integration of the 1H{13C} and

13

C-edited (gHSQC) collections of carbon 2

for taurine, carbon 4 for βOHB, carbon 1 for glucose, and carbon 4 for glutamate were as described
previously (78). Fractional enrichments of

13

C-labeled glucose, glutamate, and βOHB and tissue

concentrations (pool size) of glucose, taurine, glutamate, and βOHB were calculated as described
previously (51,313).

Results
PPARα deficient neonates exhibit hypoglycemia due to impaired gluconeogenesis from glycerol. During
fasting, the switch to a lipid-dominated nutrient supply evokes hypoglycemia in adult PPARα-KO mice
(316,317). Similarly, the shift to a high-fat, low-carbohydrate milk diet caused hypoglycemia in neonatal
PPARα-KO mice. On the first day of life, postnatal day zero (P0), glycemia did not differ between wild
type and PPARα-KO neonates (Fig. 5.1A, left). As expected, wild type neonates significantly increased
glycemia between P0 and the second day of life [(P1); Fig. 5.1A, white bars]. In contrast, PPARα-KO
neonates failed to increase glycemia between P0 and P1 (Fig. 5.1A, black bars), and on P1, blood
glucoses were significantly lower in PPARα-KO neonates compared to control mice (Fig. 5.1A, right).
Glucose tolerance tests in P0 mice demonstrated that glucose utilization was not different between wild
type and PPARα-KO neonates (Fig. 5.1B), suggesting that impaired gluconeogenesis might underlie the
hypoglycemia of PPARα-KO neonates. While hepatic mRNA abundances of the gluconeogenic mediators
Phosphoenol pyruvate carboxykinase (Pck1), Glucose-6-phosphatase (G6Pc), and Glycerol Kinase (Gyk)
did not differ between groups of mice on P0 or P1, expression of Glycerol phosphate dehydrogenase
(Gpd2) trended lower in PPARα-KO neonates on P0 and P1 (Fig. 5.2A-D). Furthermore, blood glucoses
were lower in P0 PPARα-KO neonates following intraperitoneal glycerol administration (glycerol
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tolerance test), suggesting that PPARα-KO neonates do not effectively convert glycerol to glucose (Fig.
5.2E). These results indicate that PPARα supports glycemia during adaptation to birth by promoting
gluconeogenesis from glycerol.
Loss of PPARα does not disrupt oxidation of medium-chain fatty acids in neonatal liver. PPARα
influences hepatic energy metabolism through transcriptional regulation of the mediators of fatty acid
oxidation, which is critical for gluconeogenesis. Surprisingly, mRNA abundances of many known PPARα
target genes involved in fatty acid oxidation, including Peroxisome proliferator activated receptor gamma
coactivator 1-alpha (Ppargc1a), Carnitine palmitolytransferase 1a (Cpt1a), and Acyl-CoA oxidase (ACO)
were not different between groups of mice on either P0 or P1 (Fig. 5.3A-C). In fact, PPARα-KO neonates
significantly induced Cpt1a between P0 and P1 (Fig. 5.3B). Of the mediators of fatty acid oxidation
analyzed, only medium chain acyl-CoA dehydrogenase (Acadm) transcript abundances were significantly
decreased in PPARα-KO neonates, and only on P1 (Fig. 5.3D). Next, we directly analyzed fatty acid
oxidation in neonatal liver using proton edited

13

C-nuclear magnetic resonance (NMR) spectroscopy to

quantify contribution of the medium-chain fatty acid [13C]octanoate to the hepatic tricarboxylic acid
(TCA) cycle. Following a 20 min incubation with [13C]octanoate (10µmol/g body weight), neonates were
sacrificed and livers were extracted for NMR profiling. 13C-enrichment of glutamate, which serves as a
quantitative surrogate for entry of 13C-acetyl-CoA into the TCA cycle for terminal oxidation (136), and
tissue glutamate concentrations (pool) did not differ between groups of mice on P0 or P1 (Fig. 5.3E).
Concentrations of taurine, a normalizing metabolite, also did not differ between groups of mice on P0 or
P1 (Fig. 5.3F). Moreover, 13C-glucose enrichment from [13C]octanoate was detected in both wild type and
PPARα-KO neonates on P0 and in PPARα-KO neonates on P1 (Fig. 5.3G, left). On P1, enrichment of
13

C-glucose from octanoate was 3-fold greater in PPARα-KO neonates compared to wild type mice (Fig.

5.3G, left). Since hepatic glucose pools did not differ between groups, increased enrichment reflects
increased gluconeogenesis from octanoate in the PPARα-KO neonates.
very low, as 1% enrichment occurs from naturally abundant

13

13

C –enrichments of 2-3% are

C. Nonetheless, these results indicate

preserved contribution of fatty acids to the hepatic TCA cycle in PPARα-KO neonates.
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Hepatic steatosis is linked to impaired ketogenesis in PPARα deficient neonates. To test the hypothesis
that loss of PPARα, which is an important inducer of Hmgcs2 and ketogenesis in adult mice, would
disrupt ketone body metabolism during the highly ketogenic neonatal period (2,4,20,50,316,317), we
performed a series of experiments in wild type and PPARα deficient neonatal mice. Circulating total
ketone body (TKB) concentrations were significantly lower in PPARα-KO neonates on P1 (Fig. 5.4A).
Blunted ketonemia was associated with a 3-fold decrease in Hmgcs2 transcript abundance on P1 (Fig.
5.4B). Conversely, Bdh1 transcript abundance increased significantly between P0 and P1 in both wild
type and PPARα-KO neonates (Fig. 5.4C). Immunoblots in liver demonstrated that HMGCS2 protein
abundance was decreased ~25% on P0 and ~ 20% on P1 in PPARα-KO neonates (Fig. 5.4D, middle).
Despite decreased Hmgcs2 mRNA abundance in P1 PPARα-KO livers, HMGCS2 protein abundance
increased ~ 25% in both genotypes. BDH1 protein abundance was decreased ~25% on P1 in PPARα-KO
neonates, and unlike wild type mice, did not increase from P0 to P1 (Fig. 5.4D, bottom). NMR profiling
of [13C]Octanoate metabolism in neonatal liver revealed that blunted ketonemia was due to impaired
ketogenesis. Enrichment of

13

C-βOHB was decreased ~ 33% on P0 and ~50% on P1 in PPAR-α-KO

livers (Fig. 5.5A, left). Because hepatic βOHB concentrations did not differ between genotypes on P0 or
P1 (Fig. 5.5A, right), decreased 13C-βOHB enrichment reflects decreased ketogenesis. In addition, livers
of PPAR-α-KO mice exhibited significantly increased concentrations of hepatic triacylglycerides (TAG)
and free fatty acids (FFA) on P1 (Fig. 5.5B-C). Together, these results indicate an important role for
PPARα-dependent ketogenesis in prevention of hepatic steatosis in neonatal mice.

Discussion
The transition to extrauterine life incurs marked shifts in nutrient availability and energy metabolism. In
contrast to the carbohydrate-replete nutrient state experienced in utero, the neonatal energy economy is
dominated by lipid metabolism. Thus, it is surprising that mice deficient in PPARα, a master regulator of
lipid metabolism, survive the neonatal period. Using NMR to quantitatively map substrate fate in neonatal
liver and systems physiology approaches, we have identified and mechanistically dissected the metabolic
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defects exhibited by PPARα-KO neonates. These mice showed hypoglycemia that was mechanistically
linked to decreased gluconeogenesis from glycerol. Surprisingly, livers of PPARα-KO mice exhibited
normal expression of many mediators of fatty acid oxidation. Furthermore, terminal oxidation of the
medium-chain fatty acid octanoate was normal in livers of these mice. Unlike fatty acid oxidation,
ketogenesis was markedly impaired in PPARα-KO neonates. These mice displayed hypoketonemia due to
a 50% decrease in hepatic ketogenesis that was linked to decreased expression of ketogenic enzymes and
was associated with hepatic steatosis. Together, our results identify a critical role for PPARα-dependent
ketogenesis in disposal of excess hepatic fatty acids in the neonatal period.
PPARα-KO neonates exhibited hypoglycemia, hypoketonemia, and hepatic steatosis, and thus,
phenocopy fasted adult PPARα-KO mice (316,317). The mechanisms underlying fasting hypoglycemia in
adult PPARα-KO mice are controversial. Kersten and colleagues have linked hypoglycemia to decreased
hepatic glucose production from glycerol (320), while Xu et al. has shown preserved gluconeogenesis
from glycerol (321). Our results in neonates are most consistent with the findings of Kersten et al., as
glycerol tolerance tests revealed that PPARα-KO neonates do not effectively convert glycerol to glucose.
While increased glucose utilization could drive hypoglycemia, adult PPARα-KO mice actually exhibit
decreased glucose utilization (320). Similarly, glucose tolerance did not differ between groups of neonatal
mice, suggesting that increased glucose utilization was not responsible for neonatal hypoglycemia.
Since hepatic fatty acid oxidation supports gluconeogenesis, impaired fatty acid oxidation is
frequently offered as a cause of hypoglycemia in PPARα-KOs (316,317). However, due to the challenges
associated with directly measuring contribution of fatty acids to the TCA cycle, ketonemia is often used
as a surrogate for fatty acid oxidation. Here we used [13C]Octanoate, a medium chain fatty acid avidly
enters the mitochondrial matrix independently of allosterically regulated mitochondrial carnitine
palmitoyltransferase 1a (5), to directly interrogate the activities of β-oxidation, fractional contribution to
the TCA cycle, and ketogenesis. Our results indicate that impaired fatty acid oxidation does not contribute
to hypoglycemia in PPARα-KO neonates, since contribution of [13C]Octanoate to the TCA cycle for
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terminal oxidation was normal in livers of these mice. Second, our results indicate that ketogenesis is a
poor surrogate for fatty acid oxidation, as ketonemia and ketogenesis are diminished in PPARα-KO
neonates (Fig. 5.4A and 5.5A), while contribution of fatty acid oxidation-derived Ac-CoA to the TCA
cycle is preserved (Fig. 5.3E). In fact, contribution of [13C]Octanoate to the hepatic TCA cycle is robust
enough to measure its incorporation into

13

C-glucose (Fig. 5.2G). Fatty acid carbons do not normally

contribute to gluconeogenesis because rates of pyruvate carboxylation (to the TCA cycle intermediate
oxaloacetate) and subsequent efflux into gluconeogenesis (pyruvate cycling) greatly exceed TCA cycle
flux in liver (30,322). Prospectively, impaired mitochondrial pyruvate carboxylase activity (encoded by
Pcx, a PPARα target gene) could permit increased incorporation of fatty-acid derived carbon into glucose
and impair gluconeogenesis from pyruvate. Furthermore, 13C-labeling of glucose detected in the present
study does not reflect net gluconeogenesis from fatty acids. Unlike lower organisms, mammals cannot
channel net acetyl-CoA carbon into glucose due to absence of the glyoxyalte cycle enzymes isocitrate
lyase and malate synthase (323). Ac-CoA entering the mammalian TCA cycle must instead pass through
two obligatory decarboxylation reactions, catalyzed by isocitrate dehydrogenase and alpha-ketoglutarate
dehydrogenase, before proceeding on to generate gluconeogenic intermediates. Because two moles of
carbon are lost as CO2 for every mole of Ac-CoA that enters the mammalian TCA cycle, net
gluconeogenesis from fat does not occur.
As indicated above, PPARα-KO neonates exhibited marked suppression of hepatic ketogenesis.
On P0, ketogenesis was diminished by ~33%, and by P1, the diminution of ketogenesis reached 50%.
Such ketogenic suppression seems disproportionate to the moderately decreased HMGCS2 and BDH1
protein abundances observed in livers of these mice. Prospectively, decreased activity of the NAD+dependent mitochondrial deacylases Sirtuin 3 and 5, which increase HMGCS2 enzymatic activity via
deacetylation and desuccinylation, respectively (64,324), could account for the apparent mismatch
between low

13

C-βOHB enrichment and nearly normal HMGCS2 and BDH1 protein abundances.

Nonetheless, ketogenic suppression was associated with massive hepatic steatosis. PPARα-KO livers
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exhibited 6.9- and 2.7-fold increases in TAG and FFA concentrations, respectively. Together, these
results reveal an important role for PPARα-dependent ketogenesis in disposal of excess hepatic fat that
may be relevant to nonalcoholic fatty liver diseae (NAFLD).
NAFLD and nonalcoholic steatohepatitis (NASH) affect approximately one billion individuals
worldwide and incur significant morbidity and mortality (325-327). Nonetheless, effective therapies that
directly target NAFLD and NASH do not currently exist (328). While PPARα deficiency increases
NASH susceptibility (329,330), treatment with the PPARα agonist Wy-14643 protects against dietinduced steatohepatitis in mice (330). Similarly, fenofibrate treatment ameliorated NASH in mice (331).
Unfortunately, fenofibrate treatment does not decrease hepatic triglyceride content in human NAFLD
(332,333). One resolution for this interspecies discrepancy is offered by the finding that PPARα agonists
stimulate ketogenesis much more robustly in rodents than in humans (334-338). Thus, development and
testing of direct ketogenic activators for mitigation of human NAFLD is warranted.

Figure legends:
Figure 5.1: PPARα-KO mice exhibit neonatal hypoglycemia. A. Blood glucose on postnatal day zero and
one (P0 and P1) in suckling wild type and PPARα-KO mice. B. Glucose tolerance in P0 mice. Basal
glycemia (0 min timepoint) is replicated from A since glycemia can only be measured twice in neonatal
mice. n > 10/group, ***, p < 0.001 by 2-way ANOVA, as indicated.

Figure 5.2: PPARα promoted gluconeogenesis from glycerol in neonatal mice. A-D. mRNA abundances
of gluconeogenic mediators in liver. n = 5/group, **, p < 0.01 by 2-way ANOVA, as indicated.
E. Glycerol tolerance test in fed P0 mice, n > 10/group**, p < 0.01 by Student’s t test, as indicated.
Phosphoenolpyruvate carboxykinase 1, Pck1; Glucose-6-phophatase, G6pc; Glycerol kinase, Gyk;
Glycerol phosphate dehydrogenase, Gpd2.

130

Figure 5.3: Normal hepatic fatty acid oxidation in PPARα-KO neonates. A-D. Hepatic mRNA
abundances of mediators of fatty acid oxidation. n = 5/group, *, p < 0.05 by 2-way ANOVA, as indicated.
E. Hepatic fractional 13C-enrichments of glutamate (left) and total hepatic glutamate pools (right) 20 min
after ip injection of sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in neonatal mice. n=38/group. F. Total hepatic taurine pools from the same mice as in E. G. Hepatic fractional 13C-enrichments
of glucose (left) and total hepatic glucose pools (right) from the same mice as in E. **, p < 0.01 by 2-way
ANOVA, as indicated. Peroxisome proliferator activated receptor gamma coactivator 1-alpha, Pparg1a;
Carnitine palmitoyl transferase 1a, Cpt1a; Acyl-CoA oxidase, ACO; Medium chain acyl-CoA
dehydrogenase, Acadm.

Figure 5.4: PPARα-KO neonates exhibit hypoketonemia due to decreased expression of ketogenic
enzymes. A. Serum total ketone bodies (TKB) in fed neonatal mice, n > 6/group. B-C. Hepatic mRNA
abundances

of

ketogenic

enzymes,

n

=

5/group.

D.

Immunoblots

for

mitochondrial

3-

hydroxymethylglutaryl CoA synthase 2 (HMGCS2), beta-hydroxybutyrate dehydrogenase 1 (BDH1), and
actin in neonatal liver (quanitification normalized to actin below). n = 4/group, *, p < 0.05, **, p < 0.01,
***, p < 0.001 by 2-way ANOVA, as indicated.

Figure 5.5: Ketogenic suppression is associated with neonatal hepatic steatosis. A. Hepatic fractional 13Cenrichments of β-hydroxybutyrate (βOHB) (left) and total βOHB pools (right) 20 min after ip injection of
sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in neonatal mice. n = 3-8/group,
*, p < 0.05 by 2-way ANOVA. B. Hepatic triacylglyceride (TAG) and free fatty acid (FFA; C)
concentrations in suckling mice on P1. n = 6-7/group, ***, p < 0.001 by Student’s t test, as indicated.
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Chapter 6
Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia through coenzyme A
recycling
The work presented in this chapter and subchapters has been adapted from:
Cotter, D. G., Ercal, B., Leid, J. M., d'Avignon, D. A., Graham, M. J., Dietzen, D. J., Brunt, E. M., and
Crawford, P. A. Submitted.
Summary
Nonalcoholic fatty liver disease (NAFLD) spectrum disorders affect approximately one billion
individuals worldwide, and incur significant morbidity and mortality (325-327). The driver mechanisms
that underlie NAFLD remain incompletely defined, impeding the development of effective treatments
(328,339,340). Here we use a murine model of mitochondrial 3-hydroxymethylglutaryl CoA synthase
(HMGCS2)-deficiency to demonstrate a critical role for ketogenesis in the modulation of hepatic glucose
production and prevention of hepatic injury and inflammation in ‘non-ketogenic’ nutrient states. Using
nuclear magnetic resonance spectroscopy to quantitatively map

13

C-labeled substrate fate in perfused

livers, we show that adult-onset loss of HMGCS2 increases hepatic gluconeogenesis from pyruvate and
causes mild hyperglycemia in the fed state. High-fat diet feeding of ketogenesis insufficient mice causes
extensive hepatocyte injury, pan-acinar inflammation, and elevated serum alanine aminotransferase
activity. Hepatocellular injury in ketogenesis insufficient mice fed a high fat diet was associated with
decreased glycemia, which could be mechanistically linked to fatty acid-induced sequestration of free
coenzyme A (CoASH) that caused secondary derangements of hepatic tricarboxylic acid (TCA) cycle
intermediate concentrations and impaired gluconeogenesis. Supplementation of the CoASH precursors
pantothenic acid and cysteine normalized TCA intermediates and hepatic glucose production in
ketogenesis insufficient livers. These findings identify hepatic ketogenesis as a critical regulator of
hepatic glucose metabolism and TCA cycle function via coordination of CoASH homeostasis in the
absorptive state and indicate that ketogenesis is a prospective modulator of fatty liver disease.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are now the most
common causes of liver disease in Western countries (325). NAFLD-induced liver failure is one of the
most common reasons for liver transplantation. NAFLD increases the risk of developing type 2 diabetes,
worsens glycemic control, and contributes to the pathogenesis of cardiovascular disease and chronic
kidney disease (341-343). The pathogenic mediators that favor a NAFLD or NASH phenotype are
incompletely understood, but are thought to involve abnormalities of hepatocyte metabolism, hepatocyte
autophagy and endoplasmic reticulum stress, hepatic immune cell function, adipose tissue inflammation,
and systemic inflammatory mediators (341,343-345). Perturbations of carbohydrate, lipid, and amino acid
metabolism occur in and contribute to obesity, diabetes, and NAFLD in humans and in model organisms
[reviewed in (346-350)]. While hepatocyte abnormalities in cytoplasmic lipid metabolism are commonly
observed in NAFLD (335), the role of mitochondrial metabolism, which governs the oxidative and
terminal ‘disposal’ of fats, in NAFLD pathogenesis is less clear. Nonetheless, most investigators agree
that abnormalities of mitochondrial metabolism occur in and contribute to NAFLD [reviewed in (351353)].
Ketogenesis can dispose of as much as two-thirds of the fat entering the liver (281), and thus
dysregulation of ketone body metabolism could potentially contribute to NAFLD pathogenesis. Hepatic
ketogenesis is activated in states of high fatty acid and diminished carbohydrate availability, and/or when
circulating insulin concentrations are very low (2,4,5,301). Within hepatic mitochondria, ketogenic
reactions condense β-oxidation-derived acetyl-CoA into the ketone bodies acetoacetate (AcAc) and betahydroxybutyrate (βOHB). In doing so, ketogenesis disposes of acetyl-CoA generated in excess of the
liver’s own energetic needs and simultaneously recycles two moles of free CoASH per mole of ketone
produced [reviewed in (4,5,301)]. Robust ketogenesis is limited to hepatocytes due to relatively restricted
expression of the fate-committing ketogenic enzyme, mitochondrial 3-hydroxymethylglutaryl-CoA
synthase (HMGCS2), under normal conditions (44). In contrast, oxidative disposal of ketone bodies is
nearly ubiquitous, as all cells, except for hepatocytes, express the fate-committing enzyme of ketone body
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oxidation, succinyl-CoA:3-oxoacid CoA transferase [SCOT; (74,164)]. Within mitochondria of
extrahepatic tissues, βOHB is re-oxidized to AcAc, and via a reaction uniquely catalyzed by SCOT, is
directed towards the TCA cycle for terminal oxidation (301). Despite the high capacity for disposal of
hepatic fatty acids, ketone body metabolism has been overlooked as a potential therapeutic target in
NAFLD.
Through incompletely defined mechanisms, obesity-associated hyperinsulinemia suppresses
ketogenesis creating a state of ketogenic insufficiency and leading to relative hypoketonemia in obese
animal models and humans, when compared to lean controls (12,42,238,239,354,355). To test the
hypotheses that impaired ketogenesis, even in carbohydrate replete and thus ‘non-ketogenic’ states,
contributes to abnormal glucose metabolism and provokes steatohepatitis, we generated a mouse model of
ketogenic insufficiency, and used complementary high-resolution measures of dynamic metabolism using
13

C-labeled substrates with systems physiology approaches to measure the effects of ketogenic

impairment.

Results
Ketogenic insufficiency causes abnormal hepatic glucose and lipid metabolism. The ability of
ketogenesis to influence hepatic glucose and lipid homeostasis has only been preliminarily defined. To
determine the consequences of impaired ketogenesis during the highly ketogenic neonatal period,
suckling mice were injected subcutaneously (25 mg/kg) with an HMGCS2 targeted antisense
oligonucleotide (ASO) daily beginning on the second day of extrauterine life. Compared to littermates
injected with scrambled sequence control ASO, HMGCS2 ASO treatment decreased hepatic HMGCS2
protein abundance by 70% by postnatal day 12 (Fig. 6.1A). These mice exhibited normal body weights
and blood glucose concentrations, and displayed mildly decreased plasma ketone body concentrations
(0.9 ± 0.05 mM vs. 1.3 ± 0.17 mM in controls, n =4-6/group, p < 0.05; Fig. 6.1B and Fig. S6.1A-B).
Intriguingly, this partial loss of ketogenesis was associated with a nearly seven-fold increase in hepatic
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triacylglycerol (TAG) concentrations (6.56 ± 1.2 vs. 0.96 ± 0.2 mg/g tissue in controls, n =4-6/group, p <
0.001; Fig. 6.1C). To determine whether HMGCS2-mediated ketogenesis plays a role in a model of adult
NAFLD, we performed intraperitoneal injections of HMGCS2 ASO (25 mg/kg biweekly for four weeks)
into C57BL/6 male mice maintained on a standard low-fat chow diet. After four weeks, hepatic Hmgcs2
transcript abundance was decreased by 88% (n = 8-10 per group, p < 0.001), without diminishing the
scant Hmgcs2 transcript abundance normally observed in subcutaneous adipose tissue [(356), (Fig.
S6.1C-D)], and immunoreactive HMGCS2 was eliminated from liver compared to mice treated with a
scrambled sequence control ASO (Fig. 6.1D). ASO treatment did not diminish protein abundance of
cytoplasmic 3-hydroxymethylglutaryl-CoA synthase (HMGCS1), which catalyzes the penultimate
reaction in mevalonate synthesis (Fig. S6.1E).
HMGCS2 ASO-treated mice exhibited markedly blunted ketonemia at both baseline (fed state)
and in response to nutrient deprivation (Fig. 6.1E). To confirm the inability of HMGCS2 ASO-treated
mice to effectively incorporate fatty acid-derived carbon into ketone bodies, livers from control and
HMGCS2 ASO-treated mice were perfused via the portal vein with an oxygenated buffer containing
[13C]octanoic acid. Quantitative mapping of

13

C-label into the ketone body βOHB, using

13

C-edited

proton NMR profiling (51,78,108,313), revealed markedly blunted hepatic ketogenesis in livers of
HMGCS2 ASO-treated mice in both the fed and fasted state, confirming that HMGCS2 is required for
effective derivation of ketone bodies from fatty acids, indicating that livers of these mice exhibit impaired
ketogenesis, i.e. are ketogenesis insufficient (Fig. S6.1F). Despite exhibiting marked ketogenic
impairment, HMGCS2 ASO-treated mice fed a standard low fat chow diet did not differ in body weights,
body composition, or food intake compared to control mice (Fig. S6.2A-C). HMGCS2 ASO-treated mice
also exhibited normal serum free fatty acid (FFA) and TAG concentrations and a normal physiologic
distribution of residual βOHB and AcAc (Fig. 6.2D-F). Interestingly, HMGCS2 ASO-treated mice
displayed mild, but very consistently elevated blood glucose concentrations (160.9 ± 3.2 vs. 145.0 ± 3.4
mg/dL in controls, n = 28-36/group, p = 0.0013) without changes in serum insulin concentrations (Fig.
S6.2G-H).
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Ketogenic insufficiency causes hepatic inflammation, injury, and reprogrammed intermediary
metabolism in the setting of carbohydrate-replete overnutrition. To determine the effects of ketogenic
insufficiency in the context of overnutrition, mice previously receiving ASOs for two weeks while on a
standard low-fat chow diet were then maintained for eight weeks on a 60% high fat diet (HFD) that is
commonly used to induce hyperglycemia and hepatic steatosis and inflammation in wild-type mice.
HMGCS2 immunoblots indicated that hepatic HMGCS2 protein abundance was decreased by 93% within
two weeks of ASO treatment (Fig. S6.3A), and continued to decrease to undetectable levels by the end of
the eight week HFD-feeding interval, during which time ASO treatments were continued biweekly (Fig.
S6.3B). While serum TAG and FFA concentrations did not differ between groups of HFD-fed mice (Fig.
S6.3C-D), serum ketone body concentrations were significantly decreased in HFD-HMGCS2 ASOtreated mice (0.04 ± 0.02 mM vs. 0.26 ± 0.03 mM, p < 0.0001, n = 8-10/group; Fig. S6.3E). After 8
weeks of HFD-feeding, control and HMGCS2 ASO-treated mice exhibited mild hepatic steatosis to an
equal extent, as determined by biochemical quantification of hepatic TAG (Fig. 6.2A). As expected,
serum alanine aminotransferase (ALT) activity, a circulating biomarker of hepatocellular injury, was not
elevated in HFD-fed control mice, given the relatively brief duration of HFD maintenance (Fig. 6.2B).
Conversely, HFD-feeding increased serum ALT activity by nearly four-fold in HMGCS2 ASO-treated
mice compared to those maintained on standard chow (223.5 ± 37.65 vs. 61.2 ± 4.03 U/L in chow-fed
HMGCS2 ASO-treated mice, n = 4-5/group, p < 0.0001) and three-fold compared to HFD-fed control
mice [(223.5 ± 37.65 vs. 74.25 ± 6.14 U/L in controls, n = 4/group, p < 0.0001); (Fig. 6.2B)]. Blinded
histopathologic evaluation of liver tissue from ketogenesis insufficient mice fed a HFD exhibited
evidence of injury, including pan-acinar inflammatory infiltrates and acidophil bodies [(dying
hepatocytes; (Fig. 6.2C)]. These findings were not observed in livers from HFD-fed control ASO-treated
mice or chow-fed HGMCS2-deficient mice (Fig. 6.2C). In addition, livers of HFD-fed HMGCS2 ASOtreated mice exhibited increased numbers of sinusoidal macrophages, confirmed with F4/80
immunohistochemical staining (80.47 ± 6.09 vs. 49.33 ± 3.17 F4/80+ cells/20X field, p < 0.001, n = 5
fields/liver from three livers/group; Fig. 6.2D) and increased evidence of stellate cell activation, as
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indicated by anti-smooth muscle actin immunostaining (8.19 ± 1.00 vs. 3.36 ± 0.61 SMA+ cells/10X field,
p < 0.001, n = 19 fields/liver from three livers/group; Fig. 6.2E). These results indicate that ketogenic
insufficiency in the setting of overnutrition accelerates a pronounced NASH-like phenotype.
To determine the metabolic effects of ketogenic insufficiency in the setting of overnutrition, we
monitored blood glucose concentrations during the course of HFD administration. While blood glucose
levels were higher in HMGCS2 ASO-treated mice at the onset of HFD, glycemia began to decline in
these mice after five weeks of maintenance on this diet (Fig. 6.3A-B). HFD-fed HMGCS2 ASO-treated
mice also gained significantly less weight than control mice (final weight after HFD-feeding: 26.82 ± 0.7
g vs. 30.32 ± 1.2 g in controls, p = 0.019, n = 8-10/group) and ingested fewer calories [(9.96 ± 0.3
kCal/mouse/day vs. 12.91 ± 0.3 kCal/mouse/day in controls, p < 0.0001, n = 8-10 mice/group over 16
measurements of food intake); (Fig. S6.4A-B)]. Furthermore, gluconeogenesis from [13C]pyruvate (and
its redox partner [13C]lactate, which was also included in these perfusions in physiological proportion to
maintain normal NAD+/NADH redox potential) was decreased four-fold in livers of HFD-fed HMGCS2
ASO-treated mice (1.8 ± 0.3% vs. 7.3 ± 1.1 enrichment as [13C]glucose in controls, p = 0.0009, n = 45/group; Fig. 6.3C). While the total hepatic glucose pool was expanded in perfused livers of HFD-fed
HMGCS2 ASO-treated mice (Fig. S6.5A), de novo

13

C-labeling of glucose from [13C]pyruvate was

markedly diminished in HFD-fed HMGCS2 ASO-treated livers (3.91 ± 1.67 vs. 10.44 ± 0.9 pmol
[13C]glucose produced/mg tissue in controls, p = 0.0156, n = 4-5/group; Fig. 6.). Similar to the responses
to the 60% HFD, HMGCS2 ASO-treated mice maintained on a distinct 40% fat/sucrose enriched diet for
8 weeks also exhibited decreased weight gain, decreased caloric intake, decreased body fat percentages,
and decreased blood glucoses (Fig. S6.4C-F). Ketogenesis insufficient mice fed a 40% fat diet also
exhibited equivalent hepatic steatosis to control HFD-fed mice, modestly increased serum ALT activity,
and microgranuloma formation and inflammatory infiltrates in liver (Fig. S6.6A-C). Importantly, both the
elevation of serum ALT activity and the degree of histopathologic evidence of hepatic inflammation was
diminished in HMGCS2 ASO-treated mice fed a 40% fat diet compared to those fed a 60% HFD,
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suggesting that chronic exposure to excess dietary fat drives the NASH-like phenotype observed in
HMGCS2 ASO-treated mice.
To define the specific metabolic mechanisms leading to fatty acid induced hepatocellular
dysfunction, we quantified gluconeogenesis from [13C]pyruvate in perfused livers of ASO-treated mice
fed a standard low-fat chow diet in the presence and absence of octanoic acid, a medium chain fatty acid
that enters the mitochondrial matrix independently of carnitine palmitoyltransferase 1 (CPT1), and rapidly
stimulates mitochondrial β-oxidation and gluconeogenesis (5). Consistent with hyperglycemia in chowfed HMGCS2 ASO-treated mice (Fig. S6.2G), basal gluconeogenesis from pyruvate was increased (15.21
± 2.06%

13

C-enrichment of glucose, vs. 9.04 ±1.01% in controls, n = 7-8/group, p = 0.015, Fig. 6.3D).

Because total hepatic glucose concentrations did not differ between groups (Fig. S6.5C), increased
enrichment reflects increased production from pyruvate. As expected, addition of unlabeled octanoic acid
to the perfusion buffer stimulated gluconeogenesis in livers of control animals (Fig. 6.3D, white bars) but
in contrast, HMGCS2 ASO-treated livers perfused with octanoic acid did not increase gluconeogenesis,
and in fact exhibited decreased 13C-glucose enrichment compared to control livers [(11.83 ± 1.70% 13Cenrichment of glucose vs. 17.61 ± 1.34% in controls, n-7-8/group, p = 0.018, Fig. 6.3D), without altering
total glucose pools (Fig. S6.5C). The inability of octanoic acid to stimulate glucose production in
HMGCS2 ASO-treated livers was observed despite increased mRNA abundances of Ppara, Aco, Cpt1a,
Ppargc1a, Pck1, and Me2 and normal mRNA abundances of Acadm, Fgf21, and G6Pc in liver (Fig.
S6.5D), suggesting that a metabolic mechanism, rather than insufficient expression of the enzymatic
mediators of fatty acid oxidation and gluconeogenesis, underlies the observed defect in fatty-acid
stimulated glucose production in the setting of ketogenic insufficiency.
Ketogenic insufficiency sequesters free coenzyme A. Because induction of gluconeogenesis by fatty
acids is dependent on the NADH and ATP generated through the TCA cycle (281,357,358), we
hypothesized that the failure of mitochondrial fatty acids to stimulate gluconeogenesis in the absence of
ketogenesis could be mechanistically linked to a failure to couple β-oxidation of fatty acids to their
terminal oxidation in the TCA cycle. To determine whether there were abnormalities of TCA cycle
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function in livers of HMGCS2 ASO-treated mice, we measured TCA cycle intermediate pool
concentrations in perfused livers of control and HMGCS2 ASO-treated mice. While tissue α-KG
concentrations were normal in livers perfused in the absence of octanoate, inclusion of this fatty acid in
the perfusion buffer increased concentrations of α-KG by two-fold in HMGCS2 ASO-treated livers (0.75
± 0.08 nmol/mg tissue vs. 0.34 ± 0.08 nmol/mg tissue in control livers perfused with octanoate, n = 78/group, p = 0.0032, Fig. 6.3E). Perfusion with octanoic acid also increased hepatic concentrations of
glutamate, an equilibrium partner of α-KG, by two-fold, and decreased hepatic succinate concentrations
by 43% in HMGCS2 ASO-treated livers (99.89 ± 12.89 pmol/mg tissue vs.162.8 ± 20.08 pmol/mg tissue
in controls, p < 0.01, n = 7-8/group; Fig. S6.5E and Fig. 6.3F). Collectively, these findings suggest a
block at the TCA cycle reaction catalyzed by the α-KG dehydrogenase complex. Because the oxidative
decarboxylation of α-KG to succinyl-CoA, which is subsequently converted to succinate, requires free
CoASH, we quantified CoASH concentrations in unperfused and perfused livers of ASO-treated mice.
While HMGCS2-ASO treatment did not alter CoASH concentrations in unperfused livers of standard
chow-fed mice, or in livers perfused in the absence of octanoate, hepatic CoASH concentrations were
decreased 60% in HMGCS2 ASO-treated livers perfused with octanoic acid (40.73 ± 14.35 pmol/mg
tissue vs. 106.6 ± 24.31 pmol/mg tissue in controls, p = 0.035, n = 8/group, Fig. 6.3G). Fatty acidinduced depletion of CoASH observed in HMGCS2 ASO-treated livers occurred despite normal
expression of Pank1a, and increased expression of Pank1b (1 ± 0.022 vs. 2.5 ± 0.6, p = 0.04, n = 810/group), which phosphorylate pantothenic acid in the first step of de novo CoASH biosynthesis (Fig.
S6.5F).
Consistent with the octanoate-induced derangements of TCA cycle intermediates and CoASH
depletion in livers of standard chow-fed HMGCS2 ASO-treated mice, unperfused livers of HMGCS2
ASO-treated mice fed a 60% HFD displayed increased [glutamate] (2.56 ± 0.4 vs. 1.12 ± 0.12 nmol/mg
tissue in controls, p = 0.018, n = 4-5/group), a trend towards decreased [succinate], and decreased hepatic
[CoASH] (28.40 ± 11.51 pmol CoASH/mg tissue vs.103.10 ± 32.62 in controls, p = 0.049, n = 8/group;
Fig. S6.5G-I). Finally, circulating short- and medium-chain acylcarnitine concentrations, but not those of
145

long-chain acylcarnitines, were significantly increased in HMGCS2 ASO-treated mice fed a 40% fat diet
(Fig. S6.7; for a full profile for chow-fed and 40% HFD-fed mice, see Table S6.1-2). Taken together,
these results suggest that ketogenic insufficiency in the setting of high fat delivery to mitochondria
depletes free CoASH and thereby impairs TCA cycle function, which inhibits entry of acetyl-CoA and
thus favors increased accumulation of shorter-chain acylcarnitines.
To determine if supplementation of the CoA precursors pantothenic acid (vitamin B5) and
cysteine, could restore glucose production and normalize TCA cycle intermediate concentrations in
HMGCS2 ASO-treated livers, we perfused livers of HMGCS2-deficient and control animals with
exogenous octanoate and CoA precursors. While inclusion of pantothenic acid and cysteine with
[13C]lactate, [13C]pyruvate, and unlabeled octanoic acid during a 15 min perfusion failed to normalize
gluconeogenesis in HMGCS2 ASO-treated livers, (Fig. 6.4A, left), prolonged repletion of CoASH
precursors by perfusing livers with pantothenic acid and cysteine for 45 min prior to perfusion with
[13C]lactate and [13C]pyruvate, unlabeled octanoic acid, pantothenic acid, and cysteine for 15 min
normalized 13C-glucose enrichment (Fig. 6.4A, right). Total hepatic glucose concentrations did not differ
between control and HMGCS2 ASO-treated livers in either perfusion experiment (Fig. S6.8). Moreover,
pre-perfusion with CoASH precursors attenuated the expansion of the α-KG and glutamate pools in
HMGCS2 ASO-treated livers, with pre-perfused HMGCS2 ASO-treated livers exhibiting a 29% decrease
in [α-KG] and a 43% decrease in [glutamate] compared to HMGCS2 ASO-treated livers that were not
pre-perfused with CoASH precursors (n= 5-7/group, p < 0.05 for α-KG, and p < 0.001 for glutamate; Fig.
6.4B-C). Finally, inclusion of pantothenic acid and cysteine normalized succinate concentrations in livers
of HMGCS2 ASO-treated mice irrespective of the length of the perfusion (Fig. 6.4D). Taken together,
these results mechanistically link the HFD-induced hypoglycemia and fat-induced impairment of hepatic
gluconeogenesis observed in ketogenesis insufficient mice to CoASH depletion and inhibition of the αKG dehydrogenase reaction of the TCA cycle.
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Discussion
Hepatic ketogenesis is activated when fatty acids are plentiful, carbohydrates are in short supply, and/or
circulating insulin concentrations are low (2,4,5,44,301). This spillover pathway converts β-oxidationderived acetyl-CoA, produced in excess of the hepatocyte’s own energy needs, into ketone body
intermediates, thus diverting carbon away from the hepatic TCA cycle and providing extrahepatic tissues
with an avidly oxidized fuel source. This paradigm forms an ‘altruistic’ model of ketone body
metabolism, in which the hepatocyte shares ‘pre-catabolized’ energy stored in fatty acids with other
organs that may require it, particularly in states of diminished carbohydrate availability. However, this
model neither accounts for the hepatocyte’s need to support ketogenesis for its own metabolic
homeostasis, nor considers the importance of basal hepatic ketogenesis in physiological states that are not
considered ‘ketogenic’ (i.e., carbohydrate restricted). These are the first studies to demonstrate a critical
role for hepatic ketogenesis in the normal absorptive state and in prevention of metabolic decompensation
in the setting of overnutrition, which triggers a cascade of events that culminates in hepatic injury and
hepatic inflammation when ketogenic capacity is markedly impaired.
Our data are consistent with a model in which ketogenesis that is inadequately matched to the
supply and availability of fat (ketogenic insufficient) in the normal fed state will channel β-oxidationderived acetyl-CoA into the TCA cycle, generating the ATP and NADH to support increased
gluconeogenesis from pyruvate, predisposing to hyperglycemia (Fig. 6.4E). Therefore, even in the nonlipolytic absorptive state, in which dietary carbohydrates are abundant, hepatic ketogenesis serves a
critical role in regulating glycemia. When ketogenesis is insufficient, acute delivery of fatty acids and
chronic exposure to a ‘non-ketogenic’ (not carbohydrate restricted) high-fat diet both result in the
inability to couple increased fat availability to increased gluconeogenesis through mechanisms that can be
linked to sequestration of free CoASH, a critical by-product yielded by ketogenesis. Our data are most
consistent with a model in which the CoASH liberated by ketogenesis is critical in states of high fat
delivery, supporting the α-KG dehydrogenase reaction and therefore effective TCA cycle function. Taken
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together, these results mechanistically link ketogenesis to hepatic CoASH homeostasis and
gluconeogenesis, and provide strong evidence for a previously unknown role of ketogenesis in prevention
of hyperglycemia and hepatic injury. These findings are underscored by our recent studies of germline
SCOT-knockout (KO) mice, which cannot terminally oxidize ketone bodies in any tissue. These mice
exhibit hyperketonemic hypoglycemia and die within 48 hr of birth in a manner that phenocopies human
sudden infant death syndrome [SIDS, (78)]. Despite the fact that SCOT is normally excluded from
hepatocytes, livers of SCOT-KO mice develop abnormalities of hepatic fatty acid oxidation, pyruvate
metabolism, redox potential, and even ketogenesis (164,313). In stark contrast to the severe metabolic
derangements and SIDS-like phenotype observed in neonatal SCOT-KO mice, mice that cannot oxidize
ketone bodies selectively within neurons, cardiomyocytes, or skeletal myocytes, which comprise the three
greatest consumers of ketone bodies, survive the neonatal period and starvation as adults (108). Together,
these results indicate that coordination of ketogenesis and ketone body oxidation may be of even greater
importance to preserve the dynamic intermediary metabolic network in the liver than it is to provide
energy to extrahepatic tissues.
Genome-wide association and exome sequencing studies have revealed associations between
numerous genes encoding mediators of lipid metabolism and NAFLD/NASH (327,359). Variations in the
genes encoding ketogenic mediators, including HMGCS2, HMG-CoA lyase, and βOHB dehydrogenase
have not yet been unveiled as independent predictors of liver pathology or diabetes. While complete
HMGCS2-deficiency is very rare in humans, case reports indicate that encoded variation in ketogenic
capacity exists in populations worldwide. Total HMGCS2 enzymatic deficiency is associated with
pediatric hypoketonemic hypoglycemia and hepatic steatosis (66-68,360-362). Importantly, our studies of
neonatal mice revealed that partial loss of HMGCS2 activity caused marked hepatic steatosis vastly out of
proportion to the diminution in neonatal ketosis, but did not result in neonatal hypoglycemia or failure to
thrive. These findings raise the possibility that insidious genetic polymorphisms yielding very subtle
ketogenic defects could latently predispose to fatty liver disease, and attest to the critical fine-tuning role
that hepatic ketogenesis plays in the regulation of hepatic glucose and lipid metabolism.
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In the setting of ketogenic insufficiency, perfusion with octanoate depletes CoASH, inhibiting the
α-KG dehydrogenase reaction of the TCA cycle, which manifests as increased α-KG and decreased
succinate concentrations. Similarly, perfused livers of HFD-fed HMGCS2 ASO-treated mice exhibit
decreased hepatic glucose production from pyruvate, and unperfused livers of HFD-fed HMGCS2 ASOtreated mice demonstrate a trend towards decreased [CoASH]. Only longer-term replenishment of the
CoA precursors pantothenic acid and cysteine prevented the octanoate-induced impairment of glucose
production in livers of ketogenesis-insufficient mice, diminished the increase in [α-KG], and mitigated the
decrease in [succinate]. The findings suggest severe depletion of CoASH precursors in HMGCS2 ASOtreated livers or that the kinetics of CoASH biosynthesis and mitochondrial import [(CoASH biosynthesis
and transport reviewed in (363)] occur too slowly to mitigate these metabolic abnormalities. Together,
these findings identify ketogenesis as a significant modifier of the TCA cycle and gluconeogenesis
through modulation of acetyl-CoA pools and CoASH homeostasis.
Unlike many tissues that must synthesize CoASH de novo or regenerate it via acyl-CoA
thioesterases (363,364), hepatocytes can robustly engage ketogenesis to regenerate CoASH (4,5,301).
After a brief eight week interval of HFD-feeding that is insufficient to cause hepatic injury in control
mice [(42) and Fig. 6.2B-C], mice that cannot effectively liberate CoASH from acetate through
ketogenesis exhibit significantly elevated serum ALT activity and histopathologic evidence of hepatic
injury and inflammation. The severity of hepatic injury positively correlates with dietary fat content,
indicating an important postprandial role for ketogenesis in (i) disposal of excess dietary fat and (ii)
liberation of CoASH from acetyl-CoA. Furthermore, ASO-treated mice fed a HFD developed equivalent
steatosis, but only ketogenic insufficient mice developed severe inflammation, suggesting that of the two
major NAFLD subtypes, simple steatosis and NASH, impaired ketogenesis is an important determinant of
NASH (325). Other forms of hepatocellular injury are also associated with decreased CoASH
concentrations. In acute acetaminophen toxicity, CoASH levels decrease simultaneously with decreasing
HMGCS2 enzymatic activity (365,366). Potentially fatal valproic acid therapy-induced hepatic
dysfunction, which is associated with impaired β-oxidation of fatty acids and ketogenesis due to
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sequesteration of CoASH into poorly metabolized valproyl CoA, can be prevented by administration of
CoA precursors (367,368). In rodents, hepatic CoASH concentrations decrease in response to HFD (369),
while the concentration of pantothenic acid actually increases (370), suggesting that hepatic CoASH
homeostasis is dysregulated in obesity. De novo CoASH synthesis is required for life in mice and
impaired CoASH synthesis is associated with fasting induced hepatic steatosis (371,372). Nonetheless,
the importance of de novo CoASH synthesis in obesity and its relation to NAFLD remain relatively
unexplored.
No current pharmacological therapies directly treat NAFLD or NASH. These diseases are
currently addressed through lifestyle modifications such as weight loss and treatment of dyslipidemia and
hyperglycemia (328). A variety of agents are at various stages of investigation, including compounds
targeting oxidative stress, nuclear receptor activators, insulin sensitizers, modifiers of dyslipidemias, and
immunomodulatory agents (342,345). Ketogenesis has not yet been considered as a metabolic target.
Obese humans and mice exhibit diminished whole body ketone body turnover (12,42). Furthermore,
circulating ketone body concentrations are generally decreased in obese humans (238,239,354), and serve
as predictive biomarkers for conversion to type 2 diabetes in patients with impaired fasting glucose (373).
Furthermore, compared to BMI-matched individuals, obese patients with NAFLD exhibit increased
hepatic glucose production and TCA cycle flux, but not ketogenesis (355). DNA methylation, nuclear
receptor-mediated

transcriptional

activation,

and

reversible

succinylation,

acetylation,

and

phosphorylation all exert multi-tiered transcriptional and post-translational regulation of Hmgcs2
expression and HMGCS2 enzymatic activity to coordinate ketogenesis during diverse physiologic
contexts [(11,47,64,65,324) and reviewed in (301)]. Therefore, HMGCS2 and other enzymatic mediators
of ketogenesis may be considered in future investigations of metabolic regulation of abnormal hepatic
metabolism in the setting of fatty liver disease and obesity.
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Methods
Animals. All adult mice studied were males on a C57BL/6N X C57BL/6J hybrid background. For
neonatal experiments, both sexes were studied. Unless otherwise noted, mice were maintained on
standard low fat chow diet in which 13% of the calories are from fat, 25% from protein, and 62% from
carbohydrates (Lab Diet 5053) and autoclaved water ad libitum. Lights were off between 1800 and 0600
in a room maintained at 22oC. For all adult mouse experiments, mice were housed in groups of 4-5 on
sawdust bedding. ASO treatment was initiated in six week-old mice by intraperitoneal injection (25
mg/kg) with HMGCS2 targeted ASOs (ISIS 191229; CTGTTTGTCACTGCTGGATG) or with
scrambled sequence control ASOs (ISIS 141923; 5′-CCTTCCCTGAAGGTTCCTCC-3′) biweekly for
four weeks. For HFD studies, after two weeks of ASO treatment, mice were maintained for eight weeks
on either a high fat diet in which 60% of calories are from fat, 20% from protein, and 20% from
carbohydrates (D12492, Research Diets) or, in separate cohorts, a diet in which 40.7% of calories are
from fat, 19% from protein, and 40.3% from carbohydrates (TD 110290, Harlan Teklad), during which
time biweekly ASO administration continued. For the neonatal experiments, ASOs were administered (25
mg/kg) subcutaneously daily, beginning on the second day of life and until postnatal day 12 (P12). Pups
were marked on the abdomen daily with a permanent marker to enable longitudinal monitoring of body
weight and blood glucose. Marking also enabled control and HMGCS2 ASOs to be administered to
different pups within the same litter, thus, minimizing inter-litter variance in metabolic parameters. All
experiments were conducted using protocols approved by the Animal Studies Committee at Washington
University.
Measurements of food intake, body weight, and body composition. Food intake was monitored beginning
on day 1 of ASO treatment for each cage of mice. Food intake was measured biweekly for the duration of
each experiment and normalized to the number of mice per cage and the number of days between
measurements, which was always three or four days. Mice were also weighed biweekly at the onset of all
experiments. Body weights and body composition were recorded following a four-hour fast (1000-1400),
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after which food was returned immediately. Percent body fat and lean body mass were determined in
awake adult animals using an EchoMRI instrument (Echo Medical Systems, Houston, TX).
Plasma Metabolite Quantification. Serum triacylglycerol (TAG), free fatty acids (FFAs), total ketone
bodies (TKB), beta-hydroxybutryate (βOHB), and acetoactate (AcAc) were determined using standard
biochemical assays coupled to colorimetric substrates as described previously (51). Blood glucose was
measured in duplicate using handheld glucometers (Aviva). Serum insulin was measured using an
enzyme-linked immunosorbent assay (Millipore) and serum alanine aminotransferase (ALT) was
measured using an assay from Teco Diagnostics, according to manufacturer’s instructions.
Tissue Metabolite Quantification. Hepatic [TAG] were quantified biochemically using a Folch extract of
liver, as described previously (126). Tissue CoASH concentrations were measured in freeze-clamped and
bio-pulverized liver tissue. Approximately 75 mg of tissue were homogenized using a glass on glass
dounce in 10x-volume of ice-cold deionized water. Homogenates were spun at 4oC and 15,000 x g for 20
min. Supernatants were transferred to clean tubes on ice and were then dehydrated using a rotary speedvacuum. Tissue pellets were resuspended to 2 mg/µl and 20 mg of tissue (10 µl) were loaded into a 96
well plate for CoASH detection using an enzyme linked colorimetric assay (Biovision).
Histology. Immediately following sacrifice, liver specimens were collected and fixed in 10% neutral
buffered formalin (Fisher, Wilmington, DE) or cryopreserved in Optimal Cutting Temperature Compound
(O.C.T. Tissue Tek). For hematoxylin and eosin stained sections, paraffin-embedded tissue was
microtome-sectioned, stained and photographed using standard methods. For F4/80 immunostains, rat
anti-F4/80 (Abcam, ab6640) was incubated for 1 h at room temperature on liver cryosections (diluted
1:200 in 1% bovine serum albumin/0.1% Triton X-100 in phosphate buffered saline), followed by Alexa
Fluor 594 conjugated goat anti-rat IgG (Invitrogen, Carlsbad, CA; diluted 1:250 in 1% bovine serum
albumin/0.1% Triton X-100 in phosphate-buffered saline) and coverslip application as previously
described (1). For smooth muscle actin (SMA) immunostains, mouse monoclonal anti-SMA-Cy3
conjugate (Sigma C-6198) was incubated for 1 h at room temperature on liver cryosections (diluted 1:100
in 1% bovine serum albumin/0.1% Triton X-100 in phosphate buffered saline), followed by coverslip
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application. 4’,6-Diamidino-2-phenylindole (DAPI) was used as a cell nuclear counterstain (40 ng/ml in
phosphate buffered saline for 5 min). All immunofluorescence images were acquired at 0.5 µm slice
thickness using a Zeiss LSM 700 confocal microscope and Zeiss Zen software. For F4/80 and SMA
immunostains, five random 20X fields and nineteen random 10X fields per liver, respectively (n = 3
animals/group), were quantified manually. In each case, only staining that was clearly associated with
nuclei were counted, and for SMA, only cells outside of vessel walls were counted as activated stellate
cells.
Gene expression analysis. Quantification of gene expression was performed using real-time RTquantitative PCR using the ΔΔCt approach as described (51), normalizing to Rpl32, using primer
sequences listed within Supplemental Table 6.2.
Immunoblotting. Lysates from liver were generated in a protein lysis buffer: 20 mM Tris-HCl, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1% phosphatase inhibitor cocktail (Sigma), and protease inhibitor
cocktail (complete mini EDTA-free, Roche), pH 7.5. Immunoblots to detect HMGCS2 (rabbit antimHMGCS; Santa Cruz Biotechnology), HMGCS1 (rabbit anti-HMGCS1; Thermo Scientific), and actin
(rabbit anti-actin, Sigma) were performed as described (78). Band intensities were quantified
densitometrically using Quantity One software (Bio-Rad).
Liver perfusions. Ten minutes prior to each liver perfusion, mice received an intramuscular injection of
heparin (100 Units). Mice were then anesthetized with 10µl of sodium pentobarbital (Fatal Plus, 390
mg/ml) administered IP. Once fully anesthetized, the abdomen was sprayed with 70% ethanol, and the
mouse was placed on a surgical platform within a large reservoir to contain run-off buffer and body
fluids. A transverse incision was made through the skin, fascia, and muscular layers of the lower
abdomen. A lateral sagittal incision was made on each side of the body, exposing the abdominal contents.
A second transverse incision was made inferior to the right kidney and towards the dorsal aspect of the
mouse to allow for perfusion buffer and body fluids to drain from the abdomen. The portal vein was then
exposed by gently moving the intestines laterally towards the left body wall. A suture needle was
threaded under the portal vein and tied loosely. Next, the portal vein was cannulated with a 24 gauge
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catheter needle, the needle was withdrawn, and tubing with buffer was reconnected to the catheter. The
abdominal aorta and inferior vena cava were cut and the catheter was firmly tied into the portal vein.
Finally, the heart was exposed by cutting through the diaphragm and thorax. The right atrium was cut to
prevent recirculation of buffer to the liver and to terminate perfusion to the brain. All livers were perfused
with an oxygenated Krebs-Henseleit bicarbonate buffer (118 mM NaCl, 25 mM NaHCO3, 4.7 mM
KCl, 0.4 mM KH2PO4, 2.5 mM CaCl2, 1.22 mM MgSO4-7•H20, pH 7.4), warmed to 37°C using a
counter-current heat exchange circuit and a recirculating water bath, at a rate of 8 ml/min using a
peristaltic pump for 15 min, unless otherwise noted. At the end of the perfusion, the liver was freezeclamped and rapidly frozen in a bath of liquid nitrogen. Tissue was stored at -80°C until further
processing. For measurements of ketogenesis in perfused livers, buffers contained sodium [1,2,3,413

C4]octanoate (0.2 mM), sodium lactate (1.5 mM), and sodium pyruvate (0.15 mM). For all

measurements of gluconeogenesis, livers were perfused with sodium [3-13C]lactate (1.5 mM) and sodium
[3-13C]pyruvate (0.15 mM), and in a subset of these experiments, unlabeled sodium octanoate (0.2 mM)
was included in the buffer (vendor for stable isotopes: Cambridge Isotope Laboratories). For the CoASH
repletion experiments, unlabeled pantothenic acid and L-cysteine were included in the perfusion buffer at
0.15 mM and 0.1 mM, respectively, in addition to sodium [3-13C]lactate (1.5 mM), sodium [313

C]pyruvate (0.15 mM), and unlabeled sodium octanoate (0.2mM). Livers pre-perfused with CoASH

precursors received unlabeled pantothenic acid (0.15 mM), Cys (0.1 mM), sodium lactate (1.5 mM), and
sodium pyruvate (0.15mM) for 45 min before being switched to a buffer containing pantothenic acid
(0.15 mM), cysteine (0.1 mM), sodium [3-13C]lactate (1.5 mM), sodium [3-13C]pyruvate (0.15 mM), and
unlabeled sodium octanoate (0.2 mM) for 15 min.
NMR-based quantitative substrate fate mapping. Neutralized perchloric acid tissue extracts were prepared
and profiled using
(Varian/Agilent

13

C-edited proton nuclear magnetic resonance (NMR) measured at 11.75 T

Direct
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increment

gradient
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single-quantum

correlation (gHSQC). Signals were collected from extracts dissolved in 275 µL of D2O + 1 mM
trimethylsilyl propionate (TSP), loaded into high precision, thin walled 5-mm tubes (Shigemi). Tissue
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concentrations and fractional enrichments of metabolites were determined from quantification of signals
by integration from the 1H{13C} and 13C-edited (gHSQC) collections of carbon 2 for taurine, carbon 4 for
βOHB, carbon 1 for glucose, carbon 4 for glutamate, and 1H{13C} of carbon 3 for α-ketoglutarate and
carbon 2/3 for succinate as described previously (78,313).
Tandem Mass Spectrometry (MS/MS) Analysis of Blood Amino Acids and Acylcarnitines. Blood was
spotted onto 1.3-cm spots on Whatman 903 filter paper. Amino acids were quantified as butyl ester
derivatives using multiple precursor/product combinations in a reversed-phase liquid chromatography
protocol coupled to MS/MS (22). Carnitine esters were measured by scanning for the precursors of the
common m/z 85 carnitine fragment. Quantification was achieved in all cases using stable isotope 2Hlabeled internal standards using an electrospray ionization source coupled to an API 3200-Qtrap tandem
mass spectrometer (Applied Biosystems).
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FIGURE LEGENDS
Fig. 6.1. Ketogenic insufficiency in mice treated with Hmgcs2 ASO. (A) Immunoblot for HMGCS2
and actin using protein lysates derived from livers of neonatal mice treated with either a scrambled
sequence control ASO or HMGCS2 ASO. Mice were treated with ASO daily for 11 days, beginning on
the second day of life, and tissues and serum were collected on postnatal day 12 (P12). Protein abundance
is quantified below. (B) Serum total ketone body (TKB, mM) and (C) hepatic TAG (mg/g tissue)
concentrations on P12 in ASO-treated mice. (D) Immunoblot for HMGCS2 and actin using protein
lysates derived from livers of adult mice treated with control or HMGCS2 ASO biweekly for four weeks
beginning at six weeks of age. (E) Serum [TKB] (mM) during fasting in adult mice treated with ASO for
four weeks, n = 3-5/group. *, p < 0.05, ***, p < 0.001 by Student’s t test vs. HMGCS2-ASO treated mice,
or as indicated.

Fig. 6.2. Hepatic injury in ketogenesis insufficient HFD-fed mice. (A) Hepatic [TAG] (mg/g tissue)
and (B) serum ALT activity (U/L) in ASO-treated mice fed a standard chow diet fed a low fat diet
(standard chow diet) for four weeks or a high fat diet for eight weeks, n = 4-5/group. (C) Representative
hematoxylin and eosin stained sections of liver from ASO treated mice fed the indicated diet. Arrowheads
indicate dying hepatocytes (acidophil bodies). (D) Representative 20X fields showing immunostaining for
F4/80- and (E) smooth muscle actin (SMA)-positive cells in cryosections of liver from ASO treated mice
fed HFD for eight weeks. Quantification for each is on right. **, p < 0.01, ***, p < 0.001 by Student’s t
test or 2-way ANOVA as appropriate, as indicated.

Fig. 6.3. Hepatic metabolic reprogramming in ketogenesis insufficient mice. (A) Blood glucose
(mg/dL) and (B) the percent of basal blood glucose in ASO-treated mice beginning at the onset of 60%
HFD-feeding, n = 8-10/group. (C) Quantification of
surrogate for gluconeogenesis) determined by

13

13

C-enrichment of glucose from [13C]pyruvate (a

C-edited proton NMR spectroscopy in liver extracts of

60% HFD-fed ASO-treated mice perfused via the portal vein with [13C]lactate and [13C]pyruvate in a
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physiological ratio, n =4-5/group. (D)

13

C-enrichment of glucose from [13C]pyruvate, (E) total alpha-

ketoglutarate (α-KG, nmol/mg tissue), and (F) succinate concentrations (pmol/mg tissue) determined by
NMR in liver extracts of standard chow diet-fed ASO-treated mice perfused with the indicated substrates,
n = 7-8/group. (G) Free coenzyme A (CoASH, pmol/mg tissue) concentrations in livers of unperfused
standard chow diet-fed ASO-treated mice or livers perfused with the indicated substrates, n = 3-8/group.
*, p < 0.05, **, p < 0.01, ***, p < 0.001 by Student’s t test or 2-way ANOVA as appropriate, vs.
HMGCS2-ASO treated mice, or as indicated.

Fig. 6.4. Replenishing CoA precursors restores gluconeogenesis and TCA cycle intermediate
abnormalities in livers of ketogenesis insufficient mice. (A) Gluconeogenesis in perfused livers of
standard chow diet-fed ASO-treated mice perfused with either [13C]lactate, [13C]pyruvate, octanoic acid,
cysteine, and pantothenic acid for 15 min [Pre-perfusion (-)] or Pre-perfused with for 45 min with
unlabeled lactate, pyruvate, cysteine, and pantothenic acid followed by 15 min of perfusion with
[13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and pantothenic acid. (B) [α-KG] (nmol/mg tissue),
(C) [glutamate] (nmol/mg tissue), and (D) [succinate] (pmol/mg tissue) in the same livers as in (A). n = 57/group, *, p < 0.05, **, p < 0.01, ***, p < 0.001 by 2-way ANOVA as indicated. (E) Schematic model of
fatty acid handling in normal liver and in fatty liver disease. NAFLD livers exhibit increased esterification
to and liploysis from lipid droplets, increased β-oxidation of fatty acids, increased terminal oxidation,
increased gluconeogenesis, and diminished ketogenesis, relative to the availability of fat. Our studies
demonstrate that severe ketogenic suppression sequesters CoASH due to impaired CoASH recycling,
disrupts the tricarboxylic acid (TCA) cycle, and is associated with hepatic injury and inflammation.

Fig. S6.1. Metabolic parameters of ketogenesis insufficient neonatal mice, specificity of HMGCS2
ASO treatment in adult mice, and quantification of ketogenesis in perfused livers. (A) Body weight
(g) and (B) blood glucose levels (mg/dL) in neonatal mice treated with ASO daily for 11 days, beginning
on the second day of life (P1), n > 4/group. (C) Hmgcs2 transcript abundance in liver (n = 8-10/group)
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and (D) in subcutaneous adipose tissue (n = 4/group) of adult mice treated with control or HMGCS2 ASO
biweekly for four weeks beginning at six weeks of age. (E) Cytoplasmic 3-hydroxymethylglutaryl-CoA
synthase (HMGCS1) protein content in livers of adult mice treated with ASOs for four weeks. (F)

13

C-

βOHB enrichment in perfused livers of ASO treated mice, demonstrating diminished production of
ketone bodies from [13C]octanoic acid. Decreased

13

C-βOHB enrichment in fasted control livers

compared to fed control livers is likely due to increased competition from endogenous fatty acids, which
are mobilized to the liver from adipose stores during the fast, preceding the perfusion. n = 4-8/group. **,
p < 0.01, ***, p < 0.001 by Student’s t test or 2-way ANOVA as appropriate, as indicated.

Fig. S6.2. Metabolic parameters of ketogenesis insufficient adult mice fed a standard chow diet. (A)
Body weight (g), (B) average food intake (kCal/mouse/day), and (C) body composition (g) in ASO
treated mice fed a low fat diet (standard chow diet) for four weeks. (D) Serum free fatty acids (FFAs,
mM; n = 20/group), (E) triacylglyceride (TAG, mg/dL; n = 15-19) (F) acetoacetate (AcAc) and βOHB
(mM, n = 7 group for each ketone body), (G) blood glucose (mg/dL, n = 28-36/group), and (H) serum
insulin (ng/ml, n = 20-23/group) concentrations in standard chow diet-fed ASO treated mice. **, p < 0.01
by Student’s t test as indicated.

Fig. S6.3. Serum metabolites of ASO-treated mice fed a 60% HFD. (A) Immunoblot for HMGCS2
and actin using protein lysates derived from livers of adult mice treated with control or HMGCS2 ASO
biweekly for two weeks beginning at six weeks of age, during which time mice were maintained on a
standard chow diet (quantification on right) and (B) following an additional eight weeks of 60% high fat
diet (HFD). (C) Serum [TAG] (mg/dL), (D) [FFA] (mM), and (E) [TKB] (mM) in ASO-treated mice fed
a HFD for eight weeks, n = 8-10/group. ***, p < 0.001 by Student’s t test as indicated.
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Fig. S6.4. Body weight, energy intake, and body composition of ketogenesis insufficient mice fed
either a 60% HFD or a 40% fat diet. (A) Body weight (g) and (B) caloric intake (kCal/mouse/day)
during 60% HFD and 40% fat diet (C-D) maintenance and ASO treatment, n = 8-10/group, ***, p <
0.001 by linear regression t test. (E) Body composition (g) pre- and post 40% fat diet feeding. n =
10/group, *, p < 0.05, **, p < 0.01 ***, p < 0.001 by 2-way ANOVA as indicated. (F) Blood glucose
concentration (mg/dL) in mice fed a 40% fat diet for eight weeks. n =10-15, *, p < 0.05, by Student’s t
test.

Fig. S6.5. Metabolite concentrations and gene expression in livers of ketogenesis insufficient mice.
(A) Total hepatic glucose concentration (pmol/mg tissue) and (B) moles of

13

C-glucose produced from

[13C]lactate and [13C]pyruvate, quantified by NMR profiling of perfused liver extracts from ASO-treated
mice fed a 60% HFD for eight weeks, n = 4-5/group. (C) Total [glucose] (pmol/mg tissue) in livers from
standard chow diet-fed ASO-treated mice perfused with the indicated substrates, n = 7-8/group. (D)
Relative transcript abundances of key mediators of fatty acid oxidation and gluconeogenesis in livers
from standard chow diet-fed ASO-treated mice, n = 8-10/group. peroxisome proliferator activated
receptor alpha, Ppara; peroxisome proliferator activated receptor gamma coactivator 1-alpha, Pgc1α;
acyl-CoA oxidase, Acox1; carnitine palmitoyl transferase 1a, Cpt1a; medium chain acyl-CoA
dehydrogenase, Acadm; fibroblast growth factor 21, Fgf21; malic enzyme 2; Me2; phosphoenol pyruvate
carboxykinase, Pck1; glucose-6-phosphatase, G6pc. (E) Total [glutamate] (nmol/mg tissue) in livers from
standard chow diet-fed ASO-treated mice perfused with the indicated substrates, n = 7-8/group. (F)
Pantothenate kinase 1a and 1b (Pank1a and Pank1b) relative mRNA abundance in livers of standard
chow diet-fed ASO-treated mice, n = 8-10/group. (G) [Glutamate] (nmol/mg tissue) and (H) [succinate]
(nmol/mg tissue) in unperfused livers of 60% HFD-fed ASO-treated mice n = 4-5/group. (I) Free
coenzyme A (CoASH, pmol/mg tissue) concentrations in unperfused livers of 60% HFD-fed ASO-treated
mice, n = 8/group. *, p < 0.05, **, p < 0.01, ***, p < 0.001 by Student’s t test or 2-way ANOVA as
appropriate, as indicated.
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Fig. S6.6. Hepatic injury in ketogenesis insufficient mice fed a 40% HFD. (A) Hepatic [TAG] (mg/g
tissue) and (B) serum alanine aminotransferase (ALT, U/L) activity in ASO-treated mice fed a 40% fat
diet for eight weeks, n = 9/group for [TAG] and n = 4-5/group for ALT. (C) Representative hematoxylin
and eosin stained sections of liver from ASO treated mice fed the indicated diet. Black arrowheads
indicate microgranulomas comprised of lipid laden Kupffer cells and grey arrowheads indicate nests of
inflammatory cells. *, p < 0.05, by Student’s t test as indicated.

Fig. S6.7. Elevation of short- and medium-chain blood acylcarnitines in ketogenesis insufficient
mice fed a 40% fat diet. Blood acylcarnitines (µM) in 40% fat diet-fed ASO treated mice, determined by
tandem mass spectrometry from blood spotted onto 1.3-cm spots on Whatman 903 filter paper. *, p <
0.05, **, p < 0.01 by Student’s t test, as indicated. n = 9-10/group.

Fig. S6.8. Hepatic glucose pools in livers perfused with supplemental CoASH precursors. (A) Total
hepatic glucose concentrations (pmol/mg tissue) in livers of standard chow diet-fed ASO-treated mice
perfused with [13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and pantothenic acid for 15 min, n = 67/group. (B) Total hepatic glucose concentrations (pmol/mg tissue) in livers of standard chow diet-fed
ASO-treated mice perfused for 45 min with unlabeled lactate, pyruvate, cysteine, and pantothenic acid,
followed by 15 min of perfusion with [13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and pantothenic
acid, n = 5-6/group.
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Chapter 7
13

C-edited proton NMR spectroscopy method for measurement of gluconeogenesis from pyruvate in
the perfused mouse liver

Abstract
Measurement of hepatic glucose production (HGP) in rodent models is integral to obesity and diabetes
research. Nonetheless, HGP is not routinely measured due to the challenges associated with clamp
techniques, in vivo tracer studies, and ex vivo carbon NMR methods. Thus, we have developed a simple
proton-edited

13

C-NMR method to measure HGP from pyruvate in situ in the mouse. Here we

demonstrate the validity of this method in cohorts of chow-fed and 24 hr fasted wild type male mice.
Contribution of [13C]pyruvate, delivered via the portal vein in a euthermic oxygenated buffer, to the TCA
cycle for terminal oxidation and to gluconeogenesis was quantified by NMR in mouse liver extracts. As
expected, contribution of [13C]pyruvate to hepatic gluconeogenesis increased and hepatic pyruvate
oxidation decreased with fasting. The methods contained here provide a relatively simple means of
measuring hepatic gluconeogenesis from pyruvate using proton edited

13

C-NMR and can easily be

adapted to map the fate of various substrates.

Methods
Animals. All adult mice studied were males on a C57BL/6N X C57BL/6J hybrid background. Mice were
maintained on standard low fat chow diet in which 13% of the calories are from fat, 25% from protein,
and 62% from carbohydrates (Lab Diet 5053) and autoclaved water ad libitum. Lights were off between
1800 and 0600 in a room maintained at 22oC. For all experiments, mice were housed in groups of 4-5 on
sawdust bedding. All experiments were conducted using protocols approved by the Animal Studies
Committee at Washington University.
Liver perfusions. Ten minutes prior to each liver perfusion, mice received an intramuscular injection of
heparin (100 Units). Mice were then anesthetized with 10µl of sodium pentobarbital (Fatal Plus, 390
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mg/ml) administered IP. Once fully anesthetized, the abdomen was sprayed with 70% ethanol, and the
mouse was placed on a surgical platform within a large reservoir to contain run-off buffer and body
fluids. A transverse incision was made through the skin, fascia, and muscular layers of the lower
abdomen. A lateral sagittal incision was made on each side of the body, exposing the abdominal contents.
A second transverse incision was made inferior to the right kidney and towards the dorsal aspect of the
mouse to allow for perfusion buffer and body fluids to drain from the abdomen. The portal vein was then
exposed by gently moving the intestines laterally towards the left body wall. A suture needle was
threaded under the portal vein and tied loosely. Next, the portal vein was cannulated with a 24 gauge
catheter needle, the needle was withdrawn, and tubing with buffer was reconnected to the catheter. The
abdominal aorta and inferior vena cava were cut and the catheter was firmly tied into the portal vein.
Finally, the heart was exposed by cutting through the diaphragm and thorax. The right atrium was cut to
prevent recirculation of buffer to the liver and to terminate perfusion to the brain. All livers were perfused
with an oxygenated Krebs-Henseleit bicarbonate buffer (118 mM NaCl, 25 mM NaHCO3, 4.7 mM
KCl, 0.4 mM KH2PO4, 2.5 mM CaCl2, 1.22 mM MgSO4-7•H20, pH 7.4), warmed to 37°C using a
counter-current heat exchange circuit and a recirculating water bath, at a rate of 8 ml/min using a
peristaltic pump for 15 min. At the end of the perfusion, the liver was freeze-clamped and rapidly frozen
in a bath of liquid nitrogen. Tissue was stored at -80°C until further processing. For measurements of
gluconeogenesis in perfused livers, buffers contained sodium [3-13C]lactate (1.5 mM), sodium [313

C]pyruvate (0.15 mM), and unlabeled sodium octanoate (0.2 mM; vendor for stable isotopes:

Cambridge Isotope Laboratories).
NMR-based quantitative substrate fate mapping. Neutralized perchloric acid tissue extracts were prepared
and profiled using
(Varian/Agilent

13

C-edited proton nuclear magnetic resonance (NMR) measured at 11.75 T

Direct

Drive-1)

via first

increment

gradient

heteronuclear

single-quantum

correlation (gHSQC). Signals were collected from extracts dissolved in 275 µL of D2O + 1 mM
trimethylsilyl propionate (TSP), loaded into high precision, thin walled 5-mm tubes (Shigemi). Tissue
concentrations and fractional enrichments of metabolites were determined from quantification of signals
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by integration from the 1H{13C} and 13C-edited (gHSQC) collections of carbon 2 for taurine, carbon 1 for
glucose, and carbon 4 for glutamate, as described previously (78,313).

Results and Discussion
Pyruvate oxidation decreases during fasting and gluconeogenesis from pyruvate increases. Numerous
metabolic, allosteric, and molecular mechanisms ensure pyruvate oxidation decreases and hepatic glucose
production (HGP) increases during fasting. Thus, the fed-fasted transition provides an optimal paradigm
in which to test the validity of new approaches that quantify HGP. In liver, pyruvate can enter the TCA
cycle either through oxidation to acetyl-CoA in a reaction catalyzed by pyruvate dehydrogenase (PDH) or
via carboxyaltion to OAA (oxaloacetate), which is catalyzed by phosphoenolpyruvate carboxykinase
(PEPCK, encoded by Pck1). Oxidative entry of pyruvate to the TCA cycle via PDH destines the pyruvate
for terminal oxidation, while anaplerotic entry as OAA replenishes TCA intermediates and supports
gluconeogenesis (Fig. 7.1A). As expected,

13

C-glutamate enrichment, which serves as a quantitative

surrogate for carbon entry into the TCA cycle for terminal oxidation, was decreased significantly in
perfused livers of fasted mice (Fig. 7.1B, left). Since total hepatic glutamate concentrations (pools) were
not different between fed and fasted mice (Fig. 7.1B, right), these results indicated that pyruvate
oxidation decreased during fasting. In addition, 13C-glucose enrichment was increased in perfused livers
of fasted mice (Fig. 7.1C, left), which reflected increased HGP, as total hepatic glucose pools did not
differ between fed and fasted mice (Fig. 7.1C, middle). Morevover, fasted livers produced more total
moles of

13

C-labeled glucose (Fig. 7.1C, right). Our results are consistent with published findings that

indicate that pyruvate oxidation decreases and pyruvate carboxylation increases during fasting to support
HGP, and thus, validate our NMR method.
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Figure legends
Figure 7.1: Fasting alters pyruvate fate in perfused livers. A. Schematic of mitochondrial pyruvate and
fatty acid fates. B. 13C-glutamate enrichment (pyruvate oxidation) in extracts of perfused livers of chowfed and 24 hr fasted mice (left) and total hepatic glutamate concentration (pool; right). C.

13

C-glucose

enrichment in extracts of perfused livers of chow-fed and 24 hr fasted mice (left) and total hepatic glucose
pool (middle), and moles of 13C-glucose produced per mg tissue (right). FAO, fatty acid oxidation; PDH,
pyruvate

dehydrogenase;

dehydrogenase.
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Chapter 8
Ketogenesis insufficient mice exhibit impaired fasting glucose and hepatic steatosis

Main findings:
Fasted ketogenesis insufficient mice exhibited hyperglycemia and hepatic steatosis.
13

C-pyruvate oxidation was decreased in perfused livers of ketogenesis insufficient mice, both in the

presence and absence of exogenous unlabeled fatty acids.
Exogenous fatty acids increased anaplerosis from pyruvate in perfused ketogenesis insufficient livers.
Conclusion:
Ketogenesis supports disposal of excess hepatic fat.
Decreased pyruvate oxidation is likely due to increased competition from fatty acids that cannot be
disposed of through ketogenesis.
Accumulation of Ac-CoA, due to insufficient ketogenesis, may allosterically activate pyruvate
carboxylase, and thus, stimulate anaplerosis.
Future Direction:
Determine if increased terminal fatty acid oxidation and increased pyruvate cycling support increased
hepatic glucose production in fasted HMGCS2-deficient mice.
Figure legends
Figure 8.1: Fasting-induced hyperglycemia is associated with hepatic steatosis in ketogenesis insufficient
mice. A. Blood glucose during fasting in ASO treated mice. B. Hepatic triacylglyceride (TAG)
concentrations in fasted ASO treated mice. n > 5/group, **, p < 0.01, ***, p < 0.001 by Student’s t test, as
indicated.
Figure 8.2: Altered hepatic pyruvate fate in ketogenesis insufficient mice. A. Schematzed pyruvate fate
within hepatic mitochondria. PDH, pyruvate dehydrogenase; PCx, pyruvate carboxylase; ME, malic
enzyme; OAA, oxaloacetate; α-KG, alpha-ketoglutarate. B. 13C-enrichment of glutamate carbon 4
(pyruvate oxidation) in livers of ASO-treated mice perfused with the indicated substrates. C. Immunoblot
for phosphoserine 293 PDH-E1α and total PDH-E1α in livers of chow-fed ASO-treated mice. D. 13Cenrichment of α-KG carbon 3 (pyruvate anaplerosis) in livers of ASO-treated mice perfused with the
indicated substrates. n ≥ 5/group, *, p < 0.05, **, p < 0.01, ***, p < 0.001 by 2-way ANOVA, as
indicated.
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Concluding Remarks
Ketone body metabolism is classically described as a two-compartment metabolic pathway wherein an
altruistic liver provisions extrahepatic tissues with avidly oxidized ketone bodies during states
characterized by limited carbohydrate availability. Up to two-thirds of the fat entering the liver is
channeled into ketogenesis (281). During human starvation in humans, ketogenic rates approach 150 g
ketone produced/day, which exceeds hepatic glucose production during starvation by 50% (84,374). The
bioenergetic benefits of extrahepatic ketone body oxidation are manifold (reviewed in Ch. 1). Ketone
bodies supplant glucose as the primary fuel source in the brain during starvation and can support up to
25% of the neonate’s basal energy requirements (2,71,82). While ketone bodies undoubtedly comprise a
significant and quantifiable metabolic fuel, an energetic requirement for ketone body oxidation has never
been demonstrated experimentally. Moreover, the mechanisms by which hepatic ketogenesis coordinates
intermediary metabolic homeostasis in liver has never been considered. Thus, my work has sought to
mechanistically determine i) if ketone bodies comprise an essential fuel class, ii) which tissues, if any,
energetically require ketone bodies for adaptation to birth and during starvation in the adult, and iii) novel
roles for hepatic ketogenesis in preservation of the dynamic intermediary metabolic network in liver.
Biochemistry of ketone body metabolism. Pioneering investigators, including John McGarry, Daniel
Foster, Dermot Williamson, John Williamson, and Hans Krebs originally defined the biochemistry of
ketone body metabolism [(4,5,375) and reviewed in Ch. 1]. Briefly, ketogenesis is restricted to liver due
to absence of the fate committing ketogenic enzyme mitochondrial 3-hydroxymethlglutarly-CoA
Synthase (HMGCS2) from most tissues under normal conditions. In liver mitochondria, a series of
ketogenic reactions condense acetyl-CoA derived from beta-oxidation of fatty acids into the circulating
ketone bodies, acetoacetate (AcAc) and beta-hydroxybutyrate (βOHB). In mitochondria of extrahepatic
tissues, beta-hydroxybutyrate dehydrogenase 1 (BDH1) re-oxidizes βOHB to AcAc, which is directed
towards the tricarboxylic acid (TCA) cycle for terminal oxidation by mitochondrial succinyl-CoA3:oxoacid CoA transferase (SCOT), the fate committing enzyme of ketone body oxidation.
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Human inborn errors of ketone body metabolism. Ketone body metabolism is required for normal
fitness in humans. Individuals with genetic defects in either the ketogenic or ketolytic arms of this
metabolic pathway typically present early life. Nine cases of human HMGCS2-deficiency have been
described. These patients classically present with hypoketotic hypoglycemia (66-68,360-362,376). SCOTdeficient patients, of which there have been ~30 described cases, typically present with spontaneous
ketoacidosis with or without hypoglycemia. Viral illness or brief periods of nutrient deprivation can also
trigger ketoacidosis in these patients (77,79-81,97,98,100,101,148,149,290,377,378). Acute ketoacidotic
episodes of SCOT-deficieny can raplidly progess to vomiting, coma, and even death, if intravenous
glucose, insulin, and NaHCO3 therapy is not initiated rapidly. Diagnosis of HMGCS2- and SCOTdeficiency is difficult due to the need for genetic testing, enzymatic assays, and liver biopsy in the case of
HMGCS2-deficiency. Avoidance of fasting and ingestion of carbohydrate-replete diets are primary
treatments of both of these diseases (66-68,77,79-81,97,98,100,101,148,149,290,360-362,376-378).
Latent defects in either ketogenesis or ketone body oxidation could predispose to metabolic
disease later in life. Encoded variation in both ketogenesis and ketone body oxidation occur in humans
(see case reports above) and both of these pathways are susceptible to down-regulation in response to a
variety of stimuli (Reviewed in Ch. 1). Prospectively, latent defects in ketone body metabolism may
emerge in genetically susceptible individuals and exacerbate common pathophysiologic states, including
obesity, diabetes, fatty liver disease, and heart failure.
Ketone body oxidation is required for life in neonatal mice. To mechanistically dissect the
bioenergetic roles of ketone body metabolism during the transition to extrauterine life, our lab generated
novel germline and tissue-specific SCOT-Knockout (KO) mice. SCOT catalyzes the fate committing
reaction of ketone body oxidation, is expressed in all tissues except liver, and is uniquely required for
ketone body oxidation (reviewed in Ch. 1). My studies of germline SCOT-KO mice revealed that ketone
body oxidation is required to prevent lethal hyperketonemia and hypoglycemia. SCOT-KO mice are
indistinguishable from wild littermates at birth, but die within the first 48 hr of life in a manner that
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phenocopies human sudden infant death syndrome (SIDS). During ketosis, serum βOHB concentrations
typically increase, such that the serum AcAc/βOHB ratio falls. In contrast, hyperketonemia in germline
SCOT-KO neonates is marked by a pathological increase in the serum AcAc concentration that drives an
increased serum AcAc/βOHB ratio (presented in Ch. 2). Because AcAc and βOHB are members of an
NAD+/NADH-linked redox couple, the metabolic consequences of an increased AcAc/βOHB were
investigated (presented in Ch. 4 and see below).
Ketone bodies do not comprise an essential fuel source in mice. In stark contrast to the neonatal
lethality exhibited by germline SCOT-KO mice, tissue-specific SCOT-KO mouse strains survive the
neonatal period and starvation as adults with few metabolic abnormalities. Selective genetic targeting of
SCOT in neurons, cardiomyocytes, and skeletal myocytes, which comprise the three greatest consumers
of ketone bodies, resulted in specific and complete loss of SCOT protein and enzymatic activity within
each of the targeted tissues. Of the tissue-specific SCOT-KO strains generated, only neonatal SCOTneuron-KO mice exhibited mildly elevated ketonemia, suggesting that neurons comprise a large ketolytic
sink in neonatal mice. Furthermore, compound germline SCOT-heterozygous; SCOT-neuron-KO mice
(which exhibit a 50% decrease in SCOT protein abundance in all tissues and also completely lack SCOT
in all neurons), were viable and indistinguishable from SCOT-neuron-KO mice. Adult tissue-specific
SCOT-KO strains adapted well to starvation. SCOT-Neuron-KO and SCOT-Muscle-KO mice exhibit
hyperketonemia during fasting, but maintained glycemia and body weight normally during fasting.
Moreover, all tissue-specific SCOT-KO strains exhibited the physiologic ratio of AcAc/βOHB during the
neonatal period and during starvation as adults. Together, these results demonstrated that ketone body
oxidation is not required in any single tissue for survival of the neonatal period or starvation in the adult,
and suggested that minimal ketolytic reserve is required to prevent toxic accumulation of ketone bodies
(presented in Ch. 3).
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Extrahepatic disposal of ketone bodies preserves hepatic metabolic function in neonatal mice.
SCOT-KO mice die with hypoglycemia and hyperketonemia that is marked by a pathological increase in
the ratio of AcAc/βOHB in serum. Incredibly, total loss of ketone body oxidation, an exclusively
extrahepatic process, deranged hepatic metabolism in neonatal SCOT-KO mice. βOHB accumulation in
blood impaired de novo hepatic βOHB synthesis, but permitted continued production of AcAc, which
selectively oxidized hepatic redox potential and increased the serum AcAc/βOHB ratio. Oxidized hepatic
redox potential drove a maladaptive increase in pyruvate oxidation, which contributed to depletion of the
neonate’s gluconeogenic precursor pool, and thus, limited hepatic glucose production in vivo. Together,
these results indicated that a primary role for extrahepatic ketone body oxidation is to prevent toxic
accumulation of ketone bodies, which provokes hepatic metabolic abnormalities (presented in Ch. 4).
PPARα-dependent ketogenesis prevents neonatal hepatic steatosis. Peroxisome Proliferator Activated
Receptor alpha (PPARα) is a master transcriptional regulator of hepatic intermediary metabolism. PPARα
mediates the adaptive response to fasting. Like fasting, nutrient supply is abruptly altered at birth when a
transplacental supply of carbohydrates is replaced by a high-fat, low-carbohydrate milk diet. Using 13Clabeled substrates to quantify dynamic metabolism and complimentary systems physiology approaches in
neonatal mice, I demonstrated a critical role for PPARα in hepatic metabolic adaptation to birth. PPARαKO neonates exhibited hypoglycemia, hypoketonemia, and hepatic steatosis. Hypoketonemia was
mechanistically linked to a 50% decrease in hepatic ketogenesis and was associated with neonatal fatty
liver. These findings indicated an important role for PPARα-dependent ketogenesis in disposal of excess
hepatic fatty acids during the neonatal period, and prospectively, could extend to pathological
nonalcoholic fatty liver disease (NAFLD) in adults (presented in Ch. 5).
Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia through coenzyme A
recycling. NAFLD spectrum disorders affect approximately one billion individuals worldwide. The
mechanisms driving progressive steatohepatitis remain incompletely defined, impeding the development
of effective treatments. Thus, we developed a murine model of HMGCS2-deficiency to determine if
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ketogenesis plays a critical role in prevention of diet-induced steatohepatitis. To permit mechanistic
dissection of the phenotypes offered by HMGCS2-deficient mice, I developed an in situ method to
quantify hepatic energy metabolism in the perfused mouse liver using

13

C-edited proton NMR

spectroscopy (presented in Ch. 6a). HMGCS2 deficient mice could not effectively convert fatty acids into
ketone bodies, and were thus ketogenic insufficient. Adult-onset loss of HMGCS2 caused mild
hyperglycemia and increased hepatic gluconeogenesis from pyruvate in chow-fed mice. Ketogenesis
insufficient mice also exhibited impaired fasting glucose and fasting-induced hepatic steatosis (presented
in Ch. 6b). High-fat diet (HFD) feeding of ketogenesis insufficient mice caused extensive hepatocyte
injury and inflammation, decreased glycemia, deranged hepatic TCA cycle intermediate concentrations,
and impaired hepatic gluconeogenesis due to fatty acid-induced sequestration of free coenzyme A
(CoASH). Supplementation of the CoASH precurosrs pantothenic acid and cysteine normalized TCA
intermediates and gluconeogenesis in ketogenesis insufficient livers. These findings identify ketogenesis
as a critical regulator of hepatic glucose metabolism and TCA cycle function via coordination of CoASH
homeostasis in the absorptive state and indicate that ketogenesis modulates fatty liver disease (presented
in Ch. 6).
Future directions.
Neonatal hypoglycemia has an incidence of 10% and pathological neonatal hypoglycemia occurs in
2/1000 live births. Neonates born preterm, with intrauterine growth restriction, that are small for
gestational age, with congenital anomalies or inborn errors of metabolism, and those born to diabetic
mothers are at risk of developing neonatal hypoglycemia. Nonetheless, epidemiologic factors only
identify 50% of at risk neonates and cannot predict which individuals will spontaneously recover from
transient neonatal hypoglycemia and which will develop pathological hypoglycemia. Thus, guidelines
that direct when and in which patients to intervene are lacking. My findings in neonatal mice have been
leveraged into a clinical study designed to risk-stratify neonates for hypoglycemia using metabolite
profiles. Current statewide screening protocols identify inborn errors of metabolism using tandem mass
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spectrometric (MS/MS) quantification of blood amino acids and acylcarnitines in heel stick blood that is
collected from neonates shortly after birth. Unfortunately, these screening regimens do not identify
patients at risk of developing hypoglycemia that is not due to an underlying enzymatic deficiency, nor do
they identify inborn errors of ketone body metabolism. Our current clinical study expands upon my
findings in neonatal mice by using MS/MS to quantify circulating concentrations of ketone bodies,
lactate, pyruvate, amino acids, and acylcarnitines, as well as blood AcAc/βOHB and pyruvate/lactate
ratios as reporters of hepatic redox potential, in neonatal blood collected 6-12 and 24-48 hr after birth.
Blinded statistical analyses of metabolic profiles, epidemiologic factors, and clinical course will be used
to risk-stratify individuals for neonatal hypoglycemia.
Inborn errors of ketone body metabolism are rarely diagnosed. These diseases may truly be rare.
Alternatively, because they are difficult to diagnose, many cases may go undetected and could contribute
to a subset of SIDS cases. In fact, one recent retrospective study that performed metabolic autopsies on
255 SIDS patients identified 3 individuals with underlying defects in ketone body metabolism. Finally,
identification of patients with partial loss of function within ketone body metabolism may have
prognostic value, as abnormalities of ketone body metabolism occur in and may directly contribute to
metabolic diseases, such as heart failure, diabetes, obesity, and fatty liver disease.
My work has mechanistically defined a critical and novel role for ketogenesis in regulation of
hepatic glucose production, glycemia, and prevention of diet-induced steatohepatitis. These findings
warrant follow-up studies to determine if therapeutic activation of ketogenesis can ameliorate
hyperglycemia and mitigate fatty liver disease. Genetic and viral approaches designed to augment
ketogenesis can be employed in mouse models to determine if ketogenic activation can ameliorate
hyperglycemia in diabetes models and prevent diet-induced NAFLD and NASH. Simultaneously, small
molecule screens in primary hepatocytes to identify non-toxic, specific, and potent ketogenic activators,
followed by subsequent compound optimization and validation in perfused livers and in vivo should be
performed. Hepatic injury in HFD-fed ketogenesis insufficient mice is prospectively linked to pancellular
metabolic dysfunction due to CoASH depletion. Therefore, we are currently performing interventions
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designed to replenish hepatocellular CoASH pools in vivo in HFD-fed control and ketogenesis
insufficient mice. These experiments include dietary supplementation of CoASH precursors (pantothenic
acid and L-cysteine) and genetic, viral, and pharmacologic approaches to augment CoASH biosynthesis
and/or increase CoASH liberation from acyl-CoAs. Because ketogenesis supports noncombustive and
thus ‘safe’ disposal of mitochondrial fat, we are also performing studies to determine if excessive
mitochondrial reactive oxygen species (ROS) production contributes to hepatic injury in HFD-fed
ketogenesis insufficient mice. Furthermore, studies of mitochondrial biogenesis, mitochondrial
respiration, mitochondrial Ca++ buffering, mitochondrial permeability transition pore opening, and
mitochondrial ultrastructure are underway. We are working to characterize and to deconstruct the hepatic
inflammation in HFD-fed ketogenesis insufficient mice using immunocompromised mouse models.
Finally, because ketogenic capacity decreases with increasing age, we are studying aged control and
ketogenesis insufficient mice fed a low-fat chow diet to determine if suppressed ketogenesis is sufficient
to drive fatty liver disease in mice.
Abnormal lipid and carbohydrate metabolism occur in and contribute to obesity, diabetes, and
NAFLD. In liver, fluxes of carbohydrate and fatty acid metabolism are tightly linked to ketogenic flux.
Nonetheless, ketogenesis has largely been overlooked as both a driver and as a modifier of metabolic
disease states. My work is the first to mechanistically identify insufficient ketogenesis as a driver of
hyperglycemia and NASH. Prospectively, ketonemia may serve as a predictive biomarker of fatty liver
disease and diabetes progression. Future studies may reveal that therapeutic augmentation of hepatic
ketogenesis can mitigate hyperglycemia and ameliorate fatty liver disease.
Final thought.
My most sincere hope is that this body of work will vitalize interest in ketone body metabolism as a
prospective diagnostic biomarker and therapeutic target in metabolic disease states.
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• Best Student Poster, Annual Cardiovascular Research Day, WUSM, 2013
• UNLV Outstanding Graduate, Fall Commencement 2008
• UNLV Provost’s Scholar, 2005-2009
• Governor Guinn Millennium Scholarship 2005-2009
• Barnes and Noble Book Scholarship, Spring 2008
• Mitzi and Johnny Hughes UNLV Honors Program Scholarship, 2007-2008
• UNLV Science and Art Scholarship Fund, 2006-2007
• UNLV College of Sciences Award for Academic Excellence, 2005-06, 2006-07, 2007-08
• UNLV Stan Fulton’s Honors Program Scholarship, 2005-2006
PUBLICATIONS
•
•

•

•

•

Cotter DG, Eash K, Gordon S, Schaffer A, Musiek A. Angiosarcoma of the scalp arising
within a cutaneous hemangioma. Submitted.
Cotter DG, Ercal B, Leid J, Graham M, d'Avignon DA, Dietzen DJ, Brunt E, and Crawford PA.
Ketogenesis prevents nonalcoholic fatty liver injury and hyperglycemia through coenzyme A
recycling. Journal of Clinical Investigation. E-published 27 Oct 2014.
Cotter DG, Ercal B, d'Avignon DA, Dietzen DJ, and Crawford PA. Impairments of hepatic
gluconeogenesis and ketogenesis in PPARα-deficient neonatal mice. Am J Physiol
Endocrinol Metab. 2014. E-published 27 May 2014.
Cotter DG, Ercal B, d'Avignon DA, Dietzen DJ, and Crawford PA. Impact of peripheral
ketolytic deficiency on hepatic ketogenesis and gluconeogenesis during the transition to birth.
J Biol Chem. 2013. 288 (27): 19739-19749.
Cotter DG, Schugar RC, and Crawford PA. Ketone body metabolism and cardiovascular disease.
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•

•
•

•

•

Am J Physiol Heart Circ Physiol. 2013. 304 (8): H1060-76.
Cotter DG, Schugar RC, Wentz AE, d'Avignon DA, and Crawford PA. Successful adaptation to
ketosis by mice with tissue-specific deficiency of ketone body oxidation. Am J Physiol
Endocrinol Metab. 2013. 304 (4): 363-74.
Cotter DG, d’Avignon,DA, Wentz AE, Weber ML, and Crawford PA. Obligate role for ketone
body oxidation in neonatal metabolic homeostasis. J. Biol. Chem. 2011. 286: 6902-6910.
Lenz JD, Lawrenz MB, Cotter DG, Gonzalez RJ, Palacios MG, and Miller VL. Expression
during host infection and localization of Yersinia pestis autotransporter proteins (Yaps). J.
Bacteriol. 2011. 193 (21): 5936-5949
Garbow JR, Doherty JM, Schugar RC, Travers S, Weber ML, Wentz AE Ezenwajiaku N, Cotter
DG, Brunt EM, and Crawford PA. Hepatic steatosis, inflammation, and ER stress in mice
maintained long term on a very low-carbohydrate ketogenic diet. Am J Physiol Gastrointest
Liver Physiol. 2011. 300: G956-G967.
Wentz AE, d'Avignon DA, Weber ML, Cotter DG, Doherty JM, Kerns R, Nagarajan R,
Sambandam N, and Crawford PA. Adaptation of myocardial substrate metabolism to a
ketogenic nutrient environment. J Biol Chem. 2010. 285: 24447-24456

PUBLISHED ABSTRACTS
• Cotter DG, and van Breukelen F. (2008). Dysregulation of SUMOylation during hibernation.
FASEB J. 22 (5): 757.31.
• Cotter DG, Lawrenz MB, Lenz JD, Lathem W, Goldman WE, Miller VL. (2008). Identification
and Characterization of Four Autotransporter Proteins in Yersinia pestis. 108th American
Society of Microbiology, June 2008.
PRESENTATIONS
• The Yin and Yang of ketone body metabolism: new insights into a classic metabolic pathway.
o Oral- UNLV School of Life Sciences Spring Seminar Series (Feb. 28, 2014).
• Ketogenesis protects from hyperglycemia and liver injury.
o Poster- Annual Cardiovascular Research Day, WUSM. (Dec. 5, 2013).
o Poster- Diabetes Day, WUSM. (Nov. 14, 2013).
o Oral- Cardiovascular Trainee Seminar Series, WUSM. (Oct. 15, 2013).
• Ketogenesis is a central regulator of hepatic lipid and glucose metabolism.
o Poster- WUSM MSTP Retreat. (April 20, 2013).
• Hepatic adaptations to impairments of ketone body metabolism.
o Poster- 1ST Annual Cardiovascular Research Day, WUSM. (Dec. 7, 2012).
o Poster- Diabetes Day Symposium, WUSM. (Nov. 15, 2012).
• Impact of ketone body oxidation defects on hepatic ketogenesis and gluconeogenesis.
o Oral- Cardiovascular Trainee Seminar Series, WUSM. (Nov. 14, 2012).
• Preservation of redox balance and bionergetic homeostasis by ketone body metabolism.
o Oral- Cardiovascular Trainee Seminar Series, WUSM. (April 18, 2012).
o Oral- WUSM MSTP Retreat, Pere Marquete, Il. (April 9, 2012).
• Diverse roles for ketone body utilization in neonatal and adult metabolic homeostasis.
o Poster- Diabetes Day Symposium, WUSM. (Nov. 17, 2011).
• Obligate role for ketone body oxidation in neonatal metabolic homeostasis.
o Oral- WUSM MSTP Retreat, Potosi, MO. (April 9, 2011).
o Oral- Cardiovascular Trainee Seminar Series, WUSM. (Oct 20, 2010).
• Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment.
o Oral- Cardiovascular Trainee Seminar Series, WUSM. (Feb 17, 2010).
• Dysregulation of SUMOylation during hibernation.
o Poster- Experimental Biology, San Diego, CA. (2008).
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o Oral- Nevada Undergraduate Research Symposium, Reno, NV. (2008).
Identification and characterization of four autotransporter proteins in Yersinia pestis.
o Poster- ASM 108th General Meeting, Boston, MA. (2008).
o Poster- BioMedRAP Research Symposium, WUSM. (2008).
o Poster- BioMedRAP Research Symposium, WUSM. (2007).
Differential regulation of Hsp70 in the rotifer Brachionus plicatilis in response to thermal and
osmotic stress.
o Oral- Nevada Undergraduate Research Symposium, Las Vegas, NV. (2007).

CURRENT RESEARCH INTERESTS
• Ketone Body Metabolism in Health and Disease (2009-present)
o Mentor: Dr. Peter Crawford, Department of Medicine, Genetics, and Developmental
Biology, Washington University School of Medicine
o Project: My work utilizes genetic mouse models, nutritional models, and nuclear
magnetic resonance (NMR) spectroscopy to elucidate the metabolic changes that occur in
disease states. Specifically, my studies have revealed novel roles for ketone body
metabolism during the transition to extrauterine life and in obesity, and thus, have direct
relevance to sudden infant death syndrome (SIDS), type 2 diabetes, and nonalcoholic
fatty liver disease. I have demonstrated an essential role for hepatic ketogenesis in
prevention of hyperglycemia and fatty liver disease, which is the most common cause of
chronic liver disease in the world and affects 30% of adults in the United States.
Furthermore, my studies in neonatal mice have demonstrated that defective disposal of
and generation of ATP from ketone bodies phenocopies SIDS and causes hypoglycemia
in a manner that can be predicted by alterations in other serum metabolites. These
findings have been leveraged into a clinical study aimed to establish metabolite profiles
that can risk stratify human neonates for development of hypoglycemia, a high morbidity
condition.
o Future Interests: I am highly motivated to apply my technical expertise in mouse
genetics, NMR spectroscopy, isotopic labeling strategies, and cell biology to identify
targetable molecular and metabolic adaptations employed by cutaneous neoplasms,
including malignant melanoma and cutaneous T cell lymphoma, and to disorders
characterized by abnormal dermal and/ or epidermal proliferation, including psoriasis,
keloids, and scleroderma.
PAST RESEARCH EXPERIENCES
• Dysregulation of SUMOylation during hibernation (2007-2009):
o Mentor: Dr. Frank van Breukelen, School of Life Sciences, UNLV
o Project: Examination of the post-translational modification, SUMOylation, in the
hibernating ground squirrel, Spermophilus lateralis, demonstrated an inability to regulate
SUMOylation during hibernation. Funded by a competitive, statewide grant from the
National Science Foundation-Experimental Program to Stimulate Competitive Research.
• Identification and Characterization of Four Autotransporter Proteins in Yersinia pestis
(2007-2008):
o Mentor: Dr. Virginia Miller, Department of Molecular Microbiology, Washington
University School of Medicine
o Project: Examination of the expression, localization, and function of four autotransporter
proteins in Yersinia pestis, the causal agent of plague. Funded by a nationally competitive
Biomedical Research Apprenticeship Program offered through the Division of Biology
and Biomedical Sciences at Washington University School of Medicine.
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•

Effects of temperature and salinity on motility and stress protein production in the rotifer
Brachionus plicatilis (2006-2008):
o Mentor: Dr. Peter Starkweather and Dr. Frank van Breukelen, School of Life Sciences,
UNLV
o Project: Examination of cellular and behavioral responses to thermal and saline stress in
the planktonic organism, B. plicatilis to determine if stress protein production supplants
motility as a primary mechanism to overcome changes in ambient conditions. Funded by
a competitive grant from the UNLV Office of Research, and by a statewide grant from
the National Science Foundation-Experimental Program to Stimulate Competitive
Research.

MENTORING EXPERIENCE
• Jamison Leid. Post-baccalaureate research assistant, WUSM. Summer 2013-present.
• Debra Whorms. Undergraduate research assistant, WUSM, summer 2012.
• Charles Shyng. PhD rotation student, WUSM, Summer-Fall 2011.
• Baris Ercal. MD/PhD rotation student, WUSM. Summer 2011.
• Charles Washington. Young Scientist Program Student, WUSM, summer 2007.
TEACHING EXPERIENCE
• Teaching Assistant for Histology, Washington University School of Medicine, 2011-12
• Lab Instructor for General Biology: Fundamentals of Life Science, UNLV, 2009
• Teaching Assistant for Cell Physiology, UNLV, 2008
COMMUNITY SERVICE
• Foster home for Serendipity German Shepherd Rescue, St. Louis, MO, 2011-present
• Washington University Medical Plunge, St. Louis, MO, 2009
o Week long immersion into public health and community outreach
• Habitat for Humanity, Las Vegas, NV, 2006-2008
• Biology and chemistry tutor, UNLV, 2008
• Martial arts instructor for Boys and Girls Club of Las Vegas, NV, 2006-2007
• Instructor for Honors/ Women’s Self Defense Class, UNLV, 2006-2007
• Green Up Las Vegas Wash, Las Vegas, NV, 2006 and 2008
CAMPUS INVOLVEMENT
• Capstone Committee, Washington University School of Medicine, 2014-2015.
• Martial Arts Club, Washington University School of Medicine, 2011-2012
o Founding member and head instructor to 20+ members
• Your Film Society, Washington University School of Medicine, 2009-2010
o Event Coordinator, 2009-2010
• Beta Beta Beta (biological honor society), UNLV, 2008-2009
o Executive Vice President, 2008-2009
• Honors Student Council, UNLV, 2006-2008
o Activities Director, 2006-2007
• Alpha Epsilon Delta (pre-health honor society), UNLV, 2006-2008
o Chair of Fundraising, 2007-2008
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